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INTRODUCTION
Prostate cancer (PCa) is one of the most frequent cancers in men.1 As an early screening 
method, the concentration of the glycoprotein prostate-specific antigen (PSA) is measured 
in serum. Even though this clinical test is applied worldwide, it exhibits a rather low 
sensitivity, specificity and moreover a poor predictive value.2 As a result, high PSA-levels 
often lead to a large number of unnecessary biopsies. Literature suggests that a deeper 
understanding of the glycosylation of PSA and, specifically, of the alterations in glycosylation 
profile may provide a more specific yet non-invasive PCa diagnosis.3 However, conventional 
PSA glycomics assays, like lectin-based assays, lack the in-depth isoform differentiation 
needed to provide a better understanding of the alterations in PSA glycosylation features, 
such as core-fucosylation and antenna modifications.3-5 Recently, we have developed an in-
depth PSA Glycomics Assay (PGA) based on capillary electrophoresis of tryptic glycopeptides 
that enables the discrimination between α2,6- and α2,3-sialylated isomers,6,7 the latter 
one proposed to be a hallmark of malignant types of cancer.8,9 During this research, a non-
invasive PGA7 was established in order to allow the quantification and in-depth glycosylation 
analysis of PSA in urine.
This introduction will cover information about prostate cancer, PSA, the biosynthetic pathway 
of glycosylation, as well as the basics of capillary electrophoresis and mass spectrometry, to 
further understand the research that has been described in this thesis.
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PROSTATE CANCER
It is estimated that more than a million patients will be diagnosed with prostate cancer 
(PCa) in 2018 worldwide, with approximately 11,000 new cases for the Netherlands.1,10 This 
means that PCa is the most prevalent type of cancer for men in the Netherlands and second 
worldwide after lung cancer.1,10 The prostate is known to be a key player in the reproductive 
system of the male for the production of seminal fluid and prostate-specific antigen (PSA). It 
has approximately the size of a walnut, consists of small glandular structures and is situated 
anterior to the rectum wall, distal from the bladder in the male. The prostate can be divided 
into four distinct zones; the peripheral zone, central zone, transition zone and the anterior 
fibro muscular zone (Figure 1.1). PCa generally starts with mutations that occur in the cells 
of the glandular structures, leading to cancer cells, and can further develop by spreading 
these cells into the stroma that is surrounding the glandular structures. When a patient has 
prostate related issues (e.g., the need to urinate more frequently, difficulties to urinate and 
a rather weak flow) this is most often not caused by PCa but by a different prostate disease 
namely, benign prostate hyperplasia (BPH; enlargement of the prostate), as PCa does not 

















Figure 1.1: Prostate and nearby organs. (A) Overview of the position of the (a) prostate surrounded by the (b) 
bladder, (c) rectum, (d) penis, (e) scrotum and (f) urethra. An overview of a prostate from a young adult male is 
illustrated in (B) and (C) indicating the different prostate zones and regions; (1) central zone, (2) anterior fibro 
muscular zone, (3) transition zone, (4) peripheral zone and (5) periurethral gland region.
1
| INTRODUCTION |
| 15 | 
Age, ethnicity and genetic predisposition are known risk factors for PCa. For example, in 
most cases PCa is diagnosed in men after age 50 and PCa is rarely found in men younger 
than age 40 (Figure 1.2).10 Ethnicity differences are also found; PCa occurs more often in 
African-American men and men from the Caribbean with African ancestry,13 with more 
aggressive forms of PCa being detected in African-Americans, resulting in higher mortality 
rates compared to Caucasians.13 Furthermore, the chance of developing PCa becomes 
approximately two times higher when the individual has a first degree relative that has been 
diagnosed with PCa and, intriguingly, having a brother with PCa results in a higher chance 
of developing PCa (approximately 3-fold), rather than having a father with PCa.14 Moreover, 
the risk is higher if PCa was discovered at a relatively young age of the sibling or the father 
(< 60 years) compared to a higher age (≥ 60 years), with an increased relative risk of 2.2- 
and 2.0-fold, respectively.15 Interestingly, when a first-degree female relative is diagnosed 
with breast cancer (mother or sister) there is also an increased risk of developing PCa (1.2 
fold).15 Likewise, detection of early onset PCa in first degree relatives increases the risk of 
developing breast cancer up to a 5.5-fold,16 suggesting common genetic risk factors of these 
types of cancers. 
The highest incidences of PCa are found in highly developed continents such as Northern 
America and Europe,17 which is mainly due to the implementation of an early screening 
program for PCa. This program uses the protein concentration of PSA in combination with a 
digital rectal examination (DRE) to evaluate if further investigation is necessary (e.g., biopsy). 
Even though the PSA test was widely applied, the US Preventive Services Task Force has 
recently recommended against PSA-screening18 and it has never been implemented in the 
Average Mortality Rate (2016)





















































































Figure 1.2: Incidence and mortality rates of prostate cancer in men per 100,000 population in the Netherlands.10 
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Netherlands as a broad population based screening program, as the test has not proven its 
overall benefit,19 given its high number of false negatives and poor predictive value (unable 
to distinguish patients with low-risk disease from high-risk disease). Furthermore, PCa might 
not be the only cause of elevated PSA-levels, as prostatitis (inflammation of the prostate) 
and BPH can also cause increased PSA concentrations. Even though the PSA test is unable to 
distinguish PCa from other prostate related diseases, it is the first step in the clinical pathway 
to test whether the patient has PCa (Figure 1.3).19
CLINICAL PATHWAY
PSA TEST
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Figure 1.3: Clinical pathway for patients with a suspicion of prostate cancer.19
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CLINICAL PATHWAY IN PROSTATE CANCER[i]
As mentioned previously, when a patient is suspected of having PCa, the first step in the 
clinical pathway[i] is the PSA test (Figure 1.3). Even though it is not certain if the use of the 
PSA test actually increases the certainty of the diagnosis of a patient, the patient should take 
an informed decision with the help of a healthcare professional on the possible benefits, risks 
and limitations of the test.19 When a patient decides to take the PSA test, the concentration 
of PSA in the blood circulation is tested. PSA concentrations with values below 2.0 ng/
mL lead to the suggestion of a retest within four to eight years, while a patient with PSA 
concentrations between 2.0 - 2.9 ng/mL will be recommended to have a retest within one 
to two years (Table 1.1). When elevated levels of PSA occur (PSA concentration of > 3 ng/
mL (Netherlands)19 or > 4 ng/mL (United States)2) the patient is advised to have a DRE. During 
DRE, the prostate is examined for irregularities (e.g., size of the prostate and abnormal 
areas or nodules). However, it should be noted that DRE is a limited technique: as not all 
areas can be reached, early stage tumors might be too small for detection and the outcome 
might be dependent on the expertise of the clinician. Nowadays, multi-parametric magnetic 
resonance imaging (mpMRI) can be used prior to biopsy, providing in-depth information on 
the prostate volume, cellularity and vascularity and could prevent unnecessary biopsies.20 
However, the application of this technique is still under debate as a significant number (20 
- 30%) of the tumors, especially low-risk disease, are still missed.20 The use of transrectal 
ultrasonography (TRUS) biopsy can provide useful information as to where in the prostate 
the possible PCa is located and this could be used to choose the location of the biopsy, 
although it should be mentioned that TRUS has a low sensitivity. However, the combination 
of mpMRI and TRUS-biopsy could enhance the detection of PCa with 18%.20 When mpMRI 
information is not available, biopsies will be mainly taken from the peripheral zone of the 
prostate, as this zone is known to be more prone to prostate carcinomas.21 At least eight 
biopsies should be taken, of which three on either side of the peripheral zone. It is advised 
to take at least 10 biopsies when a prostate volume of > 40 mL is present.19 The biopsies 
will be histologically evaluated and graded according to the “Gleason score”.22 Briefly, on 
the basis of the distribution of the cells, the 
tissue is assigned a double score; the first 
one (a) describes the most dominant cell 
morphology while the second one (b) 
indicates the non-dominant cell type with 
the highest grade. Grades vary from 1 up 
to 5, where 5 indicates the most aggressive 
form (Table 1.2).22,23 The sum of these two 
Table 1.1:  Usage of the PSA concentration found in 
the circulation of asymptomatic men during an early 
screening procedure.19
PSA concentration Recommendation
< 2.0 ng/mL Retest within 4 - 8 yrs
2.0 - 2.9 ng/mL Retest within 1 - 2 yrs
> 3.0 ng/mL Biopsy
[i]  The clinical pathway of prostate cancer described in this thesis is based on the national guidelines of the 
Netherlands; Nederlandse Vereniging voor Urologie, Prostaatcarcinoom, Landelijke Richtlijn. 2014; Vol.2.19
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numbers (a + b) make up the Gleason score, ranging from 2 up to 10, providing an indication 
of the aggressiveness of the cancer.22,23 However, it should be noted that a Gleason score 
from 7 can be either graded 7 (3 + 4) or 7 (4 + 3), which is important for defining the stage 
of the cancer, where 7 (4 + 3) is more aggressive.24 Each stage will be further classified by 
assessing the tissue biopsy on the (primary) tumor size, involved lymph nodes and distant 
metastasis altogether (TNM staging).25 It should be noted that a biopsy can only reflect the 
presence of PCa in the tissue that has been taken during biopsy and does not reflect the 
actual status of the whole prostate. In this respect, it should be taken into account that, 
even though a first biopsy might not indicate any malignancy, 20 - 35% of the repeated 
biopsies still results in the detection of PCa in patients with a PSA level between 4 - 10 ng/
mL (the so-called grey zone).26 Furthermore, it should be noted that biopsies could induce 
complications such as sepsis, haematuria (blood in urine), hematospermia (blood in semen), 
pain and discomfort, dysuria (painful urination), urinary retention and infections.27-29
In case of localized PCa (PCa that has not spread outside the prostate), the tumor can be 
categorized into three different risk groups: low-, intermediate- and high-risk, taking into 
account the PSA-concentration, TNM score and the Gleason score (Table 1.2).30 When the 
patient is at low-risk, active surveillance is preferred. As localized PCa often progresses 
only slowly, it has a low risk of spreading and might not cause major clinical issues during 
the lifetime of a patient. Here it has to be taken into consideration that treatment of the 
cancer causes side effects that could have a larger impact on the quality of life than PCa on 
its own. During active surveillance, the patient will be tested on a regular basis (e.g., PSA 
tests, biopsies and MRI scans) and only when progression of the PCa is found, treatment 
with curative intent will be initiated. In the case of watchful waiting the patient will also not 
be treated for PCa even though the cancer might have spread beyond the prostate (locally 
advanced or advanced PCa). This method of action is chosen when direct treatments are not 
expected to prolong life or when comorbidity is such that the chance that the patient dies 
from other causes is higher than initiating curative treatment with all its possible side effects. 
The patient will be treated only when the disease becomes symptomatic, and treatment is 
then palliative (androgen deprivation therapy). 
Table 1.2: Defining the risk groups dependent on different factors in localized PCa.19
* When the patient meets up to at least two factors the patient will be at high-risk.
# Either one of these factors will put the patient at high-risk.
PSA concentration Gleason Score TNM score Risk group
< 10 ng/mL < 7 T1c - T2a Low-risk
10 - 20 ng/mL 7 T2b - c Intermediate-risk*
> 20 ng/mL > 7 T3 High-risk#
1
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When patients are at intermediate- or high-risk, radical prostatectomy will be considered 
(removal of the prostate, seminal vesicles and the vas deferens plus or minus a lymph 
node dissection) or radiation treatment. However, early complications might occur after 
surgery, such as infections, damage to nearby organs, blood clotting in the legs or lungs, 
bleeding and reactions to anesthesia.31 In the long-term, urinary incontinence and erectile 
dysfunction (impotency) might occur.31 Another treatment option is radiation therapy, which 
can be applied for all risk groups and can be divided into two types of therapy: external 
beam radiation therapy (EBRT) and internal radiation (brachytherapy). In the case of locally 
advanced PCa (when PCa starts to spread beyond the prostate) similar treatment options are 
available as for high-risk patients with localized PCa (radical prostatectomy, radiation therapy, 
hormonal therapy or a combination thereof). When the cancer has spread throughout the 
body, this is referred to as metastatic PCa. The most likely spread is to the bones and to the 
lymph nodes.32 Unfortunately, metastatic PCa cannot be cured and the patient will undergo 
palliative treatment such as hormonal therapy with or without additional antiandrogen 
medication (e.g., abiraterone acetate) or chemotherapy.
When considering the clinical pathway of PCa, it becomes clear that there is a demanding 
need for early detection as well as for a good distinction between benign and malignant 
conditions. This is preferably achieved at an early stage in the clinical pathway, during the 
PSA test. Unfortunately, as previously mentioned, this test has shown to lack specificity, 
as increased PSA concentrations can also be induced by BPH or prostatitis,14 resulting in 
unnecessary biopsies. Therefore, there is an urgent need to improve the current clinical 
pathway by implementing an early test that uses a more specific biomarker. Even more 
importantly, there is an urgent need for a biomarker discriminating the aggressive versus non-
aggressive disease in the low PSA ranges (3 - 10 ng/mL). Interestingly, PSA is a glycoprotein 
containing a single N-linked glycosylation site and literature has provided preliminary results 
showing that the analysis of PSA glycosylation could be used as a more refined test for early 
detection of PCa.33-35
PROSTATE-SPECIFIC ANTIGEN
The glycoprotein PSA, also known as human kallikrein 3 (hK3 or KLK-3) or gamma-
seminoprotein, is produced in the prostate gland and is secreted by epithelial cells. PSA is a 
serine protease (cleaving peptide bonds using serine as an active site) that enhances sperm 
motility by liquefying the semen in the coagulum, which is achieved by cleaving semenogelin 
I and II.36,37 Even though the name prostate-specific antigen suggests that the protease is 
prostate-specific, studies have shown that this is actually not the case.38,39 Small amounts of 
PSA have been found in other body fluids and tissues, such as breast milk, amniotic fluid and 
female ejaculate (at similar concentrations as in the semen of male).40-44
| 20 |  
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PSA is a rather complex glycoprotein, present in many different subforms (Figures 1.4 and 
1.5).45,46 PSA starts as a prepropolypeptide (preproPSA) of 261 amino acids and a peptide 
mass of 28,741 Da when it is co-translated in the secretory pathway.45,46 During this process 
the 17-amino acid long prepropolypeptide is cleaved in an inactive proPSA precursor protein 
of 244 amino acids ([-7]ProPSA). However, next to this inactive form several other truncated 
inactive forms of proPSA can be found, here the signal peptides consist either of one or up 
to five amino acids; [-1]proPSA, [-2]proPSA, [-4]proPSA and [-5]proPSA.46,47 After [-7]proPSA 
is secreted, it can be cleaved at the N-terminus in the presence of human kallikrein 2 and 
4 (hK2 and hK4) into active PSA, producing a 237 amino acid long protein (26,072 Da) with 
a single N-linked glycosylation site and five disulphide bridges.48-50 However, the active PSA 
can be internally cleaved at several positions (e.g., 109 - 110, 169 - 170, 206 - 207) resulting 
in benign PSA (bPSA).50-53 This name is derived from the fact that the cleavages are thought 
to be performed post-translationally in hyperplastic BPH tissue and could be a potential 
biomarker for BPH.51 Degradation of the protein, due to proteolysis, will inactivate the PSA 
(iPSA). In seminal fluid, PSA is present at a concentration of 0.4 - 3.0 mg/mL,54 where the major 
subform (30%) is active PSA off which 5% can form complexes (cPSA) with protein C inhibitor, 
PreproPSA -7 -5 -4 -3 -2 -1
10 20 30
M W V P V V F L T L S V T W I G A A P L I L S R I V G G W E
40 50 60
C E K H S Q P W Q V L V A S R G R A V C G G V L V H P Q W V
70 80 90
L T A A H C I R N K S V I L L G R H S L F H P E D T G Q V F
100 110 120
Q V S H S F P H P L Y D M S L L K N R F L R P G D D S S H D
130 140 150
L M L L R L S E P A E L T D A V K V M D L P T Q E P A L G T
160 170 180
T C Y A S G W G S I E P E E F L T P K K L Q C V D L H V I S
190 200 210
N D V C A Q V H P Q K V T K F M L C A G R W T G G K S T C S
220 230 240
G D S G G P L V C N G V L Q G I T S W G S E P C A L P E R P
250 260









Figure 1.4: Amino acid sequence of PSA. Amino acids that are colored light green form the signal peptide, with 
the different truncated forms of proPSA indicated on top. Cysteines are colored orange and dashed lines mark their 
disulphide bridges. The star symbols mark possible internal cleavage sites of bPSA, while the hashtag indicates the 
single N-linked glycosylation site. The underlined amino acids indicate the kallikrein loop.
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Figure 1.5: Biosynthesis of PSA. The synthesis starts in the epithelial cell, where the prepropeptide (preproPSA) 
is co-translationally cleaved into the precursor protein [-7]proPSA. Due to degradation, other truncated variants 
of the precursor can be formed, resulting in [-5]proPSA, [4]proPSA, [-2]proPSA and [-1]proPSA. In the presence of 
hK2 or hK4 the precursor is cleaved and an active protein is generated (active PSA) in the lumen of the prostate 
gland. Due to proteolysis or internal cleavages within the protein, different subforms can be formed (benign 
PSA; bPSA and inactive PSA; iPSA). The presence of disulphide bridges ensures that the different residues remain 
connected resulting in only slight mass deviations and or structure. Finally, a small portion of the active PSA will 
enter the circulation where it will form complexes with protease inhibitors (cPSA). All other subforms that enter 
the circulation will not be inhibited and will remain free (fPSA).
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however, it remains unknown why the remaining active PSA does not form complexes.55,56 
The other 70% of PSA is inactive and consists of non-complexed forms, the so-called free 
PSA (fPSA) and are often derived from other PSA subforms such as proPSA, bPSA and iPSA. 
A relatively small fraction of PSA will enter the circulation where protease inhibitors will 
bind such as α1-antichymotrypsin, α2-macroglobulin, α1-protease inhibitor and protein C 
inhibitor.57 In all cases, cPSA will account for 70 - 90% of the total PSA (tPSA) in the blood 
stream; the remaining 10 - 30% will be fPSA.57 Given that the conventional PSA test is based on 
tPSA levels, an elevated PSA test value does not necessarily mean that more PSA is secreted, 
but rather that a higher amount “leaks” into the circulation.58 In case of PCa, the basement 
membrane as well as the composition of the basal cells is disrupted; this altered luminal 
architecture results in more PSA entering the bloodstream, while escaping proteolytic 
processing at the same time.58,59 Compared to men with BPH, the ratio fPSA / tPSA tends 
to be lower in men with PCa60 and this knowledge has led to the development of several 
different molecular isoform PSA tests in an attempt to outperform the golden standard (tPSA 
concentration) for the early detection of PCa. One of these tests is the so-called percentage 
fPSA (%fPSA)-test, which takes into account the ratio of fPSA compared to tPSA (fPSA/
tPSA).61-63 Another test takes into account the 
percentage of cPSA (%cPSA) compared to fPSA 
(cPSA/fPSA).64-66 The cPSA test and the fPSA 
test seem to slightly improve the specificity in 
the early detection of PCa in tPSA concentrations of 2.5 - 10.0 ng/mL.67,68 However, with 
a sensitivity of 95% the specificity remains low (34%), and with a specificity of 87% the 
sensitivity drastically decreases to 50%.67 Furthermore, no direct correlation can be made 
between the tumor stage and the concentrations of tPSA, fPSA and cPSA, indicating that 
the need for a more specific biomarker, which is able to discriminate between indolent and 
malignant tumors, remains.69 In addition, a mathematical equation has been developed 
to predict the probability of PCa, taking into account the concentration of the pro[-2]PSA, 
fPSA and tPSA (Equation 1.1), also known as the Prostate Health Index (PHI).70,71 Another 
algorithm takes into account patients information (e.g., health status, PSA history, age, DRE, 
prior biopsy status) and the concentration of four kallikrein subforms: tPSA, fPSA, iPSA and 
hK2, also known as the 4K score.72 Recently, a new screening test emerged which does not 
use PSA as an indicator for the disease. This test relies on the presence of the non-coding 
messenger ribonucleic acid (mRNA) of the gene PCA3 in the prostatic fluid as well as in the 
male urine.73-75 The main advantage of this PCA3-test is its independence from prostate 
volume and other confounding factors that might increase PSA concentration even in the 
absence of a tumor.30,76 For detection, a urine sample is collected after DRE, a necessary 
step to ensure the presence of enough prostate cells in the urine sample. While preliminary 
results, especially when combined with the PSA test for improved specificity, are promising,30 
Equation 1.1 𝑃𝐻𝐼 =  
𝑝𝑟𝑜 −2 𝑃𝑆𝐴
𝑓𝑃𝑆𝐴  𝑥 𝑡𝑃𝑆𝐴
1
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it remains unclear whether a non-optimal DRE could result in false positives, and currently 
there is no clear cutoff value which distinguishes PCa from non-PCa patients.77 One of 
the major disadvantages of the PCA3-test is the instability of the mRNA, which limits the 
processing time of the sample (addition of specific inhibitors) to 20 minutes, after which time 
no reliable amounts of mRNA can be retrieved in the sample. All these tests (PHI, 4K score 
and PCA3) reveal similar accuracies for indicating PCa and are able to distinguish different 
stages, providing a better specificity than the tPSA test. Yet, the specificity remains below 
40% with 90% sensitivity.78-80 
Other studies have focused on a specific post-translational modification of PSA: its single 
N-linked glycosylation site (N69). Preliminary results in the diagnosis of PCa when PSA 
glycosylation is taken into account are promising, with features such as sialylation and 
fucosylation being a key attribute.3,34,35 However, a detailed analysis of the molecular 
features of PSA glycosylation (e.g., antennae decoration and core-fucosylation) and their 
potential to improve the PCa diagnosis have not yet been assessed and to fully understand 
the association between PCa and alterations in PSA glycosylation the biosynthetic pathway 
should be studied.
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GLYCOSYLATION
Glycans are compounds consisting of monosaccharides that are linked glycosidically. All 
monosaccharides, except for dihydroxyacetone, have at least one asymmetric carbon atom 
and generally follow the empirical formula Cx(H2O)n;81 where n can vary from three up 
to nine and x  is dependent on the molecule, namely, if it contains either an aldose (x - 2)  
or a ketose (x - 3). In addition, one “simple” aldohexose (C6H12O6) can be present in 16 
different stereoisomers, which is dependent on the number of internal asymmetric carbons 
(24). However, due to a limited availability of glycosyltransferases, the most common 
monosaccharides found in the human body are limited to seven (Figure 1.6).82,83 
Glycans can be found attached to different biomolecules, generating glycolipids (attachment 
to a lipid), N-linked glycosylated proteins (attachment of the glycan through a nitrogen atom) 
and O-linked glycosylated proteins (attachment of the glycan through an oxygen atom). 
While there is no clear amino acid sequence consensus for O-linked glycosylation (the glycan 
attaches to the amino acids serine or threonine), the addition of N-linked glycans to a protein 
is directed by the presence of the sequon asparagine - X - serine or threonine (Asn - Xxx - Ser/
Thr or N - X - S/T), where X can be any of the amino acids with the exception of proline (Pro or 
P). Nonetheless, it should be noted that, depending on the conformation of the glycoprotein, 
not every sequon that meets the requirements will actually be occupied.
Figure 1.6: Most common monosaccharides in the human body. The corresponding symbols are illustrated as 
defined by the Consortium of Functional Glycomics.83
1
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BIOSYNTHETIC PATHWAY OF N-LINKED GLYCOSYLATION
The start of the biosynthetic pathway of glycoproteins takes place inside the eukaryotic cells 
at the membrane of the endoplasmic reticulum (ER) (Figure 1.8).82 The first phase starts in the 
cytoplasm, where a lipid carrier (dolichol; dol) containing a single phosphate (P) is attached 
to the membrane. Through a pyrophosphate linkage, a GlcNAc with an additional phosphate 
is attached and the structure is extended up to Dol-P-GlcNAc2Man3 in the presence of uridine 
diphosphate N-acetylglucosamine (UDP-GlcNAc) and guanosine diphosphate mannose (GDP-
Man). In addition, the analyte is translocated from the cytoplasmic side towards the luminal 
side of the ER, starting the second phase of constructing the precursor glycan. During this 
phase, more monosaccharides are added via residue donors (Dol-P-Man and Dol-P-Glc) 
resulting in the final structure Dol-P-GlcNAc2Man9Glc3 (Figure 1.7).
82
Via an oligosaccharyltransferase (OST) the glycan is transferred to the nitrogen atom on the 
Asn side chain of the polypeptide (available on the luminal side of the ER) containing the 
sequon N - X - S/T or in rare cases the sequon N - X - C. From this point, the glycan is trimmed 
by α-glucosidase I (an exoglycosidase, which sequentially removes the terminal α1,2-linked 
glucose) and α-glucosidase II (which sequentially removes the α1,3-linked glucoses), while the 
chaperones calnexin (CNS) and calreticulin (CRT) ensure the monoglucosylated glycoprotein 
is retained in the ER until properly folded (misfolding will cause reglucosylation by UDP-
Glc). Due to the addition of the N-glycan, the physical properties of the glycoprotein will be 
modified (e.g., its solubility, see Section Biological Role of N-linked Glycans of Chapter 1), 
as a large, non-charged, hydrophilic molecule is added to the protein. Only after successful 
folding the glycoprotein will be released from its chaperones by α-glucosidase II and will 
be translocated into the Golgi apparatus for further processing, resulting in a glycoprotein 
with a glycan composition of GlcNAc2Man8-9. The number of Man is mainly dependent on 
the presence of the α-mannosidase in the ER, as this enzyme is able to remove the α1,2-
linked mannose on the central arm of the N-glycan. Moreover, some incompletely processed 
glycoproteins with glucoses still attached may find their way to the Golgi apparatus. In this 
case the presence of endo-α-mannosidase can ensure the removal of the glucose by cleaving 
Figure 1.7: Final glycan structure attached to a dolichol (lipid) phosphate before it is being translocated onto 
a polypeptide.82
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Figure 1.8: Biosynthetic pathway of the formation of a N-linked glycoprotein within an eukaryotic cell. 
The first stage of the synthesis takes place in the endoplasmatic reticulum where a glycan is attached to a lipid 
(dolichol). In the second stage the glycan will be transferred from the lipid onto a polypeptide. After properly 
folding of the glycoprotein the third stage is initiated where the molecule is translocated to the Golgi apparatus. 
Specific exoglycosidases, endoglycosidases and glycosyltransferases define the final structure of the N-glycan on 
the protein before being secreted by the eukaryotic cells.82
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between the mannoses that are α1,2-linked. Dependent on the position of the glycoprotein 
in the Golgi apparatus (cis-, medial- or trans-Golgi) different enzymes will be present. In the 
cis-Golgi mannoses will be trimmed from the glycoprotein by α1,2-mannosidases, generating 
glycans with composition GlcNAc2Man5-9 (Figure 1.9.A), while the formation of hybrid and 
complex N-glycans is initiated in the medial-Golgi. Here, a GlcNAc is added to the α1,3-linked 
mannose (C-2 position) on the trimannosyl core by the N-acetylglucosaminyltransferase 
(GlcNAcT-I). Further trimming of the α1,3- and α1,6-mannoses (present on the terminal end 
of the N-glycan) is performed by α-mannosidase II. A reversed order would not be possible 
as the α-mannosidase II only acts after GlcNAcT-I. Subsequently, GlcNAcT-II ensures to add 
a GlcNAc to the now freely available α1,6-linked mannose (C-2 position) of the trimannosyl 
core furthering the synthesis of a complex N-glycan. When α-mannosidase II does not come 
into action, the mannoses remain in their position resulting in a hybrid N-glycan structure 
with one arm being high mannose and the other arm being complex (Figure 1.9.B). Bisection 
may occur in the medial-Golgi on the hybrid and complex N-glycans by GlcNAcT-III, which 
adds a GlcNAc to the β-mannose of the trimannosyl core. Finally, after the N-glycosylated 
protein is transferred into the trans-Golgi, the N-glycan structures are further extended by 
the addition of one or more GlcNAc, Gal, Fuc and Neu5Ac residues resulting in complex 
N-glycans (Figure 1.9.C). Further branching of the N-glycan may occur on the α1,3- (C-4 
position) and α1,6- (C-6 position) linked mannose on the trimannosyl core by GlcNAcT-IV and 





























HIGH MANNOSE HYBRID COMPLEX
A. B. C.
Figure 1.9: Different subspecies of N-linked glycosylation found on human proteins. (A) High mannose type, (B) 
complex type and (C) hybrid type. All subtypes contain the same trimannosyl core (Man3HexNAc2).
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GlcNAcT-V, respectively, producing tri- or tetra-antennary N-glycans. The addition of Gal to 
the GlcNAc is initiated by β1,4-galactosyltransferases (β4GalT), while a fucose can be either 
added to the innermost GlcNAc of the chitobiose core via α1,6-fucosyltransferase (FUT8) 
or to the GlcNAc present on the antenna via an α1,3 linkage initiated by the α1,3-/α1,4- 
fucosyltransferase (FUT3). The addition of N-acetylneuraminic acids is performed by α2,3-, 
α2,6- and α2,8-sialyltransferases. α2,3-linked Neu5Ac can only be found on Gal residues (by 
ST3Gal), while α2,6-linked Neu5Ac can be either inked to a Gal or to a GalNAc by ST6Gal and 
ST6GalNAc, respectively; the α2,8-linkage is only possible on α2,3-linked Neu5Ac, and it is 
performed by ST8Sia3)82. It needs to be noted that N-glycans that were not fully processed 
in the cis-Golgi to GlcNAc2Man5 cannot be synthesized into hybrid or complex structures, but 
remain as oligomannosidic N-glycans. 
This broad overview on the biosynthetic pathway of N-glycan formation in mammalian 
cells does not cover the entire variety of N-glycans, whose complexity is often regulated 
in a cell-type specific manner via the presence of specific transferases that e.g., introduce 
branches and extended branches with poly-Gal-GlcNAc units (LacNAc repeats). Also, protein 
glycosylation differs between organisms as illustrated in Figure 1.10. 























Core fucosyla�on (α1,3/6) - an�genic to humans
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A glycoprotein will present glycosylation macroheterogeneity when multiple N-linked 
glycosylation sites are found on a glycoprotein; furthermore, different N-glycans can be 
detected on a single glycosylation site, or the site can even be found unoccupied. This is 
known as glycosylation microheterogeneity (Figure 1.11.A and B). However, it remains still 
unclear where this array of different compositions and isomers originates from. Most likely 
different aspects play a role such as the competition between enzymes during the glycan 
biosynthesis as well as differences between cells and cell types, where every cell delivers a 
specific glycosylation. 
BIOLOGICAL ROLE OF N-LINKED GLYCANS
Next to their extensive diversity in composition, N-glycans also have a wide range of effects 
on the properties of a glycoprotein: from protein folding to the alteration of its physiological 
state, its recognition and interaction with pathogens, lectins and toxins, as glycans are 
often the first contact in cellular interactions.82,84 For example, the main functions of the 
antibody immunoglobulin G (IgG) in the immune system are the binding to pathogens and 
the neutralization of toxins, ensuring that the human body is protected from infection.82 
However, numerous studies have shown that the efficacy of defense mechanisms is highly 
dependent on which glycosylation features are present on the antibody, with Fc (fragment 
crystallizable) receptors for protein-protein interaction being hampered or stimulated 
by glycans and resulting thus in either pro- or anti-inflammatory responses.85,86 The main 
glycosylation features contributing to this aspect are core-fucosylation,86 galactosylation87,88 
and sialylation.88 Next to inflammation, several studies have shown that changes in 
glycosylation can be associated with various autoimmune diseases and cancer.84,87,89,90 
It remains unclear whether changes in the glycosylation promote the disease or the 
disease induces glycosylation changes, a topic where more in-depth studies are needed to 




Figure 1.11: Macro- versus microheterogeneity of a glycoprotein. (A) Macroheterogeneity is the heterogeneity 
of a glycoprotein based on different N-linked glycosylation sites. (B) Microheterogeneity is the variety in different 
N-glycan structures that can be found on a single N-linked glycosylation site.
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the changes in micro-, and macroheterogeneity in glycosylation of specific proteins might 
provide a better correlation to specific disease features, compared to concentration changes 
related to the protein on its own. Because the synthesis of N-linked glycans occurs in 
eukaryotic cells, the glycan diversity mirrors the physiological state of the cells themselves 
and, ultimately, depicts lifestyle, age, gender and certainly also pathologies related to the 
organism itself. For example, an aberrant regulation of the cells, like in the case of cancer, 
will be marked by altered protein glycosylation: in this case the biological marker is known 
as a glycan biomarker.91-93
Interestingly, of the few serum cancer biomarkers currently Food and Drug Administration 
(FDA)-approved, most are glycoproteins.94 The group is rather heterogeneous, ranging in 
the number of glycosylation sites (from 1 to many) and in the specificity for a given type 
of cancer;94 so, while α-fetoprotein (AFP) has one single N-linked glycosylation site and is 
specific for e.g., hepatocellular cancer and testicular cancer, human epidermal growth 
factor receptor 2 (HER2) is specific for breast cancer, but displays potentially 13 N-linked 
glycosylation sites; thyroglobulin is specific for thyroid cancer, with potentially 17 N-linked 
and a single O-linked glycosylation site, and carcinoembryonic antigen (CEA) has a broad 
specificity for several types of cancers (e.g., colon, gastric, pancreatic, lung and breast cancer) 
with 28 potential N-linked glycosylation sites. High concentrations of these biomarkers often 
indicate a poor prognosis and provide an indication for the clinician to further investigate 
and treat the patient with a more aggressive treatment. However, in the case of early stage 
cancers these biomarkers often lack specificity and sensitivity.95,96 Therefore, the study of 
the alterations in the glycosylation of these biomarkers could further improve the diagnostic 
and prognostic performance of the current assays. The main changes found in glycosylation 
seem to be related to fucosylation, sialylation and bisection.97 The combination of the protein 
concentration with the levels of these glycan features could be used as a more defined 
biomarker for specific types of cancer. 
GLYCAN BIOMARKER DISCOVERY IN PROSTATE CANCER
The glycosylation pattern of PSA, also an FDA-approved biomarker, with a single N-linked 
glycosylation site, is getting more attention as several studies have shown the glycosylation 
to be altered in features such as sialylation and fucosylation.
SIALYLATION
One of the most intriguing changes in the glycosylation of PSA is the variation in linkages of 
the sialic acids and their abundance.98 The percentage of α2,3-linked sialic acids was recently 
evaluated as potential glycan biomarker (the so-called %α2,3-Neu5Ac-test); during this 
study, high-risk PCa patients could be distinguished from intermediate-risk PCa, low-risk PCa 
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and BPH patients.99 When the %α2,3-Neu5Ac-test was combined with PHI a 100% sensitivity 
and 94.7% specificity was found.100 This work was further supported by the research from 
Yoneyama et al., where the amount of α2,3-linked sialic acids was quantified using a magnetic 
microbead-based immunoassay.3 This study is of particular interest, as it focused on patients 
that had PSA levels in the grey zone (2.0 - 10.0 ng/mL), and an increased level of α2,3-linked 
sialic acids was found in the PCa patients compared to non-PCa patients. The validation 
sample set (176 non-PCa and 138 PCa patients) showed a sensitivity cutoff value of 90.6%, a 
specificity of 64.2% for their developed immunoassay with a specificity of 20.5% and 11.4% 
found for the PSA test and %fPSA test, respectively.
Interestingly, the analysis of cell lines from lymph node carcinoma of the prostate (LNCaP, 
derived from a metastastic lesion from a human adenocarcinoma of the prostate) revealed 
minor levels of sialylation, while PSA derived from seminal plasma of healthy volunteers 
contained a large amount of di-sialylated N-glycans.34 Even though differences are found, 
these might reflect the differences in origin of the sample rather than differentiation 
between PCa and non-PCa.
FUCOSYLATION
Saldova et al. explored the total serum N-glycome (TSNG) of PCa and BPH patients, and 
found an increase in core-fucosylation for the PCa patients.35 Furthermore, antenna 
fucosylation in high branched N-glycan structures appeared to be decreased in patients with 
a Gleason score of 7, when compared to patients with a Gleason score of 5, and provided 
a better discrimination between indolent and aggressive PCa. Significant differences were 
found between PSA fucosylation in serum for PCa patients with Gleason score 6, when 
compared to patients with a Gleason score > 6 (7 - 9),101 thus indicating that an increased 
amount of fucosylation correlated with the aggressiveness of the PCa. Overall, this method 
provided a better prediction compared to the gold standard (PSA test), especially when the 
percentage of fucosylated PSA was used (%fucPSA/tPSA). However, this study did not 
provide information whether the increased fucosylation was derived from core-fucosylation, 
antenna fucosylation or a combination of the two. 
Several studies have shown an increase in fucosylation for PCa patients compared to BPH 
patients using the lectin Ulex europaeus (UEA-1), which specifically binds to the fucose that 
is α1,2-linked to a galactose.102,103 In addition, one of these studies revealed an increase in 
N-acetylgalactosamine for PCa patients implying that next to an increased expression of 
the transferase, fucosyltransferase I (FUT1) there is also an increased expression of β-N-
acetylgalactosaminyltransferase 4 (β4GalNAcT4).103
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Vermassen et al. have extensively studied the urinary glycosylation and showed an overall 
decrease in core-fucosylation of multiantennary N-glycans (di-, tri- and tretra-antennary) 
and total tri-antennary N-glycans for PCa patients compared to healthy volunteers and BPH 
patients.5,104,105 This observation lead to the development of a urinary glycoprofile marker 
(UGM; Equation 1.2). The use of the UGM enabled the discrimination of PCa patients from 
BPH patients and remained significant when only patients with PSA concentration in the grey 
zone (4 - 10 ng/mL) were taken into account. However, it should be noted that the prostate 
volume on its own resulted in a significant difference between the two patient groups. In 
addition, the sialylation was not taken into account, as the samples were desialylated prior 
to analysis.
In conclusion, these studies, focusing on total glycosylation from either urine or serum, would 
be further improved when protein specific alterations are taken into account. In addition, 
most of the abovementioned studies used assays that were not able to study in-depth the 
diversity of the N-linked glycosylation of PSA. For example, it remains rather unclear whether 
the higher abundance of α2,3-linked sialic acids results in an overall lower abundance of the 
α2,6-linked sialic acids and which N-glycans are involved in these major changes. Therefore, 
more defined glycan biomarkers should be investigated that will hopefully show potential in 
reflecting or predicting the progression of a disease.
Equation 1.2 𝑈𝐺𝑀 =  
𝑛𝑜𝑛 − 𝑓𝑢𝑐𝑜𝑠𝑦𝑙𝑎𝑡𝑒𝑑 𝑚𝑢𝑙𝑡𝑖𝑎𝑛𝑡𝑒𝑛𝑛𝑎𝑟𝑦 𝑁 − 𝑔𝑙𝑦𝑐𝑎𝑛𝑠
𝑡𝑜𝑡𝑎𝑙 𝑡𝑟𝑖𝑎𝑛𝑡𝑒𝑛𝑛𝑎𝑟𝑦 𝑁 − 𝑔𝑙𝑦𝑐𝑎𝑛𝑠 𝑝𝑟𝑜𝑠𝑡𝑎𝑡𝑒 𝑣𝑜𝑙𝑢𝑚𝑒 (𝑚𝐿)�
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ANALYTICAL METHODS 
High microheterogeneity hinders, especially in combination with macroheterogeneity, the 
identification of the glycan structures, especially when isomers are concerned. However, 
recent technical advances show high analytical potential as more progress is being made for 
quantitative analysis (implementation of standards) and more in-depth analytical platforms 
have become available.106,107 
Many different analytical platforms have been developed, and have shown their 
complementarity when it comes to the detection of glycans. Researchers can rely on 
high-throughput methods like MALDI-TOF-MS (matrix-assisted laser/desorption ionization 
time-of-flight mass spectrometry) and microarrays, as well as isomeric elucidation with 
NMR spectroscopy (nuclear magnetic resonance). The extra dimension offered by coupling 
separation techniques to high accuracy mass detectors often results in higher sensitivity and 
more exhaustive glycan information. Among the separation techniques, liquid chromatography 
(LC), porous graphitized carbon (PGC), hydrophilic interaction liquid chromatography (HILIC) 
and capillary electrophoresis (CE) should be noted; while high accuracy mass detection relies on 
techniques such as TOF, orbitrap and Fourier-transform ion cyclotron resonance (FT-ICR) MS. 






Figure 1.12: General CE setup.
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CAPILLARY ELECTROPHORESIS
Nobel prize winner Arne W.K. Tiselius introduced for the very first time electrophoresis as a 
separation mechanism in 1937 with the development of the “Tiselius apparatus”.108 However, 
the separation efficiency was restricted due to thermal conduction. In 1967, Hjertén explored 
the use of open tube electrophoresis and found that narrow capillaries resulted in minor 
Joule heating due to the low conductivity they offer, enabling the use of high electrical fields 
with only minor heat generation.109 This characteristic was further explored with Teflon 
capillaries (internal diameter (i.d.) of approximately 200 µm)110 and glass capillaries (i.d. of 
approximately 75 µm): it was the beginning of CE as an analytical technique.111 Nowadays, 
capillaries with an i.d. of 25 - 150 µm are used, providing fast analysis, high efficiency and a 
high-resolution power. The overall configuration of a CE platform is rather straightforward 
(Figure 1.12), with a bare fused capillary, filled with buffer and both ends placed in buffer 
reservoirs. A sample can be loaded into the capillary by either applying an external pressure 
(hydrodynamic injection) or applying an electric field (electrokinetic injection). After sample 
loading, separation can be performed by applying a voltage (10  - 30 kV): a high electrical 
field (100 up to 500 V/cm) is generated between the two extremities of the capillary and 
the separation of the analytes will be dependent on the charge of the ion (q), the viscosity 
of the buffer (n) and the radius of the ion (r). The rate of migration of the charged analytes 
within the electric field, known as electrophoretic mobility (µe ) can be calculated according 
to Equation 1.3. The equation shows the inverse relation between mass and charge with 
regards to migration time. A higher mass will result in a longer migrationtime whereas an 
increase in charge reduces the migration time. However, this formula is applicable only in the 
case of a fully ionized molecule (α- 1) ; in all other cases, the degree of ionization of a molecule 
(which depends on its pKa and buffer properties like pH, ionic strength and concentration), 
is introduced as a coefficient to calculate the effective mobility (µeff ) (Equation 1.4). The 
application of a voltage is responsible for the flow of liquid across the capillary, known as 
electro-osmotic flow (EOF): the mobility of this flow (µEOF ) depends on the capillary material, 
capillary coating, the applied voltage as well as the composition of the buffer. The mobility of 
the analyte will depend on the combination of its effective mobility and that of the EOF. The 
time an analyte needs to reach the detector is called migration time (mt). The mobility of the 
analyte (µa ) can be calculated using its mt and the used experimental settings (Equation 1.5). 
In most cases, fused silica capillaries are used, which contain silanol groups, these groups 
get deprotonated at high pH and the capillary surface will be negatively charged. Based 
Equation 1.3 




= charge of the ion
= viscosity of the buffer






𝜇𝑒𝑓𝑓  =  µ𝑒  �  𝑎𝑖
= effective mobility
= electrophoretic mobility
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on Coulombs law, cationic analytes will migrate towards the cathode and anionic analytes 
will migrate towards the anode. In addition, based on Equation 1.3 and 1.6, the highly 
charged and small analytes will move fast while analytes with lower charges as well as larger 
analytes will move slowly through the capillary. The presence of cations in the buffer will 
form an electric double layer at the capillary wall and by applying an electric field, a potential 
difference will be generated at the capillary wall, also known as the zeta-potential (ζ). The 
cations of the buffer will migrate towards the cathode and due to their solvation it will take 
the bulk solution along resulting in a flat profile due to the rather uniform velocity within the 
capillary (Figure 1.13.A). In addition, when the EOF moves towards the detector, it takes the 
neutral analytes along and when normal polarity is applied (detector at the cathode), anions 
can be detected when they have a lower µeff than the velocity of the EOF (vEOF ). However, 
when the solution is pressure driven, the flow velocity will have a more parabolic distribution 
(e.g., as in LC), resulting in more band broadening, loss in resolution as well as sensitivity 
(Figure 1.13.B).
Even though there are numerous separation modes for CE available (e.g., capillary gel 
electrophoresis (CGE), capillary electrochromatography (CEC), micellar electrokinetic 
chromatography (MEKC), capillary iso-electrofocusing (CIEF)), the most common mode 
Equation 1.5 
𝜇𝑎  =  
𝑙
𝑡𝑎𝐸
 =  
𝑙𝐿
𝑡𝑎𝑉
= electrophoretic mobility of the analyte (𝜇𝑒 + 𝜇𝐸𝑂𝐹)
= effective capillary length (until detector, cm)
= migration time of the analyte (sec)
= electric field (V/cm)
= total capillary length (cm)








𝑣 =  µ𝑒  �  𝐸
= velocity of the analyte
= electrophoretic mobility




Figure 1.13: Flow velocity profiles obtained with either (A) electro-osmotic flow or (B) pressure driven flow.
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of operation is capillary zone electrophoresis (CZE). This technique uses a background 
electrolyte as buffer to enable separation in the capillary. Dependent on the velocity of the 
analytes, different zones will be generated (Equation 1.4). 
TRANSIENT ISOTACHOPHORESIS
Sample loading is seen as one of the main limiting factors in CE as normally no more than 
1 - 2% of the capillary volume can be used for sample loading to limit band broadening. 
This results in a loss of sensitivity compared to other separation techniques, such as LC. 
The implementation of isotachophoresis (ITP) can increase the loadability of the sample, 
providing an improved sensitivity.112 The use of two co-ions with different mobilities, the 
leading electrolyte (LE, fastest mobility) and the terminating electrolyte (TE, slowest mobility) 
allows the analytes of interest to form zones behind the LE with the same velocity of the 
LE.113 This occurs due to the differences in electric field per zone, where the highest mobility 
has the lowest field strength. Furthermore, dependent on the concentration of the LE, the 
concentration of each zone is determined; analytes that would be less concentrated will 
form sharper peaks to ensure a similar and constant concentration of the zone. Based on this 
principle, 30 - 50% of the capillary can be filled while maintaining proper resolution.114 When 
ITP is used as an on-line pre-concentration step, the technique is referred to as transient-ITP 
(t-ITP), where the LE is normally injected prior or together with the sample. After the t-ITP 
process, the analytes in the individual zones will migrate and separate based on the CZE 
principle.115
CAPILLARY ZONE ELECTROPHORESIS AND GLYCAN ANALYSIS
Already since the early 1990s CE has proven to be an excellent separation technique for 
monosaccharides in combination with a laser induced fluorescence detector (CE-LIF).116 
This is mainly due to the high-resolution power of CE and the excellent sensitivity of the 
LIF detector. With this platform, isomeric variants can be elucidated based on migration 
behavior. Since the separation of neutral glycans is often less effective, N-glycan mixtures 
are modified by reductive amination with 8-aminopyrene-1,3,6-trisulfonic acid (APTS), 
which introduces a negative charge. However, the identification of new analytes remains a 
time-consuming task, as several experiments are needed to enzymatically release specific 
monosaccharides of the N-glycans. In addition, CE-LIF lacks the ability to provide information 
when it comes to mass precision and separation of co-migrating analytes in complex 
mixtures. The hyphenation of CE to mass spectrometry (MS) combines the advantages of 
both techniques (the high separation power of CE and the ability of MS to elucidate complex 
analytes), providing structural information of the separated glycans. It should be noted that 
detection with MS relies on the analytes being in the gas phase, while CE separation is based 
in the liquid phase: to couple these two techniques, electrospray ionization (ESI) is often used. 
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Figure 1.14: Schematic overview of different interfaces to couple CE to MS (via ESI): (A) sheath liquid interface, 
(B) liquid junction interface and a (C) sheathless interface.
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CAPILLARY ELECTROPHORESIS - ELECTROSPRAY IONIZATION - MASS 
SPECTROMETRY
Even though CE-MS was established for the first time in 1987,117 the coupling of the two 
platforms remains a challenge. As both CE and ESI are electrically driven, it is difficult to 
maintain a closed circuit for CE, given the different polarities and the large difference in 
applied voltages often needed for both techniques. Nowadays, the most common interfaces 
are sheath liquid,118 liquid junction119 and the sheathless interface120 (Figure 1.14). Depending 
on the sample, research question and stability, each interface has its advantages and 
disadvantages. For example, the sheath liquid interface provides easy handling, reliability and 
flexibility regarding the usage of buffers and the liquid that can be used for the sheath flow. 
The liquid junction interface improves stability, but hampers the separation efficiency by 
band broadening. The main disadvantage for both interfaces is the usage of a make-up flow 
to maintain the closed circuit. As this make-up flow is added at the very end of the capillary, 
the sample will be diluted prior to detection, hampering the previously obtained sensitivity 
that CE can deliver and resulting in higher detection limits. The sheathless interface avoids 
the use of a make-up flow and enables separation and a stable spray at very low flow rates, 
allowing for increased sensitivity and an overall improvement in resolution. 
Figure 1.15: Different approaches for identifying the glycosylation of a protein with mass spectrometry.
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MASS SPECTROMETRY IN GLYCOMICS
Mass spectrometry (MS) is a well-known and widely applied technique for the detection 
and identification of analytes, enabling the separation of ionized compounds based on the 
ratio between their mass (m) and electric charge (z): m/z (measured in Thomsons (Th)). Each 
mass spectrometer should at least contain an ion source, one or several mass analyzers and 
a detector. Dependent on the research question, different mass analyzers can be used such 
as a quadrupole (Q), TOF, ion trap (IT), FT-ICR mass analyzers or a combination of these.121,122
To investigate the glycosylation of a protein several approaches can be used, as illustrated in 
Figure 1.15. The analysis of intact glycoproteins is especially of interest when the glycoprotein 
can be present in different isoforms. However, it should be noted that identification would 
be complicated when non-pure substances are used. In contrast, glycan analysis allows the 
analysis of complex mixtures by releasing the glycans from the proteins. Here, N-linked 
glycans are often released with the enzyme peptide-N-glycosidase F (PNGase F) providing a 
free reducing end. Unfortunately, there is currently no known enzyme which allows a similar 
approach for the release of O-glycans, therefore, a chemical approach is applied; reductive 
β-elimination.123,124 The disadvantage of the glycan release is the loss of protein information; 
after release all information is lost about the origin of the glycan such as protein specificity and 
site specificity. By digesting the glycoprotein into glycopeptides and peptides, the advantages 
of both approaches, the 
intact and the released 
glycans, are combined, 
providing information 
about site specificity and 
protein specificity when 
unique peptide backbones 
are produced for a specific 
glycoprotein. However, 
it should be noted that 
the obtained data can be 
rather complex, especially 
when there is a large 
microheterogeneity. To 
provide more certainty on 
the structural composition of 
a glycan or glycopeptide, next 
to mass alone, tandem MS 
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Figure 1.16: Fragmentation of a peptide (top panel) and which 
fragment ions are induced (lower panel). The subscript indicates 
the number of residues from the N-terminus (a, b and c ions) or the 
C-terminus (x, y and z ions). 
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GLYCAN AND GLYCOPEPTIDE FRAGMENTATION
As the name already implies, MS/MS consists at least out of two mass analyzers. Here, the 
first mass analyzer will isolate the ion (precursor ion) and the second mass analyzer will 
fragment the precursor ion into product ions. When a peptide is being fragmented (Figure 
1.16),125,126 the fragments will either correspond to the N-terminus (NH2) or the C-terminus 
(COOH) of the peptide. For the N-terminus the fragments are categorized as a, b or c ions, 
while the fragments from the C-terminus are called either x, y or z ions. The subscript 
indicates the number of residues from the terminus. It should be noted that fragmentation 
can be induced via different techniques and the technique defines which fragment ions can 
be observed. For electron transfer dissociation (ETD) and electron capture dissociation (ECD) 
mainly c and z-type ions are detected, while the most commonly used technique, collision 
induced dissociation (CID), results in b and y-type ions.127 Furthermore, dependent on the 
ionization technique, peptides are able to carry more than a single charge (e.g., more than 
one proton).
The nomenclature of glycan fragmentation was already established by Domon and 
Costello in 1988 (Figure 1-17).128 Compared to peptide fragmentation, a similar trend for 
the fragmentation of glycans can be observed. Here, A, B and C ions are the fragments 
corresponding to the terminal (non-reducing end) of the glycan moiety, while the X, Y and Z 
ions present the fragments from the non-reducing end. Next to the subscript, which indicates 
the position, internal ring cleavages are illustrated by a superscript. Dependent on the glycan 
composition fragmentation provides information whether it is composed of deoxyhexoses, 
hexoses, N-acetylhexosamines and N-acetylneuraminic acids (Table 1.3). However, it is not 
capable to reveal from which isomeric hexose or N-acetylhexosamine it is composed of. Some 
C0,C2A1 B1 C1 C2,C4A2 B2 C2 C2,C5A3 B3 C3
Y2 Z2 C1-C5X1 Y1 Z1 C1-C5X0 Y0 Z0
Figure 1.17: Fragmentation of a glycan species. The subscript indicates the position to either the terminal (A, B 
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studies suggest that information regarding the linkages between different monosaccharide 
residues can be defined by diagnostic oxonium ions, which seem to be more distinct in 
negative ionization mode compared to positive ionization mode.129,130 For the analysis of 
glycopeptides, the fragmentation pattern can be more related to the fragmentation of the 
peptide backbone or the glycan moiety. However, this is highly dependent on the chosen 
fragmentation technique (Figure 1.18). When conventional CID is chosen, the fragmentation 
spectra will mainly contain information regarding the glycan moiety that is attached to the 
peptide and no information will be available about the peptide backbone.127,131 On the other 
hand, ETD or ECD do provide the necessary information about the peptide backbone and, 
in addition, enable the identification on which residue the glycan is attached.127 This could 
be of great use when site-occupancy needs to be determined or identification is needed 
on which amino acid residue the O-glycan is attached. However, other information about 
the glycan, such as which monosaccharides residues are present and in which order, is not 
possible. An intermediate approach would be the use of a stepping energy in either CID or 
higher-energy CID (HCD).132 Here, lower-energy and higher-energy are alternated, enabling 
complex fragmentation patterns containing information about the complete glycopeptide. 
In summary, the combination of CE-ESI-MS allows to study protein glycosylation in an in-depth 
manner, with high sensitivity, and on different levels (e.g., intact, bottom-up or released). 
Next to this, MS/MS allows the elucidation of the glycan structure by fragmentation, 
which can shed light on the functionality as well as the biology of relevant proteins such 
as PSA (and other potential glycosylated cancer markers). Specific cancer characteristics 
can be discovered and evaluated if differences are observed in the glycosylation of these 
glycoproteins between patients groups (e.g., BPH, indolent and malignant PCa tumors). 
Table 1.3: Monosaccharide residues that are most abundant in humans.







Deoxyhexose dHex dF C6H10O4 146.0579
Fucose Fuc F C6H10O4 146.0579
Hexose Hex H C6H10O5 162.0528
Glucose Glu H C6H10O5 162.0528
Mannose Man H C6H10O5 162.0528
Galactose Gal H C6H10O5 162.0528
N-acetylhexosamine HexNAc N C8H13NO5 203.0794
N-acetylglucosamine GlcNAc N C8H13NO5 203.0794
N-acetylgalactosamine GalNAc N C8H13NO5 203.0794
N-acetylneuraminic acid Neu5Ac S C11H17NO9 291.0954
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STEPPING CID/HCD HCDCID
Iden�fica�on of glycan moiety, 
composi�on and branching
Iden�fica�on of glycan moiety, 
composi�on, branching 
and pep�de moiety
Iden�fica�on of pep�de 
backbone and glycosyla�on site
No informa�on regarding 
pep�de backbone Complex fragmenta�on pa�erns
No informa�on regarding the
glycan moiety
Figure 1.18: Fragmentation patterns of a glycopeptide, dependent on the applied fragmentation method.
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SCOPE
The aim of this thesis is to explore the glycosylation of PSA as well as to study if alterations 
can be observed between patients with indolent and malignant PCa. For this purpose the 
powerful analytical platform CE-ESI-MS(/MS) was explored with a special focus on the analysis 
of glycan and glycopeptides, by employing a porous nano-sprayer for the MS coupling. 
The first part of this thesis includes a general overview on PCa from the clinical perspective, 
as well as a focus on the glycobiology of PSA and its potential as a biomarker. Furthermore, 
an introduction to the CE-ESI-MS platform is provided (Chapter 1). Chapters 2 and 3 
describe the different method developments that have been implemented for the analysis 
of PSA with CE-ESI-MS. As literature has shown that differently linked sialic acids could 
potentially be better biomarkers compared to the conventional PSA test (which is based 
on the concentration of the glycoprotein in the circulation), the first aim was to investigate 
if differently linked sialic acids could be separated with CE-ESI-MS on a glycopeptide level, 
without any additional sample treatment, as well as to identify which N-glycans could 
be expected on the single N-linked glycosylation site of PSA (Chapter 2). Furthermore, 
the sensitivity of the test was assessed in Chapter 3, where the introduction of a dopant 
enriched nitrogen (DEN) gas between the CE and the MS was explored to see how this could 
improve the limit of detection (sensitivity) of glycopeptides. The last chapter (Chapter 4) 
of the method development section includes the novel labeling procedure of total plasma 
N-glycome with the hydrazide Girard’s reagent P in combination with the DEN-gas developed 
in Chapter 3. Furthermore, this research explored the additional benefit of CE-ESI-MS 
compared to the conventional and high-throughput MALDI-TOF-MS platform. 
The last section of this thesis is focused on the application of PSA glycosylation analysis and 
its correlation with PCa. Chapter 5 describes the development of a PSA Glycomics Assay 
which allows the capture of intact PSA from patients urine followed by tryptic digestion 
and the analysis with the optimized CE-ESI-MS platform (Chapters 2 and 3). This approach 
allows to investigate the glycosylation of PSA in-depth on a glycopeptide level and explores 
glycosylation features that would hopefully enable the distinction between patients with 
BPH and PCa and, of more interest, between indolent and aggressive PCa.
Finally, Chapter 6 offers a general discussion about future developments as well as the 
potential of PSA glycosylation in the clinical setting, showing the relevance of our results and 
how these may contribute to further clinical applications towards personalized medicine.

2
Based on Guinevere S.M. Kammeijer, Bas C. Jansen, Isabelle Kohler, Anthonius A.M. Heemskerk, Oleg A. 
Mayboroda, Paul J. Hensbergen, Julie Schappler, Manfred Wuhrer, “Sialic Acid Linkage Differentiation of 
Glycopeptides using Capillary Electrophoresis - Electrospray Ionization - Mass Spectrometry”, Scientific Reports 
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Sialylation is a glycosylation feature that occurs in different linkages at the non-reducing end of 
a glycan moiety, the linkage isomers are often differentially associated with various biological 
processes. Due to very similar physico-chemical properties, the separation of isomeric 
sialylated glycopeptides remains challenging but of utmost importance in the biomedicine 
and biotechnology, including biomarker discovery, glyco-engineering and biopharmaceutical 
characterization. This study presents the implementation of a high-resolution separation 
platform based on capillary electrophoresis - electrospray ionization - mass spectrometry 
(CE-ESI-MS) allowing for the selective analysis of α2,3- and α2,6-sialylated glycopeptides. 
These differentially linked glycopeptides showed an identical fragmentation pattern 
(collision induced dissociation) but different electrophoretic mobilities, allowing for baseline 
separation of the different linkages without the need for an extensive sample preparation. 
The different migration behavior between the two moieties was found to correlate with 
differences in pKa values. Using a novel methodology adapted from the so-called internal 
standard CE approach, a relative difference of 3.4·10
-2 in pKa unit was determined. This 
approach was applied for the analysis of tryptic glycopeptides of prostate-specific antigen, 
which shows highly complex and heterogeneous glycosylation. The developed platform 
therefore appears attractive for the identification of differentially linked sialic acids that may 
be related to pathological conditions. 
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Glycosylation is one of the most complex post-translational modifications of proteins 
that affects protein folding, stability, half-life, protein-protein interactions, signaling and 
trafficking.133-135 Carbohydrate moieties are attached to the peptide backbone either via the 
nitrogen atom of the side-chain of asparagine (N-linked) with the sequence N - X - S/T (X 
≠ P) or via an oxygen atom (O-linked) of serine or threonine. Next to the diversity in site 
occupancy (macroheterogeneity), a large variety in glycan structures may also be observed 
at a given glycosylation site (microheterogeneity). 
Changes in glycosylation may be associated with various factors, including age and 
pathophysiological conditions.136-139 In certain disease settings, specific glycan features 
such as fucosylation, bisection, galactosylation or sialylation are known to be affected.140,141 
Sialylation, i.e., a process by which sialic acids are attached to glycans, occurs on different 
monosaccharides and in different linkage positions, namely α2,3, α2,6 or α2,8. The motifs 
are located at the non-reducing end of the glycans, creating binding sites for multiple human 
lectins, toxins and pathogens.82 Sialic acids are involved in numerous pathophysiological 
processes. For instance, α2,3-linked sialic acids have shown to be associated with malignancy 
in several types of cancers via formation of sialyl-Lewisx structures (attachment of an 
α1,3 linked-fucose to an antennary N-acetylglucosamine) which are linked to metastasis 
progression.142-144 Furthermore, α2,6-linked sialic acids are presumed to be involved in 
blocking galectin binding and enhancing the tumor cell survival.8,9,145 
Glycosylation, and especially changes thereof, has become of great importance due to 
the potential use of glycopeptides as clinical biomarkers.91,97,146 Similarly, the structural 
characterization of protein-linked glycans is essential in the biopharmaceutical industry to 
ensure the safety and efficacy of novel therapeutics.133,134,147,148 In recent years, molecular 
engineering of carbohydrates, referred to as glyco-engineering, has emerged in this field 
to enhance efficacy and design functional properties of monoclonal antibodies (mAbs).149-
151 Notably, terminal carbohydrate moieties on glycan chains are often affected by subtle 
changes in the cell culture environment.147,148,152 
The characterization of protein glycosylation often requires information about site occupancy 
as well as about the glycan structures. This information is often obtained via proteolytic 
cleavage and subsequent glycopeptide analysis by mass spectrometry (MS).127,153 However, 
an exhaustive characterization of sialic acid linkages of glycopeptides using MS remains 
rather challenging. Only recently, ion mobility mass spectrometry has demonstrated to allow 
for the separation of glycopeptide sialic acid linkage isomers.154 Likewise, the differentiation 
between the differently linked sialic acids of immunoglobulin G (IgG) fragment crystallizable 
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(Fc) glycopeptides has been achieved using a linkage-specific derivatization method prior to 
MS analysis.155 Nonetheless, such methods are not broadly accessible and there is a clear 
need for the differentiation of sialic acid isomers in conjunction with MS detection.
In this study, we present a novel approach based on capillary electrophoresis (CE) - 
electrospray ionization (ESI)-MS for glycopeptides analysis, enabling baseline separation of 
the α2,3- and α2,6-sialylated isomers without the need for any sample pre-treatment. The 
CE-ESI-MS method was developed using IgG Fc glycopeptides derived from recombinant 
IgG which contains only α2,3-sialylated glycopeptides,147,156 as well as IgG Fc glycopeptides 
derived from human plasma IgG, which only contains α2,6-sialylated glycopeptides.157 The 
observed difference in electrophoretic mobilities was further investigated by determining 
the difference in pKa values of two representative compounds, namely, α2,3-sialyllactose 
and α2,6-sialyllactose. The relative difference in acidity constant was assessed using a novel 
methodology based on the internal standard (IS)-CE approach first proposed by Fuguet et 
al.,158 identifying differences in acidity between sialic acid isomers as one of the plausible 
causes for sialic acid isomer separation. Finally, the developed platform was applied to 




Ammonium bicarbonate (ABC), methanol (MeOH) of LC-MS grade and sodium dodecyl 
sulfate (SDS) were obtained from Merck (Darmstadt, Germany). Glacial acetic acid (HAc), 
DL-dithiothreitol (DTT), iodoacetamide (IAA), 1-hydroxybenzotirazole (HOBt) hydrate 
and Nonidet P-40 (NP-40) were acquired from Sigma-Aldrich (Steinheim, Germany). 
Ammonium acetate (AAC), formic acid (FA), trifluoroacetic acid (TFA) and water of LC-
MS grade were purchased from Fluka (Steinheim, Germany). Sequencing Grade Modified 
Porcine Trypsin was obtained from Promega (Madison, WI). Phosphoric acid (H3PO4), MES 
(2-(N-morpholino)ethanesulfonic acid), MOPS (3-morpholinopropane sulfonic acid), TRICINE 
(N-(tris(hydroxymethyl)-methyl)glycine), and CHES (2-(cyclohexylamino)ethane sulfonic acid) 
were purchased from Fluka (Buchs, Switzerland). Milli-Q water (MQ) was used for the matrix-
assisted laser desorption ionization time-of-flight MS (MALDI-TOF-MS) experiments and 
obtained using a Q-Gard 2 system (Millipore, Amsterdam, Netherlands). HPLC supraGradient 
acetonitrile (MeCN) originated from Biosolve (Valkenswaard, Netherlands). 1-Ethyl-3-(3-
(dimethylamino)propyl)-carbodiimide (EDC) hydrochloride was purchased from Fluorochem 
(Hadfield, United Kingdom). For the pKa determination, HPLC grade MeOH was supplied by 
Romil (Kölliken, Switzerland), analytical reagent grade acetone by Acros Organics (Basel, 
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Switzerland), hydrochloric acid by Riedel-de-Haën (Buchs, Switzerland), and 1 M Titrinorm 
sodium hydroxide by VWR (Dietikon, Switzerland). The CEofix® pH 2.5 solutions were 
obtained from Analis (Namur, Belgium). Recombinant peptide-N-glycosidase F (PNGase F) 
was acquired from Roche Diagnostics (Mannheim, Germany) and 2,5-dihydroxybenzoic acid 
(2,5-DHB) from Bruker Daltonics (Bremen, Germany). Lyophilized sialidase S (Streptococcus 
pneumoniae) was obtained from PROzyme (Hayward, CA) and reconstituted in 20 µL MQ 
prior to use. Recombinant monoclonal IgG1 antibody (IgGmAb1) is derived from Chinese 
hamster ovary (CHO) cells. Human polyclonal IgG (intravenous immunoglobulin; IVIgG) was 
provided by Sanquin Research (Amsterdam, The Netherlands). Prostate-specific antigen 
(PSA) was acquired from Lee BioSolutions (St. Louis, MO). The two oligosaccharide standards 
3’-sialyllactose sodium salt and 6’-sialyllactose sodium salt were obtained from Carbosynth 
(Compton, United Kingdom).
TRYPTIC DIGEST
A PSA solution (1 µg/µL) was prepared in 25 mM ABC buffer. The reduction of disulphide 
bridges was carried out at 60˚C for 30 min after addition of DTT (final concentration 2 mM) 
to the PSA solution. After cooling at room temperature, the sulfide alkylation was performed 
using IAA (final concentration 6 mM) and the sample was kept in the dark for 30 min. Sulfide 
alkylation reaction was stopped by addition of DTT (final concentration 6 mM). Finally, 
porcine trypsin was added to the sample (1:30, w/w) followed by overnight digestion at 37˚C. 
Tryptic digests of IgGmAb1 and IVIgG solutions were prepared in 25 mM ABC buffer (1 µg/
µL) with the addition of porcine trypsin (Promega Madison, WI, enzyme:sample 1:30, w/w). 
Digestion was performed overnight at 37˚C.
N-GLYCAN RELEASE
N-glycans were released from PSA as described previously.159 Briefly, 10 µL of 2% SDS was 
added to 5 µL of PSA (21.5 µg) for denaturation and incubated for 10 min at 60˚C. A mixture 
(10 µL) consisting out of 4% NP-40, 5x PBS and 1 mU PNGase F (10:10:1, v/v/v) was added for 
the release of the N-glycans and incubated overnight at 37˚C.
EXOGLYCOSIDASE TREATMENT
Ten microliters of the digested PSA sample (5.67 µg) was lyophilized and reconstituted in a 
mixture of 1 µL enzyme sialidase S, 1 µL of 50 mM sodium acetate (pH 5.5) and 8 µL of MQ, 
followed by overnight incubation at 37˚C.
ETHYL ESTERIFICATION
Ethyl esterification was performed as described by Reiding et al.160 Briefly, the ethylation 
reagent was a mixture of EDC with HOBt dissolved in ethanol with a final concentration at 
0.25 M for both compounds. One microliter of the PNGase F treated PSA was added to 20 µL 
of ethylation reagent and incubated for 1h at 37˚C. 
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GLYCAN ENRICHMENT BY COTTON HILIC SPE
Glycan enrichment was performed using cotton wool hydrophilic interaction liquid 
chromatography (HILIC) solid phase extraction (SPE) microtips, with a protocol modified from 
Selman et al.161 Pipette tips with a volume of 20 µL (Rainin Instrument, Oakland) were filled 
with approximately 3-mm long cotton thread (Pipoos, Netherlands). This HILIC-SPE sorbent 
was activated with 20 µL MQ prior to conditioning with a solution of 85% MeCN (v/v), each 
step being repeated three times. Approximately 0.9 µg of the ethylated PSA glycans was 
dissolved in 85% MeCN and loaded onto the cotton thread. The ethylated glycans were 
washed, first with a 20 µL solution of MeCN-MQ-TFA, 85:14:1 (v/v/v) followed by 20 µL with 
a solution of 85% MeCN, both steps were repeated three times. Analytes were eluted with 
20 µL of MQ.
DETERMINATION OF pKA VALUES
Details about the theory and comprehensive explanations on the experimental procedure 
are available in Section S-2-2 and S-2-3 of the Supporting information.
In order to investigate the possible difference in pKa values for α2,3- and α2,6-sialyllactose, an 
in silico prediction was initially performed as described in S-2-3-2, Supporting information. 
pKa values were then experimentally determined using CE with ultraviolet (UV) detection. CE-
UV experiments were performed with an HP3DCE system (Agilent Technologies, Waldbronn, 
Germany) equipped with an on-capillary diode array detector (8.5 cm from the anode), an 
autosampler, and a power supply able to deliver up to 30 kV. UV detection was carried out 
at 195 nm for target compounds and 260 nm for acetone (neutral marker of electro-osmotic 
flow, EOF). CE ChemStation (Agilent Technologies) was used for CE and UV control, data 
acquisition, and data handling. Analyses were performed with fused silica capillaries (BGB 
Analytik AG, Böckten, Switzerland) with 50 μm i.d., 32.5 cm total length, and 8.5 cm effective 
length. The capillaries were coated with a dynamic coating (CEofix®, Analis, Namur, Belgium) 
to generate a large EOF (ca. > 2.2∙10-4 cm2·V-1·s-1) regardless of the buffer pH. Samples were 
kept at room temperature in the autosampler and introduced by short-end injection, 
namely, the polarity was reversed and samples were injected at the detector side. Applying 
a pressure of 12 mbar for 4 s performed an injection equivalent to 0.4% of the capillary 
total length. The capillary was thermostated at 25˚C by a high velocity air stream. Before 
its first use, the capillary was sequentially rinsed (1 bar) with MeOH, 1 M hydrochloric acid 
(HCl), water, 1 M sodium hydroxide (NaOH), 0.1 M NaOH, and water (5 min each) prior to 
the coating procedure. The latter involved capillary rinses with aqueous polymer solutions 
(CEofix® initiator and accelerator). Between different pH buffers, several washing steps (1 
bar) were employed, namely water (1 min), CEofix® initiator (0.5 min), CEofix® accelerator (1 
min), and background electrolyte (BGE; 5 min), followed by pre-electrophoresis (3.5-8 kV, 5 
min). Between analyses, the capillary was rinsed (1 bar) with buffer for 1 min. When not in 
use, the capillary was rinsed with water and stored dry.
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For the determination of absolute pKa values, a voltage of 3.5 to 8 kV (depending on the 
running buffer, see Table S-2.2, Supporting information) was applied to avoid detrimental 
effect of Joule heating. Other experimental conditions for the absolute pKa values are 
described in S-2-3-3, Supporting information.
For the relative pKa determination, two phosphate buffers at pH 2.0 and 6.0 were prepared. 
They were set at a constant ionic strength of 50 mM to avoid variations in effective mobility 
and keep activity coefficients constant (Table S-2.3, Supporting information). The buffer 
pH values were selected to ensure that both forms coexist (i.e., at pH 2.0) and only the fully 
deprotonated form exists (i.e., at pH 6.0). The pH values were measured with a Mettler-
Toledo SevenMulti pH meter that was calibrated on a daily basis. The injected sample was 
a mixture of both investigated compounds at a concentration of 0.1 mg/mL in MQ and 
acetone 95:5 (v/v). They were injected twice (N = 2) at each pH. Voltages of 8 kV and 5 kV 
were applied when using the BGEs at pH 6.0 and 2.0, respectively.
MALDI-TOF-MS
MS experiments of ethylated PNGase F released N-glycans were performed with MALDI-
TOF-MS (UltrafleXtreme, Bruker Daltonics, Bremen, Germany) using FlexControl 3.3 software 
(Bruker Daltonics) in positive ionization mode. The ethylated PNGase F released N-glycans 
were spotted on an 800 µm AnchorChip plate (Bruker Daltonics) together with 1 µL of 2,5-
DHB matrix (5 mg/mL, 1 mM NaOH in MeCN-MQ, 50:50, v/v). A peptide calibration standard 
(Bruker Daltonics) was used for external calibration. FlexAnalysis (Bruker Daltonics) was used 
for the analysis of the acquired MALDI-TOF-MS data. Modifications of the sialic acids were 
taken into account (lactonization or ethylation) and all glycan masses were recorded using 
[M + Na]+ ions.
CAPILLARY ELECTROPHORESIS - ELECTROSPRAY IONIZATION - MASS 
SPECTROMETRY
All CE experiments were carried out on a CESI 8000 system (SCIEX Separations, Framingham, 
MA), and 90-cm long bare fused capillaries (i.d. of 30 µm, o.d. of 150 µm) were used. Prior to 
analysis, the capillary was rinsed thoroughly with 0.1 M NaOH (2.5 min), 0.1 M HCl (2.5 min), 
water (4 min) and BGE which consisted of 10% HAc (v/v, pH 2.3). The sample was on-line pre-
concentrated using transient isotachophoresis (t-ITP). Prior to injection, AAC at pH 4.0 (final 
concentration 100 mM) was added to the sample, which acted as the leading electrolyte. 
Samples were injected using hydrodynamic injection of 1 psi for 60 s (9 nL, corresponding 
to 1.4% of the capillary volume). For all experiments, a BGE post plug was added by applying 
0.5 psi for 25 s (corresponding to 0.3% of the capillary volume). Separation was carried out 
by applying a voltage of 20 kV.
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The CE system was hyphenated to a UHR-QqTOF maXis Impact HD MS (Bruker Daltonics) 
via a sheathless CE-ESI-MS interface from SCIEX. A capillary voltage of -1300 V was applied 
to ensure a stable electrospray. All experiments were performed in positive ionization 
mode. The drying gas (nitrogen) flow rate and temperature were set at 1.5 L/min and 180˚C, 
respectively. MS data was acquired between m/z 200-2200 with a spectral acquisition rate 
of 1 Hz.
CE-ESI-MS data was analyzed with DataAnalysis 4.2 (Build 387, Bruker Daltonics). Prior to data 
analysis, all MS spectra were calibrated using sodium adducts detected at the beginning of 
the electropherogram. The data was manually screened for glycopeptides and compositions 
were matched based on the exact mass, selectivity and relative intensities (Table S-2.1, 
Supporting information). Fragmentation spectra were acquired for 27% of the identified 
compositional glycopeptide variants of PSA (Figure S-2.4 - S-2.7, Supporting information). 
Extracted ion electropherograms (EIEs, smoothed with a Gaussian fit) were acquired with 
the first three isotopes of the doubly, triply and quaternary charged analytes using a width 
of ± 0.05 m/z unit. 
For data alignment, to ensure comparable migration times and reveal the separation 
of sialic acid linkage isomers, the analysis of IgGmAb1 and IVIgG glycopeptides used 
2-aminobenzamide labeled dextran ladder as an internal calibrant. For the alignment of PSA 
glycopeptides no IS was needed as the sample was rich enough to ensure proper alignment 
without an IS. The alignment program is an in-house and open source program, based on the 
LaCyTools alignment tool.162 The alignment program is supplied with this manuscript and can 
be found in S-2-4 of the Supporting information. Briefly, an alignment procedure referred to 
as “targeted alignment” was achieved by supplying a list (.txt file) of the calibrants with their 
theoretical m/z and expected migration time (mt) values. After converting the data file to 
an mzML file, the algorithm examines the mt and m/z regions containing the calibrants. The 
local maximum within each region is isolated. The mt matching to the local maximum is then 
coupled to the specified mt of the calibrant. All observed mt and expected mt combinations 
are then taken as an input array for a second-degree polynomial fit. The function (f) 
returned by the polynomial fit is used to transform the observed mt of the whole spectrum 
by performing mt(new) = f(mt(old)), resulting in well-aligned spectra. This alignment 
strategy is opposed to an unbiased alignment,163 which uses random selection of features 
and is typically suited for unknown samples that contain a wide range of analytes. Targeted 
alignment is more adequate for highly purified samples in which the analytes are well known 
and characterized.162 Afterwards, the aligned runs were plotted using an in-house developed 
and open source plotting program (S-2-5 of the Supporting information).
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ANALYSIS OF IgG FC GLYCOPEPTIDES USING CE-ESI-MS
A sheathless CE-ESI-MS platform was used for the analysis of Fc glycopeptides derived from 
IVIgG and IgGmAb produced in CHO cells. In order to correct for the significant differences 
observed in mt, a targeted alignment of the data was applied using an IS. Figure 2.1 
illustrates the analysis of IgGmAb1 (Figure 2.1.A) and IVIgG (Figure 2.1.B) after alignment. 
For both samples, the extracted ion electropherograms of the non-sialylated glycopeptides 
of subclass 1 (G1F and G2F) showed the same apparent mobility while different mt were 
obtained for the mono-sialylated species (G1FS and G2FS). IgG Fc glycopeptides derived from 
CHO cells are well-known to contain only α2,3-linked sialic acids while IgG Fc glycopeptides 
derived from human plasma are expected to only contain α2,6-linkages.147,156,157 The co-
injection of IgGmAb1 and IVIgG1 glycopeptides (Figure 2.1.C) emphasized this difference 
in apparent mobilities for α2,3- versus α2,6-linked sialylated species, where α2,3-linked 
mono-sialylated and α2,6-linked mono-sialylated glycopeptides were baseline resolved. The 
differentiation between both linkages is highly relevant since α2,3- and α2,6-linkages may 
have significantly different biological effects.155 CE is not the only separation platform that 
Figure 2.1: Extracted ion electropherograms 
(EIEs) of IgGmAb1 and IVIgG1 glycopeptides 
obtained with CE-ESI-MS after targeted 
alignment. (A) EIEs of IgGmAb1 glycopeptides 
derived from CHO cells, (B) EIEs of IVIgG1 
retrieved from human plasma and (C) EIEs of a 
co-injection of IgGmAb1 and IVIgG1. The “PEP” 
label illustrates the tryptic peptide sequence 
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enables separation of sialylated isomers: zwitterionic -HILIC and porous graphitized carbon 
(PGC)-LC have proven to be suitable for separation of glycan species with isomeric sialic 
acid linkages.164,165 Specific fragmentation features have been reported for anionic glycans, 
enabling the distinction between isomers.166,167 However, many other conventional positive-
mode MS(/MS) approaches do not provide sufficient differentiation between α2,3- and 
α2,6-linked sialylated species due to an identical exact mass as well as similar fragmentation 
patterns using collision induced dissociation.168 
Our preliminary data obtained for the analysis of IgG Fc glycopeptides using CE-ESI-MS 
showed different electrophoretic mobilities of sialic acid linkage isomers, implying a different 
charge-to-size ratio that may be used to discriminate both α2,3- and α2,6-linked sialylated 
species. This difference may be either caused by differences in the hydrodynamic radius of 
the analytes and/or by a difference in acidic constant between α2,3- and α2,6-linked sialic 
acids. To the best of our knowledge, only a general pKa value for both linkages (pKa ca. 2.6-
2.9) has been described so far.169-171 Therefore, the potential difference in pKa values between 
the two differently linked sialic acids was further investigated using two representative 
compounds, namely, α2,3-sialyllactose and α2,6-sialyllactose.
pKA DIFFERENCES BETWEEN α2,3- AND α2,6- SIALYLATED LACTOSE
The in silico prediction as well as the experimental determination of the pKa values are 
described in Supporting information, Section S-2-1.172 As summarized in Table 2.1, both 
approaches were not sufficient to demonstrate a significant difference in the pKa values 
of α2,3- and α2,6-linked sialyllactose due to the relative close values and the associated 
error with the measurements. In order to further explore the expected difference in pKa 
values and to enable a clear differentiation between both pKa with minimized measurement 
errors, a novel methodology based on the so-called IS-CE approach was implemented for 
the determination of the relative difference in pKa values. This IS-CE approach, first proposed 
by Fuguet et al.,158 is based on the assessment of acidity constants using CE with concomitant 
injection of the analyte of interest and an IS. The pKa values of the latter are known and its 
selection is based on its close similarity in nature and pKa value to the analyte of interest. 
Here, this procedure was adapted to 
assess the relative difference in pKa unit 
where one of the sialyllactose acted as 
the IS and the other one as the analyte 
of interest. The relative difference was 
estimated by calculating the mean 
limiting mobilities (migration under 
fully deprotonated form, namely, at 
pH 6.0, N = 2 ) and mean effective 
Table 2.1: pKa values determined for analogs of sialyllactose.
ACD/Lab method Predicted pKavalue
α2,3 sialyllactose 1.9 (± 0.7)
α2,6 sialyllactose 2.0 (± 0.7)
Conven�onal CE method Absolute pKa value
α2,3 sialyllactose 1.8 (± 0.1)
α2,6 sialyllactose 1.8 (± 0.1)
IS-CE method ( N = 2 ) Rela�ve pKa value
3.4·10 -2
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mobilities (migration under partially ionized form, namely, at pH 2.0, N = 2 ) for both 
analytes (α2,3- and α2,6-linked sialyllactose) injected simultaneously therefore no alignment 
was needed (Figure S-2.1, Supporting information). Mean limiting mobilities for both 
compounds were found to be -6.0·10-5 cm2 V-1 s-1 (± 3.4·10-6 cm2 V-1 s-1) and -6.5·10-5 cm2 V-1 
s-1 (± 3.4·10-6 cm2 V-1 s-1), while the mean effective mobilities were estimated at -4.2∙10-5 cm2 
V-1 s-1 (± 9.7·10-7 cm2 V-1 s-1) and -4.6·10-5 cm2 V-1 s-1 (± 8.6 ·10-7 cm2 V-1 s-1). Using the measured 
mobilities and Eqs. S-2-7, S-2-8 and S-2-9 in Section S-2-2 of the Supporting information, a 
∆pKa of 3.4·10
-2 unit was assessed (Table 2.1).
This relative ∆pKa therefore reflects a difference in the acidity constants of the two sialylated 
glycan isomers. Consequently, this led to different electrophoretic mobilities in the working 
BGE (i.e., 10% HAc at pH 2.3) for α2,3- and α2,6-linked sialylated glycopeptides of IgGmAb1 
and IVIgG. Considering that other experimental conditions are used in the CE-ESI-MS 
approach compared to the IS-CE approach (i.e., longer capillary (90 cm versus 32.5 cm), long-
end injection versus short-end injection (89 cm versus 8.5 cm effective length of the capillary) 
and a higher voltage (5/8 kV versus 20 kV)), a migration time difference of 1 min with MS 
detection was estimated between the α2,3- and α2,6-linked sialyllactose on the basis of the 
deduced pKa difference (see Eq. S-2.7 in Section S-2.2 of the Supporting information). This 
finding supports the result obtained with the co-injection of IgGmAb1 and IVIgG1 illustrated 
in Figure 2.1. The different linkage affects the charge of the sialyllactoses, which may also 
present a different size, overall impacting the charge-to-size ratio and, thus, the migration 
behavior. Therefore, the CE-ESI-MS technique appears to be a promising tool for separating 
sialic acid linkage isomers.
ANALYSIS OF PROSTATE-SPECIFIC ANTIGEN GLYCOPEPTIDES USING 
CE-ESI-MS
Due to the heterogeneous glycosylation character of PSA, including differentially linked sialic 
acids, this glycoprotein was selected to investigate the potential of using of CE-ESI-MS for 
sialic acid linkage isomer differentiation.3 A state-of-the-art MALDI-TOF-MS platform was 
also used as orthogonal technique after enzymatic release of the glycans from PSA and an 
ethyl esterification to distinguish α2,3- from α2,6-linked sialic acids of released glycans, the 
results were compared to the CE-ESI-MS platform.160 Moreover, in order to evaluate the 
migration behavior of the sialylated isomers of PSA, an exosialidase step was performed to 
allow for the release of α2,3-linked sialic acids from complex glycopeptides.
ETHYL ESTERIFICATION
The enzymatically released N-glycans from PSA were derivatized using a procedure developed 
by Reiding et al., converting α2,3-linked sialic acids into a lactone (- 18 Da) while α2,6-linked 
sialic acids formed an ethyl ester (+ 28 Da).160 The MALDI-TOF-MS profiling confirmed that 
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the acquired PSA consisted of differentially linked sialic acids (Figure 2.2), enabling the 
identification of 37 glycans (Table S-2.1, Supporting information). It is worth mentioning 
that sialic acid attached to a N-acetylgalactosamine only revealed an α2,6-linkage, which is 
supported by literature.82
CE-ESI-MS(/MS) ANALYSIS OF A PSA TRYPTIC DIGEST
Figure 2.3 displays the base peak electropherogram and the EIEs obtained for the analysis of 
a PSA tryptic digest. A relatively high number of glycopeptides (i.e., 75 glycopeptides, S/N > 
9, ppm error < 10) were identified with the CE-ESI-MS setup. All glycans were attached to the 
peptide “N69K” and are listed in Section S-2-6 of the Supporting information, Table S-2.1. 
Notably, a relatively low amount of PSA (ca. 1 ng protein weight injected) was necessary 
to detect these 75 glycopeptides. The base peak electropherogram of a PSA tryptic digest 
analysis is shown in Figure 2.3.A while the EIEs of non-sialylated, mono-sialylated, and di-
sialylated glycoforms are shown in Figure 2.3.B-D. Figure 2.3.C and 2.3.D clearly emphasize 
that α2,3- and α2,6-linked isomers are baseline resolved, confirming the ability of CE-ESI-
MS to discriminate between the different linkages, independently of the glycopeptide 
structure. The identified compounds are represented in terms of number of hexoses (H), 
N-acetylhexosamines (N), fucoses (F) and sialic acids (S). As illustrated in Figure S-2.2 and 
S-2.3 of the Supporting information, isomer separation was observed for the α2,3- and 
α2,6-linked sialylated species (H5N4S2, H5N4F1S2, H4N5S2 and H4N5F1S2). Interestingly, a 
peak with a higher apparent mobility compared to the fully α2,6-di-sialylated species was 
detected, with a similar isotopic distribution. This peak could not be assigned with MS/MS 
due to the relatively poor signal intensity. Given the migration in the di-sialylated region of the 
electropherogram, this unidentified analyte may also be a glycopeptide containing two sialic 
acids, from which one is an α2,8-linked sialic acid on top of the second sialic acid. However, 
the presence of a di-sialic acid motif with an α2,8-linkage could not be confirmed with the 
MALDI-TOF experiments as this α2,8-linked sialic acid is expected to readily form lactones 
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Figure 2.2: MALDI-TOF-MS spectrum of PNGase F released PSA N-glycans treated with ethyl esterification. 
In total, 37 different glycans were identified (not all data shown, a complete overview can be found in Table 
S-2.3, Supporting Information).
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α2,3-linked sialic acid even though there is a difference in linkage position.173 Next to that, 
there are hitherto no IS available that would contain this specific linkage. Therefore, similar 
experiments as performed with the α2,3- and α2,6-linked sialyllactose with IS-CE could not 
be performed. As a result, further investigations are needed to confirm this hypothesis.
Next to the isomer separation of the differentially linked sialic acids, Figure 2.3 also highlights 
that the glycopeptide separation is highly influenced by the degree of sialylation. This is 
expected as the migration of the glycopeptide is dependent on the charge-to-size ratio of the 
analyte in the capillary. Figure 2.3.B illustrates that the non-sialylated glycopeptides migrate 
first out of the capillary followed by the mono- and di-sialylated species. The sialic acids are 
expected to carry a negative charge when 10% HAc is used as BGE (pH 2.3), resulting in a 
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Figure 2.3: CE-ESI-MS analysis of PSA tryptic (glyco)peptides. (A) Representative base peak 
electropherogram observed for a tryptic digest of PSA. Based on the electrophoretic separation, three 
distinct clusters were defined. (B) Cluster with only non-sialylated glycopeptides of PSA. (C) Cluster 
containing mono-sialylated glycopeptides of PSA. (D) Cluster with di-sialylated glycopeptides of PSA. In 
total, 75 different glycopeptides were identified (not all data shown, a complete overview can be found in 
Table S-2.3, Supporting Information). Peaks with a star (*) were not assigned. The “PEP” label illustrates the 
tryptic peptide sequence N69K to which the glycan is attached.
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migration time. Figure 2.3.B illustrates the EIEs observed for non-sialylated glycopeptides 
and revealed no isomer separation (co-migration of isomers), indicating that the separation 
mostly relies on the number of sialic acids attached to the analyte as well as the ∆pKa of the 
differentially linked sialic acids. Differences in hydrodynamic radii of the analytes appeared to 
have only a minor influence, as illustrated for glycopeptides with neutral glycans containing 
zero, one or two galactose residues, which only showed minor differences in migration 
without differentiation between isomers. 
CE-ESI-MS ANALYSIS AFTER EXOSIALIDASE TREATMENT
Figure 2.4 shows the EIEs observed for the di-sialylated glycopeptides H5N4F1S2 (blue trace) 
and H4N5F1S2 (green trace) prior (Figure 2.4.A) and after (Figure 2.4.B) treatment with 
α2,3-sialidase. Both analyses were aligned using the targeted alignment program to ensure 
that a proper identification could be made of the different isomeric species between the two 
analysis. The electropherograms obtained for α2,3- and α2,6-sialylated species indicated 
a significant decrease of the relative abundance of α2,3-sialylated variants. The intensities 
observed for α2,6-linked mono-sialylated glycopeptide (H5N4F1S12,6) and the non-sialylated 
glycopeptide (H5N4F1) increased compared to the most abundant peak (α2,6-linked di-
sialylated glycopeptide, H5N4F1S22,6) while all α2,3-linked sialylated species (H5N4F1S12,3, 






















30 35 40 45 50 Time [min]
PEP PEP





B. After excoglycosidase treatment
A. Before excoglycosidase treatment
PEP PEP




Mannose Galactose N-Acetylglucosamine N-Acetylgalactosamine Fucose α2,3 Sialic Acid α2,6 Sialic Acid
Figure 2.4: CE-ESI-MS analysis of PSA with and without α2,3-sialidase treatment using CE-ESI-MS after 
targeted alignment. (A) EIEs of the non-sialylated glycopeptide (H5N4F1), the mono-sialylated glycopeptides 
(H5N4F1S1) and the di-sialylated glycopeptides (H5N4F1S2) of PSA prior to exoglycosidase treatment and (B) after 
exoglycosidase treatment.
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reaction was observed for the exoglycosidase treatment, which may most likely be attributed 
to experimental conditions such as (too short) incubation time and (low) amount of enzyme 
added. Nonetheless, these results confirmed that the CE-ESI-MS setup enabled a baseline 
separation of α2,3- and α2,6-sialylated glycopeptides, with α2,3-variants showing a slower 
migration. 
SYNOPSIS
Little attention has been devoted to the analysis of glycopeptides with CE-ESI-MS so far. 
This is unfortunate since this technique has shown high separation efficiency and sensitivity 
in the context of large biomolecules analysis, especially in combination with a sheathless 
ESI interface.112,174-176 For instance, Heemskerk et al.177 showed that a 40-fold increase in 
sensitivity with CE-ESI-MS compared to nano-LC-ESI-MS was observed for the analysis of 
plasma derived IgG1 Fc glycopeptides.
This study presented a novel approach for in-depth and direct analysis of complex 
glycoproteins with differently linked sialic acids using a CE-ESI-MS platform, without the 
need for tedious and time-consuming sample preparation.34,155,160 With the developed setup, 
75 different glycopeptides with one single N-linked glycosylation site, position R-N69K-S, 
were detected for the analysis of PSA tryptic digest. This CE-ESI-MS platform shows a 
great potential for PSA glycopeptide analysis with results comparable to an interlaboratory 
study performed on PSA and PSA high isoelectric point isoform (bulk-purified proteins 
based on isoelectric point).178 The latter reported that 61 N-glycan compositions could be 
detected using multiple analytical strategies including bottom-up versus top-down analysis, 
released N-glycans analysis by PNGase F, polymeric reversed-phase versus monolith and C8 
chromatography, as well as CE. 
Nowadays, the concentration of PSA in serum is widely used in clinics for the screening of 
prostate cancer (PCa) since elevated PSA serum levels can be indicative of malignancy.179 
However, this screening method shows a poor specificity as various other causes also lead 
to increased PSA levels in serum.180,181 Previous studies indicated that alterations in the 
glycosylation profile of PSA could provide a more specific tool for diagnosis and prognosis of 
PCa.3,46,99,182-184 This study presents a compelling platform for the analysis of these alterations, 
offering a very competitive tool to improve both specificity and sensitivity. Moreover, it 
allows to evaluate the PSA glycosylation, a promising approach for early detection, for better 
prognosis or staging of PCa. However, while currently one ng of protein weight was injected 
and analyzed, such amounts will be difficult to retrieve from serum of PCa patients, who often 
have PSA concentrations lower than 10 ng/mL. On the opposite, urine PSA concentrations 
of PCa patients have been reported with a median value of 425 ng/mL, a sufficient 
concentration level for this CE-ESI-MS platform.5 Therefore, the potential of PSA biomarkers 
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derived from urine should be investigated and could open new possibilities for establishing a 
less invasive but hopefully more specific diagnostic marker than the current clinical PSA test. 
This has, to the best of our knowledge, not yet been explored. Future perspectives include 
the analysis of glycoproteins with higher complexity and more glycosylation sites, as well 
as highly sialylated glycopeptides which may show a negative apparent mobility, rendering 
their detection critical with the current setup. Further method development is therefore 
needed to achieve the analysis of, for instance, tri- or tetra-sialylated glycopeptides.
CONCLUSION
This study presents the implementation of a CE-ESI-MS platform enabling the differentiation 
between α2,3- and α2,6-sialylated glycopeptides without prior derivatization. Where 
conventional MS(/MS) approaches cannot resolve these isomers due to identical molecular 
formulas and similar fragmentation patterns, CE enabled the baseline separation of 
sialylated glycopeptides due to a difference in their electrophoretic mobilities, correlated 
by a difference in acidity, as shown for the two representative compounds α2,3-sialyllactose 
and α2,6-sialyllactose. The developed platform was used for the analysis of tryptic PSA 
glycopeptides, enabling the identification of 75 PSA glycopeptides, a significantly higher 
amount compared to the 37 PNGase F released N-glycan signals detected by MALDI-TOF-
MS. This highlights the gain in sensitivity obtained with the developed platform and its 
potential for biomarker discovery, enabling the possible differentiation between clinically 
relevant glycopeptides revealing differentially-linked sialic acids.
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Over the last years, numerous strategies have been proposed to enhance both ionization 
efficiency and spray stability in electrospray ionization (ESI), in particular for nanospray 
applications. In nano-liquid chromatography - mass spectrometry (nano-LC-ESI-MS), a 
better ESI performance has been observed when a coaxial gas flow is added around the ESI 
emitter. Moreover, enrichment of the gas with an organic dopant has led to an improved 
desolvation and ionization efficiency with an overall enhanced sensitivity. In this study, 
the use of a dopant enriched nitrogen gas (DEN-gas) combined with sheathless capillary 
electrophoresis (CE)-ESI-MS was evaluated for glycopeptide analysis. Using acetonitrile as a 
dopant, an increased sensitivity was observed compared to conventional sheathless CE-ESI-
MS. Up to 25-fold higher sensitivities for model glycopeptides were obtained, allowing for 
limits of detection unachieved by state-of-the-art nano-LC-ESI-MS. The effect of DEN-gas 
on the repeatability and intermediate precision was also investigated. When compared to 
previously reported nano-LC-ESI-MS measurements, similar values were found for CE-ESI-
MS with DEN-gas. The enhanced repeatability fosters the use of DEN-gas sheathless CE-
ESI-MS in protein glycosylation analysis, where precision is essential. The use of DEN-gas 
opens new avenues for highly sensitive sheathless CE-ESI-MS approaches in glycoproteomics 
research, by significantly improving sensitivity and precision. 

DOPANT ENRICHED NITROGEN GAS COMBINED WITH SHEATHLESS CE-ESI-MS FOR 
IMPROVED SENSITIVITY AND REPEATABILITY IN GLYCOPEPTIDE ANALYSIS
|
|





Electrospray ionization (ESI) - mass spectrometry (MS) hyphenated to chromatographic and 
electrophoretic separation techniques is a key technology in proteomics and glycoproteomics. 
Glycosylation is known to influence protein structure and function in multiple manners. An 
important aspect is the efficient and stable formation of gas-phase ions from solution. In 
nano-liquid chromatography (LC)-ESI-MS, the flow rates are typically kept in a range of 10 - 
1000 nL/min and used in combination with a spray emitter with a narrow internal diameter, 
leading to the formation of sub-µm diameter droplets.185,186 Placing the emmiter tip close 
to the MS entrance results in an improved sampling efficiency towards the MS without 
the need for pneumatic assistance. However, the early limitations of nanospray ionization, 
e.g., poor spray stability and overall low robustness, have driven the development of more 
adapted emitter geometries (with respect to inner and outer diameter and aperture of the 
needle) and configurations which allow for a better desolvation and ion transmission.187-190 
Both droplet desolvation and sampling efficiency may be further improved by adding solvent 
vapors to the source,191 a strategy that recently has been made commercially available by 
Bruker Daltonics.132 Used with a patented closed ionization source,192 the vapor-enriched 
gas flows coaxially around the ESI emitter. In combination with nano-LC-MS and by using 
acetonitrile (MeCN) as dopant, this commercial setup has shown to increase the ionization 
efficiency of peptides with a factor of ca. 2.6-fold.193,194 This setup, hereafter referred to as 
dopant enriched nitrogen (DEN)-gas, has also shown its benefits in glycopeptide analysis by 
providing a more than 10-fold improved sensitivity since glycosylated species usually show 
lower ionization efficiencies compared to non-glycosylated species.195-197 
Capillary electrophoresis (CE) is a miniaturized technique working in the nano-flow regime 
leading to high sensitivities especially when used with a sheathless interface. The commercial 
sheathless CE-ESI-MS setup (CESI technology, SCIEX, Framingham, MA, US) is based on a 
sheathless interface designed by Moini where the porous end of the separation capillary 
which is inserted into the grounded needle and filled with conductive liquid, providing 
electrical contact via the pores.120 This interface has shown to display a mass-flux sensitive 
response at CE-ESI flow rates lower than ca. 25 nL/min, with maximum intensity obtained 
at very low flow rates (< 10 nL/min).112 Applications in proteomics and glycoproteomics 
emphasized the higher sensitivities that can be obtained with such a setup compared to 
nano-LC-ESI-MS, especially when used in combination with on-line pre-concentration 
techniques such as transient isotachophoresis (t-ITP).174,177,198-200 
In the present study, the DEN-gas supply was connected to the commercial sheathless CE-
ESI-MS system via an in-house built cone. The performance of this setup was evaluated for 
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glycopeptide analysis. ESI and MS parameters were optimized with tryptic glycopeptides 
from polyclonal immunoglobulin G subclass 1 (IgG1). MeCN, isopropanol (IPA) and ethanol 
(EtOH) were investigated as dopants, as well as different injection volumes. The effect of the 
flow rate on MS signal was also systematically evaluated. The DEN-gas setup was compared 
to a conventional sheathless CE-ESI-MS platform without DEN-gas and a state-of-the-art 
nano-LC-ESI-MS platform with DEN-gas, highlighting relevant differences in terms of limits 
of detection (LODs) and charge state distribution. Finally, the influence of the DEN-gas setup 
on glycopeptide analysis of two other model glycoproteins was studied. 
MATERIALS AND METHODS
CHEMICALS, REAGENTS AND ENZYMES
IPA, EtOH and methanol (MeOH), all of LC-MS grade, as well as ammonium bicarbonate and 
sodium hydroxide (NaOH) were obtained from Merck (Darmstadt, Germany). Glacial acetic 
acid (HAc), hydrochloric acid (HCl), DL-dithiothreitol (DTT), iodoacetamide (IAA), ammonium 
acetate (AAC), formic acid (FA), and trifluoroacetic acid (TFA) were purchased from Sigma-
Aldrich (Steinheim, Germany) and were of analytical grade or higher. Porcine trypsin was 
obtained from Promega (Madison, WI) and TPCK treated trypsin from bovine pancreas was 
obtained form (Sigma-Aldrich). Milli-Q water (MQ) was obtained from a Q-Gard 2 system 
(Merck Millipore, Amsterdam, Netherlands). MeCN of LC-MS grade originated from Biosolve 
(Valkenswaard, the Netherlands). 
SAMPLES
The purified native (polyclonal) IgG and IgG1 standards from human plasma were obtained 
from Athens Research and Technology (Athens, GA). IgG recombinant human monoclonal 
antibody was produced in CHO cells (IgGmAb1). Polyclonal IgG1 standard was used for the 
determination of optimal CE-ESI-MS operating conditions and dopant choice after tryptic 
cleavage and glycan enrichment (see S-3-1-1 and S-3-1-2, Supporting Information). A more 
complex standard was used for the investigation of the injection volume, namely tryptic 
polyclonal IgG peptides (including the different subclasses, prepared without hydrophilic 
interaction liquid chromatography (HILIC) enrichment). In-house data was available of 
IgGmAb1 (monoclonal) for nano-LC-ESI-MS and HILIC-fluorescence (FLD) platforms and 
IgGmAb1 after tryptic cleavage was therefore used for all other experiments with the CE-
ESI-MS allowing comparison between the different platforms. Prostate-specific antigen 
(PSA) originated from human seminal fluid and haptoglobin (Hp) from human serum, both 
acquired from Lee BioSolutions (St. Louis, MO). The tryptic cleavage procedures used for the 
proteins are described in S-3-1-1, Supporting Information.
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CAPILLARY ELECTROPHORESIS - ELECTROSPRAY IONIZATION - MASS 
SPECTROMETRY
CE experiments were carried out on a SCIEX/Beckman Coulter CESI 8000 system (SCIEX, 
Framingham, MA) equipped with a temperature-controlled sample tray and a power supply 
able to deliver up to 30 kV. Separation was performed using bare fused silica capillaries (90 
cm × 30 µm i.d. × 150 µm o.d.) and carried out by applying a voltage of 20 kV without any 
pressure applied. Prior to each sample injection, the capillary was rinsed with 0.1 M NaOH 
for 2.5 min, 0.1 M HCl for 2.5 min, water for 4 min, and background electrolyte (BGE) for 4 
min. The BGE was composed of a solution of 10% AA, v/v (pH 2.3). Prior to injection, samples 
were dissolved in 250 mM AAC at pH 4.0 (3:2, v/v) which acted as the leading electrolyte for 
the on-line pre-concentration step, namely t-ITP. 
All samples were injected using hydrodynamic injection with an application of 5 psi for 60 s 
(corresponding to 6.9% of the capillary volume, 44 nL injected), except PSA that was injected 
by applying a pressure of 1 psi for 60 s (corresponding to 1.4% of the capillary volume, 9 nL 
injected). The performance of different injection volumes was evaluated by application of 
different pressures between 1 and 40 psi for 60 s (corresponding to 1.4 - 55.0% of the capillary 
volume, 9 - 350 nL injected). In all experiments, a post-plug of BGE followed sample injection 
by applying a pressure of 0.5 psi for 25 s (corresponding to 0.3% of the capillary volume). 
The dependence of signal intensity on the flow rate was evaluated in triplicate with and 
without DEN-gas via direct infusion of purified IgGmAb1 in 10% HAc (0.17 ng/nL) at flow 
rates in the range 1 - 88 nL/min.
The CE apparatus was hyphenated to a UHR-QqTOF maXis Impact HD mass spectrometer 
from Bruker Daltonics (Bremen, Germany) via a sheathless CESI-MS interface based on a 
custom made platform from SCIEX/Beckman Coulter (Brea, CA) allowing for an optimal 
position of the capillary porous tip in front of the MS nanospray shield (Bruker Daltonics). 
For experiments with DEN-gas, an in-house made polymer cone was slid onto the housing of 
the porous tip as illustrated in Figure S-3.1, Supporting Information, allowing for a coaxial 
sheath flow of the DEN-gas around the ESI emitter. The concentration of MeCN in the DEN-
gas has been experimentally determined and corresponds to ca. 4% (mole percentage). All 
CE-ESI-MS experiments were carried out in ESI positive mode with a capillary voltage of 
1200 V. MS parameters including drying gas flow rate and temperature as well as quadrupole 
ion energy and collision cell energy were similar for both setups. Optimal values are listed 
in Table S-3.1, Supporting Information. MS data was acquired between m/z 200 and 2000 
with a spectral acquisition rate of 1 Hz. 
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DATA ANALYSIS
CE-ESI-MS and nano-LC-ESI-MS data was analyzed with DataAnalysis 4.2 (Build 387, Bruker 
Daltonics), except for the direct infusion experiment. MS spectra were recalibrated using 
sodium adducts detected at the beginning of the electrophoretic run. Extracted ion 
electropherograms (EIEs, smoothed with a Gaussian fit) were generated for the first three 
isotopes of the doubly, triply and quaternary charged analytes with a width of ± 0.05 
m/z units. For PSA and Hp glycopeptides, fragmentation spectra were acquired for 68% 
of the compositions (Figures S-3.2 - S-3.7, Supporting Information). IgG and IgGmAb1 
glycopeptides were assigned according to literature.201 All compositions were matched 
based on exact mass, selectivity and relative intensities (Tables S-3.2 - S-3.5, Supporting 
Information). Identified compounds are represented in terms of number of hexoses (H), 
N-acetylglucosamines (N), fucoses (F) and sialic acids (S). The three main glycopeptides from 
IgG are defined as G0F (H3N4F1), G1F (H4N4F1) and G2F (H5N4F1).Results of direct infusion 
experiments were processed using LaCyTools, a LC(/CE)-ESI-MS data processing tool based 
on MassyTools.202 A sum spectrum was created for each flow rate, using a total time window 
of 1 min. Sum spectra were calibrated using at least five calibrants with signal-to-noise (S/N) 
ratio ≥ 9, including the three main glycopeptides G0F, G1F and G2F measured both under 
doubly- and triply-charged form. Subsequently, the peak area was integrated using 75% of 
the theoretical isotopic pattern of each analyte, corresponding to the first three isotopes of 
all glycopeptides with a window of ± 0.1 m/z units. The background was measured in a ± 10 
Da mass window around each glycopeptide and subtracted from the compound peak area.
Operating conditions for nano-LC-ESI-MS experiments are described in S-3-1-3, Supporting 
Information. Experimental procedures for the determination of LODs, repeatability and 
intermediate precision, as well as evaluation of the influence of the flow rate on MS signal 
intensity are described in S-3-1-4, S-3-1-5, and S-3-1-6, Supporting Information.
RESULTS AND DISCUSSION
This study presents the integration of a DEN-gas setup with the commercially available 
sheathless CE-ESI hyphenated to a MS system to improve the overall sensitivity and 
repeatability in glycopeptide analysis. After optimization of ESI source and MS parameters, 
the performance (i.e., sensitivity, repeatability, and detector response) of the CE-ESI-MS 
setup equipped with DEN-gas was investigated and compared to the conventional CE-ESI-
MS system without DEN-gas. Where possible, figures of merit from a state-of-the-art nano-
LC-ESI-MS setup were also included in the method comparison. 
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OPTIMAL CE-ESI-MS OPERATING CONDITIONS
The technical modifications of the commercial sheathless CE-ESI-MS system, described and 
illustrated in Figure S-3.1, Supporting Information, allowed for a straightforward addition 
of the DEN-gas into the ion source while providing a simple way to change between both 
setups (i.e., CE-ESI-MS with and without addition of DEN-gas). The best source conditions 
for the CE-ESI-MS setup were determined using MeCN as DEN-gas, similar to nano-LC-
ESI-MS with DEN-gas where MeCN showed optimal performance as a dopant.195 Optimal 
parameters were determined based on signal intensities, background noise, in-source 
fragmentation and repeatability of the relative abundances of glycopeptides during analysis 
of tryptic fucosylated Fc (fragment crystallizable) glycopeptides from polyclonal IgG1 (Table 
S-3.1, Supporting Information). As shown in Figure 3.1, the relative peak areas observed 
for the studied glycopeptides were 
consistent with or without DEN-
gas.177 Compared to CE-ESI-MS 
without DEN-gas, an overall higher 
intensity (ca. 2-fold enhancement for 
all glycopeptides) was observed with 
the DEN-gas supply (Figure S-3.8.A, 
Supporting Information). Moreover, 
the addition of DEN-gas led to a lower 
abundance of noise and interferences 
over the whole MS detection range 
(i.e., m/z 200-2000), especially in 
the region between m/z 500-800 
which showed the highest level of 
interferences in the spectra without 
DEN-gas (Figure S-3.9, Supporting 
Information). Thus, by adding MeCN 
as solvent vapor during ionization, an 
overall 2-fold increase in sensitivity 
(expressed as S/N ratios) was 
observed (Figure S-3.8.B, Supporting 
Information). 
The presence of the DEN-gas in the ESI source was found to have a slight effect on the 
electrophoretic separation, as illustrated in Figure 3.2. With the DEN-gas, the observed 
mobilities were slightly higher, which might be explained by a suction effect caused by the 
gas flow rate. However, the impact on both separation efficiencies and peak resolution was 
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Figure 3.1: Relative peak areas observed for 
IgG1 glycopeptides with CE-ESI-MS and CE-
ESI-MS with DEN-gas setup. Tryptic fucosylated 
glycopeptides were studied from IgG1. Error 
bars represent the standard deviation (N = 3). 
PEP illustrates the tryptic peptide sequence 
EEQYNSTYR.
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EFFECT OF DIFFERENT DOPANTS
The effect of the solvent composition (i.e., MeCN, IPA and EtOH) was investigated by 
comparing the peak areas obtained for fucosylated glycopeptides from IgG1. As shown in 
Figure S-3.10, Supporting Information, S/N ratios were significantly higher for all fucosylated 
glycopeptides with MeCN compared to the other two studied dopants. EtOH and IPA lead to 
relatively lower intensities than MeCN for most of the glycopeptides. Moreover, a different 
ionization behavior was observed with EtOH and IPA compared to MeCN with lower relative 
abundances of sialylated glycopeptides (i.e., G1FS, G2FS, G1FNS, and G2FNS). MeCN was 
selected for further DEN-gas experiments due to higher intensities, better coverage of 
sialylated glycopeptides and similarity of the glycosylation profiles with the conventional 












































































































































































Figure 3.2: Influence of DEN-gas on the EIE of the tryptic Fc N-glycopeptides from IgG1. (A) Without 
DEN-gas and (B) with DEN-gas, a sum MS spectrum recorded for the different IgG subclasses between 
25.8 and 26.8 min of Figure 3-2.B is shown in panel C. A.2 and B.2 show the base peak electropherograms 
and highlight the time window extracted for A.1 and B.1.
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The sensitivity enhancement observed for fucosylated glycopeptides obtained from polyclonal 
IgG1 was also observed with the analysis of tryptic Fc N-glycopeptides from IgGmAb1 
where an average 2-fold increase in S/N ratios was measured (Figure S-3.11, Supporting 
Information) while the relative abundances of glycopeptides remained constant. Moreover, 
similar relative abundances were observed with CE-ESI-MS configuration equipped with DEN-
gas compared to two state-of-the-art methods, i.e., nano-LC-ESI-MS (tryptic glycopeptides) 
and HILIC-FLD (PNGase F released N-glycans labelled with 2-aminobenzamide), as illustrated 
in Figure 3.3.203 
Besides sensitivity improvement, a higher charge state was observed for all glycopeptides 
when using the DEN-gas. This is illustrated in Figures S-3.12 - S-3.15, Supporting Information, 
which show the mass spectra recorded for glycopeptides G0F, G1F, G2F and sialylated 
glycopeptide G2FS. For instance, for glycopeptide G0F (Figure S-3.12), more than half of 


































Figure 3.3: Relative abundance observed for IgGmAb1 with CE-ESI-MS with DEN-gas, HILIC-FLD and 
nano-LC-ESI-MS. Data from HILIC-FLD and nano-LC-ESI-MS was retrieved from Reusch et al.203 Relative 
abundance was measured for the most abundant glycopeptides (A) and low abundant glycopeptides (B) 
on two consecutive days with multiple injections (N = 6). Error bars represent the standard deviation. 
The R attached to the glycan illustrates either the 2-aminobenzamide label (2-AB) on PNGase F released 
glycans used for HILIC-FLD analysis or the tryptic peptide sequence EEQYNSTYR for nano-LC-ESI-MS and 
CE-ESI-MS with DEN-gas. *: glycan form was not detected.
| 74 |  
| CHAPTER 3 |
charge state was observed with the DEN-gas supply where the most abundant ions detected 
were [M+3H]3+ (89%). Additionally, the [M+4H]4+ ions were observed (0.4%), which were not 
detected in the conventional setup. Likewise, the glycopeptide G2FS showed a relatively high 
abundance of ions [M+4H]4+ with DEN-gas (14%) than without (0%) (Figure S-3.15).
EFFECT OF FLOW RATE ON MS SIGNAL INTENSITY
The influence of the flow rate on MS signal intensity was evaluated for IgGmAb1 glycopeptides 
via direct infusion over a large range of flow rates (i.e., 1 - 88 nL/min) with and without 
the presence of DEN-gas. An overall increase in MS signal was observed with the DEN-
gas setup regardless to which flow rate was employed, as shown in Figure 3.4. A similar 
increase in signal has been observed for different glycoforms. Notably, a 5-fold increase in 
signal intensities was found at flow rates hgher than ca. 50 nL/min. At these flow rates, both 
setups showed a concentration-sensitive response (i.e., detector signal is proportional to 
the analyte concentration, but is independent of the mass flow).112 The benefits of using the 
DEN-gas setup in glycopeptide analysis are therefore predominant in this regimen which is 
known to be more prone to signal suppression effects compared to a mass-sensitive regime 
(i.e., detector signal is proportional to the mass flow).189,190 At lower flow rates, the mass flow 
of the analyte seemed to be predominant when using the DEN-gas resulting in a ca. 2- to 
4-fold sensitivity enhancement depending on the flow rate. Thus, a mixed regime area was 
observed between ca. 4 and 50 nL/min, which was mainly concentration-sensitive with a 
slight mass-sensitive contribution.
The presence of the DEN-gas led to improved ionization efficiencies over the large range of 
flow rates studied. The increased gain at higher flow rates suggests that further sensitivity 
enhancement might be expected for more concentrated samples. Additionally, an enhanced 
sensitivity can be expected when higher sample volumes would be injected with an on-line 




















Figure 3.4: MS intensity as a function of the flow 
rate with and without DEN-gas for glycopeptide 
G1F of IgGmAb1. Purified IgGmAb1 (0.17 ng/
nL) was infused in 10% HAc (v/v). The error bars 
represent the deviation (N = 3 ). Peptide backbone 
EEQYNSTYR.
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EFFECT OF INJECTION VOLUME
CE features the possibility to perform on-line sample pre-concentration within the separation 
capillary. This approach allows for the injection of more than 50% of the capillary volume 
(versus conventional injection of 1 - 2%) without peak broadening by focusing the analytes 
into a minimal volume, an approach referred to as sample stacking. The t-ITP approach used 
in this study relies on the injection of the sample dissolved in AAC, acting as the leading 
electrolyte, followed by a small post-plug of BGE acting as the terminating electrolyte.198 
When applying the separation voltage, an electric field gradient is established due to the 
different zone conductivities leading to the stacking of the analytes of interest behind the 
leading electrolyte, as a function of their respective mobility and the Kohlrausch regulating 
function.204,205 The combination of t-ITP with DEN-gas supply was evaluated with different 
injection volumes (9 - 352 nL, according to Hagen-Poiseuille equation and assuming a BGE 
viscosity of 1.04 mPa·s, corresponding to 1.4 - 55% of the capillary volume)112 and compared 
to the conventional CE-ESI-MS setup. 
Figure 3.5 illustrates the increase in peak areas with and without DEN-gas as a function 
of the injected volume for the IgG1 glycopeptides G1F (Figure 3.5.A) and G2FS (Figure 
3.5.B). For the tryptic Fc N-glycopeptide G1F, the ionization behavior showed distinct trends 
dependent on the volume injected, i.e., a linear relationship at low injected volumes, while 
a plateau was observed at higher injected volumes followed by a decline in MS intensity. 





























Injec�on volume (percentage of capillary volume) Injec�on volume (percentage of capillary volume)
Figure 3.5: Peak areas of IgG glycopeptides G1F (A) and G2FS (B) obtained with conventional CE-
ESI-MS and CE-ESI-MS with DEN-gas with different volumes injected. Different volumes injected are 
expressed as percentage of the total capillary volume. The error bars represent the range (N = 2 ) 
which are shown with an x-axis offset of 1% from the original data point. PEP illustrates the tryptic 
peptide sequence EEQYNSTYR.
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volume) with DEN-gas and ca. 95 nL (corresponding to 15% of the capillary volume) without 
DEN-gas, a deleterious effect was not only observed on the MS ionization but also on the 
CE separation, despite the t-ITP stacking procedure. By injecting higher sample volumes, 
the separation window became narrower, leading to the co-migration of the non-sialylated 
glycopeptides with an autolysis product from bovine trypsin, as illustrated in Figure S-3.16, 
Supporting information. One may speculate that the presence of this co-migrating autolysis 
product led to significant ionization suppression of the glycopeptides of interest (Figure 
S-3.17, Supporting information), explaining the plateau and subsequent decrease in MS 
intensity observed in Figure 3.5.A. Glycopeptide G2FS showed a slightly different ionization 
behavior (Figure 3.5.B) when increasing the injected volume. The sialylated species were 
less impacted by co-migration of other analytes (as illustrated in Figure S-3.18, Supporting 
information), but injection of larger volumes of samples led to unacceptable peak shapes 
for sialylated species, as clearly emphasized in Figure S-3.16, Supporting information, 
hampering a proper integration of the MS signal.
Overall, these results show that combining the DEN-gas with a relatively large injected 
volume allowed for a significant improvement in sensitivity compared to the conventional 
CE-ESI-MS setup. Moreover, adding MeCN vapor during the ionization process allowed for 
a higher dynamic acquisition range, rendering this approach very promising for quantitative 
purposes. The combination of the t-ITP pre-concentration technique and DEN-gas represents 
an attractive approach to reach the highest sensitivities in CE-ESI-MS, provided that a 
compromise is found between maximum volume injected and optimal separation efficiency. 
LIMITS OF DETECTION
LODs were determined for the G2F glycopeptide of IgGmAb1 with both CE-ESI-MS setups 
and compared to LODs determined for nano-LC-ESI-MS. Table 3.1 shows the LODs of the 
lowest concentration that could still be detected with a S/N ratio of ≥ 3. The minimum 
absolute molar amount detected is additionally translated to total IgGmAb1, factoring in the 
relative abundance of the G2F glycoform and the glycosylation site duplicity in the Fc-dimer. 
LODs of 0.9 amol were obtained with CE-ESI-MS with DEN-gas compared to 1.7 fmol with 
nano-LC-ESI-MS. This improvement is illustrated in Figure 3.6, which shows the differences 
observed in the S/N ratios between the three methods at relatively high, medium, and low 
concentrations. At relatively low concentrations (Figure 3.6.C), no signal was detected with 
the reference method (nano-LC-ESI-MS) while CE-ESI-MS with DEN-gas led to higher S/N 
ratios (10-fold) compared to the conventional setup. This higher sensitivity was confirmed 
when reporting the peak areas, as illustrated in Figure S-3.19, Supporting Information. 
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CE-ESI-MS is usually considered to have a lower concentration sensitivity than chromatographic 
approaches due to the significantly lower amount of sample that can be injected (nL versus 
µL range). However, by combining the sheathless approach with DEN-gas supply and on-line 
pre-concentration techniques, CE-ESI-MS showed better concentration sensitivity than the 
state-of-the-art nano-LC-ESI-MS approaches, making it a very competitive and attractive 
technique for glycopeptide analysis. 
REPEATABILITY AND INTERMEDIATE PRECISION
Compared to chromatographic techniques, CE-ESI-MS is usually considered less repeatable, 
especially when using the sheathless approach due to a lower stability of the ESI 
interface.206 The effect of the DEN-gas supply on repeatability and intermediate precision 
was investigated at low, medium, and high concentrations for the three most abundant 
tryptic glycopeptides from IgGmAb1. Tables 3.2 and 3.3 report the results on relative peak 










Nano-LC-ESI-MS 250.0 250.0 1700.0 320.0
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Figure 3.6: Signal-to-noise ratio (S/N) of IgGmAb1 
glycopeptide G1F obtained with nano-LC-ESI-
MS, conventional CE-ESI-MS, and CE-ESI-MS with 
DEN-gas at different concentrations. For CE-ESI-
MS experiments, samples were further diluted with 
leading electrolyte (3:2, v/v) prior to injection. (A) 
S/N observed at relatively high, medium, and low 
concentrations. Magnifications of the medium and 
low concentration are displayed in (B) S/N observed 
at 1.25 ng/µL and (C) S/N observed at 0.13 ng/µL. This 
concentration was below the LOD of nano-LC-ESI-
MS and hence G1F was not detected (*). Error bars 
represent the standard deviation (N = 3 ). The PEP 
illustrates the tryptic peptide sequence EEQYNSTYR.
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areas observed for repeatability (intraday variability) and intermediate precision (interday 
variability), respectively. Relative standards deviations (RSDs) were lower than 4% for all 
studied concentrations, which is similar to results reported for nano-LC-ESI-MS.207 A high 
repeatability is especially beneficial in profiling research, where an RSD of maximum 5% 
is generally accepted in the glycoproteomics field.203,208 This repeatability is for instance 
essential in the development of biopharmaceuticals and analysis of clinical biomarkers, 
since differences in glycosylation are known to have a significant impact on conformation, 
stability, and function of glycoproteins.209,210 
EFFECTS OF DEN-GAS SUPPLY ON OTHER GLYCOPEPTIDES
The investigation of CE-ESI-MS with DEN-gas supply was further extended with two 
additional glycoproteins, namely haptoglobin (Hp) and prostate-specific antigen (PSA). Hp 
has four N-linked glycosylation sites, resulting in three glycopeptides after tryptic cleavage 
with one glycopeptide containing two N-linked glycosylation sites. Using the DEN-gas 
supply, the most abundant glycopeptides showed relative peak areas that were very similar 
to those observed without DEN-gas (Figures S-3.20.A, S-3.21.A, and S-3.22.A, Supporting 
Information). However, different improvement factors of S/N ratios and absolute peak areas 
were observed depending on the peptide backbone. For instance, glycosylation site N184 
has a peptide backbone of 24 amino acids and showed a ca. 11-fold increase in peak area 
and ca. 31-fold increase in S/N ratios (Figure S-3.20, Supporting Information), while the 
peptide with glycosylation site N241 (16 amino acids) showed a ca. 4-fold increase in peak 
Table 3.2: Intermediate precision of tryptic Fc N-glycopeptides from IgGmAb1 with CE-ESI-MS using the 
DEN-gas. Relative abundances (normalized to the sum of these three glycoforms) for low, medium and high 
concentrations are shown with their relative standard deviation (N = 3).
Relative abundance
Concentration (ng/µL) G0F G1F G2F
0.03 38% (1.5%) 50% (1.5%) 12% (1.7 %)
0.30 38% (1.2%) 51% (0.7%) 11% (5.5%)
3.00 37% (0.1%) 52% (0.3%) 11% (1.1%)
Table 3.3: Repeatability of tryptic Fc N-glycopeptides from IgGmAb1 with CE-ESI-MS using the DEN-gas. 
Relative abundances (normalized to the sum of these three glycoforms) for low, medium and high concentrations 
are shown with their relative standard deviation (N = 3).
Relative abundance
Concentration (ng/µL) G0F G1F G2F
0.03 37% (3.2%) 51% (2.6%) 12% (1.5 %)
0.30 37% (1.1%) 51% (0.9%) 12% (2.7%)
3.00 37% (0.6%) 52% (0.4%) 11% (1.0%)
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area and ca. 6-fold increase for S/N ratios (Figure S-3.21, Supporting Information). For 
the glycopeptide with 13 amino acids and two potential glycosylation sites, namely N207 
and N211, the H5N4S1 glycoform showed a 2-fold increase in peak area and S/N ratio, while 
H10N8S2 gave a 3-fold increase in peak area and a 2-fold increase in S/N ratio (Figure S-3.22, 
Supporting Information). PSA, which contains a single N-linked glycosylation site, resulting 
in a peptide backbone of two amino acids (N69K) after tryptic cleavage, showed a 2-fold 
and 3-fold enhancement in absolute peak area and S/N ratio, respectively (Figure S-3.23, 
Supporting Information).
All studied glycopeptides displayed similar relative ratios between the CE-ESI-MS-platform 
with and without DEN-gas. When using the DEN-gas supply, an overall gain in sensitivity 
(i.e., 2- to 31-fold increase) was observed for diverse glycopeptides with different peptide 
backbones, glycan structures and glycosylation sites, where singly-glycosylated peptides 
showed higher sensitivity improvement than non-glycosylated species. 
MECHANISTIC CONSIDERATIONS
The combination of the DEN-gas setup with the commercial sheathless CE-ESI-MS system 
showed significantly higher sensitivities and improved repeatability for glycopeptides 
analysis. The positive impact of adding a dopant to the gas-phase may be explained by 
the combination of complex and multimodal mechanisms acting on both evaporation and 
ionization. For instance, Nguyen and Fenn already showed that the addition of polar solvent 
vapors to a nitrogen sheath gas led to a substantially higher abundance of desolvated ions 
and, thus, a higher intensity.191 The enthalpy of condensation, released by adsorption of the 
solvent vapor molecule to the droplet surface, might lead to the formation of “hot spots” 
which help nearby solvent molecules to evaporate from the surface. Another mechanism 
may be linked to the proton transfer occurring in the gas-phase in presence of a solvent. The 
difference in both ionization efficiencies and charge state distributions may be explained 
by the different gas-phase basicity and proton affinity of MeCN present in the DEN-gas 
compared to water.211 Other relevant mechanisms may contribute to these observations and 
further research is necessary to enable the prediction of glycopeptides ionization behavior 
in the presence of a DEN-gas.
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CONCLUSION
This study evaluated the integration of a DEN-gas supply with sheathless CE-ESI-MS for 
glycopeptides analysis. An overall improved ionization efficiency was found using the DEN-
gas which is in line with previous findings of nano-LC-ESI-MS measurements. The optimized 
sheathless CE-ESI-MS setup equipped with DEN-gas and using MeCN as a dopant showed 
improved sensitivities for all the glycopeptides studied compared to the conventional CE-
ESI-MS setup. Notably, by combining an on-line pre-concentration technique and an optimal 
flow rate with the DEN-gas, a considerable factor of improvement was reached. LODs 
were found to be significantly lower than observed with state-of-the-art nano-LC-ESI-MS. 
Moreover, the usage of DEN-gas showed an excellent repeatability with RSDs lower than 4%, 
showing its benefits in protein glycosylation analysis.
Overall, this study presents a powerful analytical tool for glycopeptide analysis with 
an enhanced sensitivity and repeatability. Further investigations are needed to better 
understand the complex and multimodal mechanisms underlying the observed sensitivity 
improvement (e.g., using a larger set of compounds). Additional perspectives of this work 
include the investigation of ionization tuning via addition of modifiers to the dopant, for 
instance a base or acid, and variation of the dopant concentration. Moreover, the effect of 
DEN-gas in metabolomic or proteomic applications remains open and needs to be evaluated. 
Notably, the addition of DEN-gas to a CE-ESI-MS setup may be beneficial in proteomics, 
allowing for the addition of supercharging agents (e.g., m-nitrobenzyl alcohol, sulfolane, etc.) 
to MeCN, leading to detection of higher charge states of peptides and resulting in a higher 
number of identified peptides.
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ABSTRACT
The in-depth characterization of released N-glycans remains a challenging task from low 
abundant proteins, limited sample amounts and of minor glycoforms in complex mixtures. 
Both high sensitivity and differentiation of isomeric N-glycan structures are required in 
biomarker research focused on protein glycosylation. A suitable approach for the highly 
sensitive and in-depth analysis of N-glycans is the hyphenation of capillary electrophoresis 
(CE) to mass spectrometry (MS), via electrospray ionization (ESI). However, N-glycans are 
either neutral (non-sialylated) or negatively charged (carrying one or several sialic acids), 
which hampers their efficient separation by CE and results in ionization biases during MS 
detection. Here, we present an easy workflow for the neutralization of sialic acids, which 
additionally enabled the differentiation between α2,3- and α2,6-linked sialic acids by 
MS based on their derivatized mass. Furthermore, an uniform charge was introduced to 
all N-glycans via reducing end tagging with a cationic hydrazide (Girard’s reagent P). The 
sensitivity of the CE-ESI-MS method was optimized by the implementation of dopant 
enriched nitrogen gas to aid the ionization for MS detection. A highly sensitive detection 
of N-glycans was achieved with the presented platform in positive mode MS. Studying the 
total human plasma protein N-glycome, 167 glycoforms were identified, including sialic acid 
linkage-isomers. Being at least 100 times more sensitive than conventional matrix-assisted 
laser/desorption ionization time-of-flight (MALDI-TOF)-MS methods, CE-ESI-MS provides a 
highly complementary tool in the field of N-glycan analysis. 
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INTRODUCTION
Glycosylation is known as one of the most complex post-translational protein modifications 
and is involved in many biological processes, including protease binding and antibody-
receptor interactions.82 In addition, the structure of a protein, as well as its solubility, are 
largely influenced by its glycosylation82 and alterations in protein glycosylation have been 
associated with diseases such as rheumatoid arthritis and cancer.3,212,213 Furthermore, 
the efficacy of biopharmaceuticals, and their half-life, is highly affected by associated 
glycosylation features.149-151 Therefore, it is of utmost importance to have instruments that 
can characterize the glycosylation of a protein, or a set of proteins, in an in-depth manner. 
However, differentiating glycan isomers and obtaining information about monosaccharide 
linkage-positions remains a challenging task. Of particular importance is the differentiation 
of N-acetylneuraminic acids (further referred to as sialic acids) linked to galactoses (α2,3 or 
α2,6), as these are implicated in different biological processes, such as protein clearance 
(protein half-life) and glycan interaction with glycan-binding proteins such as galactins.8,9,144 
In addition, the differently linked sialic acids have biomarker potential for a range of 
diseases.92,97 For example, in the case of prostate cancer, where it has been suggested 
that the sialic acid linkage-isomers present on prostate-specific antigen (PSA) provide a 
better sensitivity and specificity in the early detection of this type of cancer than serum 
PSA concentration alone.33-35,214 Besides the need for a platform that can provide extensive 
structural information about protein glycans, there is also a great demand for more sensitive 
techniques to perform glycosylation analysis on minimal amounts of sample and (glyco)
proteins that are only present in low concentrations.107,215
Capillary electrophoresis (CE), hyphenated to mass spectrometry (MS) via electrospray 
ionization (ESI), provides an attractive approach to characterize N-glycans released from 
proteins, as it allows highly sensitive detection as well as a good separation efficiency.216-218 
However, released N-glycans are not uniformly charged, as they might carry either zero, one 
or multiple negatively-charged sialic acids. This hampers the analysis by CE-ESI-MS in multiple 
ways, namely by the introduction of an ionization bias during MS detection, by the migration 
of the sialylated species towards the inlet in normal mode CE (detection at the cathodic end 
of the capillary), and by compromising the separation of the neutral (non-sialylated) species 
in both normal and reversed mode CE separation, as the migration will only be driven by 
the electro-osmotic flow (EOF). Previous work showed that the labeling of N-glycans at 
their reducing end with a negatively charged label, like 8-aminopyrene-1,3,6-trisulfonic 
acid (APTS) or 8-aminoapthalene-1,3,6-trisulfonic acid (ANTS), enables the simultaneous 
and efficient separation of both sialylated and non-sialylated glycoforms by reversed mode 
CE.217,219 The combination of sialic acid neutralization and the introduction of an uniform label 
to the N-glycans results in the same charge for all species, enabling separation based on the 
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hydrodynamic volume only. For example, sialic acid neutralization and positive labeling of 
the N-glycan reducing end by aminoxy-tandem mass tag (TMT) provided the opportunity 
to separate and detect N-glycans in an efficient manner using normal mode CE and positive 
mode MS.220 In addition, the linkage-specificity of the sialic acid neutralization in the latter 
approach (either with APTS or TMT tag), resulted in the differentiation between α2,3- and 
α2,6-linked sialic acids by MS.216,221 Linkage-specific sialic acid derivatization can be performed 
via both esterification and amidation reactions,155,160,222-224 often leading to lactone formation 
for the α2,3-linked sialic acids. However, lactones are prone to hydrolysis during subsequent 
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Figure 4.1: Reaction scheme for the linkage-specific 
derivatization of sialic acids and subsequent Girard’s 
reagent P (GirP) reducing end labeling. (A) The α2,6-
linked sialic acid gets ethyl-esterified during the first 
step of the reaction and remains stable throughout. (B) 
The α2,3-linked sialic acid initially loses water forming a 
lactone. After the addition of ammonia, the lactone ring 
is opened and a stable amide is formed. (C) The reducing 
ends of all N-glycans are labeled with GirP.
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In this study, the use of CE-ESI-MS was explored for an in-depth analysis of released 
N-glycans by combining linkage-specific sialic acid derivatization with the introduction of a 
permanent cationic label at the N-glycan reducing end. To overcome the instability of the 
lactonized α2,3-linked sialic acids during reducing end labeling, a simple additional step was 
implemented turning lactones into amide derivatives, while keeping the ethyl esters on 
the α2,6-linked sialic acids intact (Figure 4.1.A and 4.1.B). For the reducing end labeling, a 
low-cost, readily available hydrazide label, Girard’s reagent P (GirP), was employed (Figure 
4.1.C).225 To enhance the sensitivity of the CE-ESI-MS platform for the analysis of the N-glycan 
derivatives, dopant enriched nitrogen (DEN)-gas was implemented.226 The sensitivity of the 
current CE-ESI-MS method was assessed and compared to a frequently used matrix-assisted 
laser desorption/ionization (MALDI) time-of-flight (TOF)-MS platform. Furthermore, using 
this novel CE-ESI-MS(/MS) approach, the total human plasma protein N-glycome (TPNG) was 
studied, resulting in the identification of 167 N-glycan compositions, with differentiation of 
sialic acid linkage-variants. 
MATERIALS AND METHODS
The materials used in this research can be found in Section S-4-1-1, Supporting Information. 
Additional details on the N-glycan release, the optimization of linkage-specific sialic acid 
neutralization by ethyl esterification and amidation (EEA), sialic acid derivatization by double 
amidation (DA)222 and the purification of N-glycans and sialyllactose standards can be found 
in Section S-4-1-2 - S-4-1-4, Supporting Information. 
PERMANENT CATIONIC LABELING OF THE N-GLYCAN REDUCING END
After sialic acid derivatization, either by EEA or DA, released N-glycans were labeled at 
the reducing end with GirP. Initial reaction conditions were as follows, 5 µL of sialic acid-
derivatized N-glycans, purified by hydrophilic interaction chromatography (HILIC), were 
mixed with 95 µL GirP reagent (15 mM GirP in 85% ethanol (EtOH), 10% acetic acid (HAc) and 
5% ultrapure deionized water (MQ)) and incubated for 2 h at 60˚C. After incubation, 105 µL 
acetonitrile (MeCN) was added and cotton HILIC solid phase extraction (SPE) was performed 
as described in Section S-4-1-3, Supporting Information, using 85% MeCN washing solutions 
and 10 µL elution volume. Optimization of the protocol included decreasing the percentage 
of MQ in the reagent, increasing the concentration of GirP, decreasing the sample volume, 
decreasing the reagent volume and decreasing the incubation time (Section S-4-1-5 and 
Table S-4.1, Supporting information). The optimized reaction conditions included a drying 
step of the N-glycan sample prior to adding 2 µL of GirP reagent (50 mM GirP in 90% EtOH 
and 10% HAc) and 1 h incubation at 60˚C. After incubation, the samples were dried by 
vacuum concentration at 60˚C and dissolved in 10 µL MQ for CE-ESI-MS analysis or 33.3 µL 
85% MeCN for HILIC purification and MALDI-TOF-MS analysis.
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SENSITIVITY ASSESMENT FOR MALDI-TOF-MS AND CE-ESI-MS METHODS
Two glycan standards (H3N4 and H5N4) were dissolved in water and mixed in a final 
concentration of 3333 fmol/µL for each glycoform. The mixture was diluted 10, 20, 100, 200, 
1,000, 2,000 and 10,000 times and 6 replicates of 3 µL of each of the dilutions (10,000, 1,000, 
500, 100, 50, 10, 5 and 1 fmol of each glycan) were subjected to EEA and HILIC purification, 
and eluted in 10 µL MQ (Table S-4.2, Supporting information). Three of the replicates were 
analyzed by MALDI-TOF-MS. The remaining three replicates were dried, labeled with GirP 
following the optimized protocol as described above and analyzed by CE-ESI-MS.
Procedures for the MALDI-TOF-MS and CE-ESI-MS analysis are described in Section S-4-1-7 
and S-4-1-8, Supporting Information, respectively. In addition, Section S-4-1-9, Supporting 
Information describes the data processing of MALDI-TOF-MS and CE-ESI-MS data using 
MassyTools202 and LacyTools162, respectively.
RESULTS AND DISCUSSION
LINKAGE-SPECIFIC SIALIC ACID NEUTRALIZATION
It is known that N-glycan conjugates with differentially linked sialic acids can be 
separated without any further modification of the analytes by CE,6 porous graphitized 
carbon liquid chromatography (LC)165 or ion mobility MS.154 However, during this study 
it was chosen to neutralize the sialylated species in a linkage-specific way, in order to 
analyze them simultaneously with the non-sialylated species in normal mode CE and to 
simplify their identification in MS(/MS). A variety of methods are known for the linkage-
specific neutralization of sialic acids, resulting in either lactonization,160,224 amidation222 or 
methyl amidation223,227 of the α2,3-linked sialic acids and methyl esterification,160,224 ethyl 
esterification,160 isopropylamidation223 or dimethylamidation155,222 of α2,6-linked sialic acids. 
Approaches resulting in (methyl)amidation of the α2,3-linked sialic acids are preferred over 
those inducing lactone formation, as the latter is prone to hydrolysis, especially during 
further processing or storage of the samples.221,222 Most of these two-step approaches need 
a cleanup-step in between, to ensure stability as well as the differentiation of the differently 
linked sialic acids.223,227 However, this extra cleanup is prone to (biased) sample loss, making 
it preferable to have a one-pot sample preparation, avoiding intermediate cleanup while 
keeping the required two-step reaction.222 In order to generate a derivative of the α2,3-linked 
sialic acids with long-term stability, we introduced an amidation step using ammonia after 
the ethyl esterification (α2,6-linked sialic acids) and lactonization (α2,3-linked sialic acids) 
step of the original ethyl esterification protocol.160 The ammonia step turned the lactonized 
α2,3-linked sialic acids into amides (290.111 Da), while keeping the ethyl esters on α2,6-
linked sialic acids intact (319.127 Da; Figure 4.1.A and 4.1.B). The method was optimized 
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using sialyllactose standards and optimization was further monitored using 23 N-glycan 
compositions of the TPNG (Figure S-4.1, Supporting information). The optimal concentration 
of ammonium hydroxide (NH4OH) in the second step of the reaction was found to be 1.15 M, 
resulting in 100.0% ± 0.02% (± standard deviation) of amide formation and 99.1% ± 0.3% of 
ethyl ester formation for 3’-sialyllactose and 6’-sialyllactose, respectively (m/z 775.286 and 
804.301; Figure S-4.1.A and B, Supporting information). The reaction specificity was highly 
comparable to the specificity reported for ethyl esterification alone (above 97% specificity 
for both sialyllactoses),160 while higher concentrations of NH4OH (1.60 or 1.98 M) resulted 
in a minimum specificity of 94.4% ± 3.0% on 6’-sialyllactose. When applying the optimized 
reaction conditions (using a final concentration of 1.15 M NH4OH; EEA) on TPNG N-glycans, 
the profiles obtained were highly comparable to those resulting from the original ethyl 
esterification protocol (Figure S-4.1.C, Supporting information). The most intense signal 
resulted from a diantennary N-glycan with two α2,6-linked sialic acids and without core-
fucose (H5N4F1S
2,6
2, m/z 2301.835)160 with a relative intensity of 54.0% ± 4.0% after EEA 
and 56.3% ± 1.3% after ethyl esterification. The EEA conditions were furthermore compared 
to the DA conditions for released N-glycans as described previously,222 which resulted in 
highly comparable TPNG profiles, showing the relative abundance of the highest signal to be 
53.4% ± 1.0% and 54.3% ± 0.6% for the DA and EEA, respectively (Figure S-4.2, Supporting 
information). 
The adapted linkage-specific sialic acid neutralization resulted in ethyl esterification of α2,6-
linked sialic acids and amidation of α2,3-linked sialic acids, by implementing an amidation 
step with ammonia directly after the original ethyl esterification incubation period. The end 
products remained intact during subsequent reducing end labeling at 60˚C and compared to 
previously mentioned methods no intermediate cleanup was necessary.223,227
PERMANENT CATIONIC LABELING OF THE N-GLYCAN REDUCING END
As both the non-sialylated and neutralized N-glycans do not carry a readily chargeable group, 
a chargeable group should be introduced to all glycoforms to enable CE separation. This is 
often achieved by labeling the reducing end of the N-glycans, for which reductive amination, 
using an arylamine, is the most common method.228,229 After the reaction with the amine, 
reductive amination converts the Schiff-base into a stable secondary amine. Unfortunately, 
the resulting excess of reducing agent is usually not compatible with the subsequent analysis 
methods and a cleanup step is needed, inevitably inducing sample loss. The use of hydrazine 
or hydrazide labels has the advantage that no reduction (and subsequent clean up) is required, 
as the generated hydrazones are reasonably stable and have multiple resonance forms which 
lower their susceptibility to nucleophilic attacks.225,230 Both hydrazine and hydrazide labels 
have proven their applicability in the analysis of released N-glycans by LC-ESI-MS and MALDI-
TOF-MS methods, enhancing ionization and/or separation efficiency.225 Here, we introduced 
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the hydrazide GirP, carrying a permanent positive charge, to all N-glycans after the linkage-
specific neutralization of the sialic acids by either EEA (current study) or DA (Figure 4.1.C).222 
The optimization of the reducing end labeling with the hydrazide label started with reaction 
conditions based on literature,231-233 as described in Section S-4-1-5, Supporting Information. 
However, instead of the commonly used methanol, we used EtOH as solvent, because of its 
lower toxicity. Labeling efficiency was evaluated based on MALDI-TOF-MS analysis of the 
HILIC SPE-purified reaction products, taking into account seven N-glycan signals covering 
di- and tri-antennary species with and without sialic acids (Figure S-4.3, Supporting 
information). Initial experiments revealed the labeling efficiency to be highly dependent on 
the vacuum concentrator used to dry the samples after the reducing end labeling (data not 
shown). To improve the robustness of the labeling, the reaction conditions were optimized 
in such a way that the labeling was already at its maximum before vacuum concentration. 
In the first optimization step, the fraction of water in the GirP reagent was reduced from 5% 
to 0% resulting in a labeling efficiency of 52% ± 7% (Table S-4.1, Supporting information). 
Reducing the water content was expected to push the equilibrium to completeness, as water 
is one of the reaction products. Subsequently, the GirP concentration was increased to 50 
mM, resulting in a labeling efficiency of 72% ± 4% (Table S-4.1, Supporting information). 
Drying the N-glycans prior to addition of the reagent further reduced the water content of 
the final mixture. In this way we were able to reduce the reagent volume to 2 µL (labeling 
efficiency 89% ± 5% (Table S-4.1, Supporting information). Finally, the incubation time was 
reduced to 1 h for practical reasons, resulting in a labeling efficiency of 87% ± 4% for the 
optimized protocol (Table S-4.1, Supporting information).
CE-ESI-MS(/MS) OF GIRARD’S REAGENT P LABELED N-GLYCANS
IMPLEMENTATION OF DOPANT ENRICHED NITROGEN GAS AT THE INTERFACE 
BETWEEN CE AND MS
Previously, an improved ESI efficiency for peptides and glycopeptides was obtained when a 
nebulizer, a dry gas enriched with MeCN, was infused into the ionization source (DEN-gas) 
for both (nano)LC-ESI-MS and CE-ESI-MS platforms.194,226 Here, we evaluated the added value 
of using DEN-gas for the sensitivity of GirP labeled N-glycan detection with CE-ESI-MS. The 
incorporation of DEN-gas at the interface between the CE and the MS resulted in an overall 
lower background, particularly in the higher m/z region (m/z > 500; Figure S-4.4, Supporting 
information). Furthermore, a higher intensity for the base peak electropherogram was 
obtained (Figure S-4.4.A.2 and S-4.4.B.2, Supporting information). The advantages of 
using DEN-gas were further supported by comparing the analysis of the 20 most abundant 
N-glycans with and without the use of DEN-gas (Figure S-4.5, Supporting information). While 
the relative abundances of the N-glycans remained the same (Figure S-4.5.A, Supporting 
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information), an average 3-fold increase in S/N (Figure S-4.5.B, Supporting information) 
and a 2-fold increase in absolute peak area (Figure S-4.5.C, Supporting information) were 
observed when using DEN-gas. Based on this, DEN-gas was employed for all further analyses.
SENSITIVITY ASSESSMENT
The sensitivity of the CE-ESI-MS platform with DEN-gas was evaluated using two N-glycan 
standards in known amounts (H3N4 and H5N4, Table S-4.2, Supporting information). These 
standards were selected, as they have no likely isomeric structural variants, which would 
hamper an exact determination of the sensitivity. The sensitivity of the CE-ESI-MS platform 
was compared to that of a commonly used MALDI-TOF-MS platform for released N-glycan 
analysis. Starting with 10,000 fmol of both standards, a dilution range down to 1 fmol 
covered the limit of quantification for both the CE-ESI-MS and the MALDI-TOF-MS platform. 
A starting amount of 5 fmol of N-glycans was sufficient for detection and quantification by 
CE-ESI-MS, while for MALDI-TOF-MS starting amounts of 500 fmol were necessary (Table 
4.1). 
The relative abundances of the two standards remained consistent between the different 
concentrations (down to the aforementioned minimum starting amounts) and platforms 
(Figure S-4.6, Supporting information). For the CE-ESI-MS platform, the 5 fmol starting 
amount corresponded to the injection of 20 amol (43 nL corresponding to 1/250 of the 
sample) of H3N4 and H5N4 with detection at S/N 49 ± 18 and 146 ± 52, respectively (Figure 
4.2, Table 4.1). For MALDI-TOF-MS, 50 fmol of H3N4 and H5N4 was spotted on the target (1 
µL corresponding to 1/10 of the sample) with detection at S/N 23 ± 8 and 45 ± 26, respectively 
(Table 4.1). These results indicate the potential use of the presented CE-ESI-MS workflow for 
the analysis of samples for which ultrahigh-sensitivity is needed. We additionally envision 
that, for samples primarily analyzed by MALDI-TOF-MS after EEA, in-depth analysis can be 
performed by CE-ESI-MS with minimal sample consumption.
Table 4.1: Sensitivity assessment of the H3N4 and H5N4 N-glycan standards as analyzed with MALDI-TOF-MS 
following EEA, or CE-ESI-MS with DEN-gas after additional labeling with GirP. The presented values correspond to 
the lowest amounts of material measured, that still allowed reliable quantification (N = 3, Supporting information, 
Table S-4.2).
Starting amount Consumed molar amount
Average S/N ± SD
H3N4 H5N4
CE-ESI-MS 5 fmol 20 amol * 49 ± 18 146 ± 52
MALDI-TOF-MS 500 fmol 50 fmol 23 ± 8 45 ± 26
* Corresponding to an injection volume of 43 nL (2 µl sample vial)
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IN-DEPTH ANALYSIS OF TPNG RELEASED N-GLYCANS
The CE-ESI-MS(/MS) platform for the analysis of GirP-labeled N-glycans was used to perform 
an in-depth investigation of the TPNG (Figure 4.3). Collision-induced dissociation (CID) MS/
MS spectra were obtained for 82 unique N-glycan compositions revealing a broad range of 
structural features. Based on mass accuracy (< 10 ppm error) and migration behavior, an 
additional 85 N-glycans could be identified bringing the total number of detected N-glycans 
to 167. Table S-4.3.1 in the Supporting information (Excel file) provides an overview of 
the TPNG N-glycans found in the current study as compared to literature. An overview of 
the N-glycans that were not observed in this study but were observed in previous studies 
is given in Table S-4.3.2, Supporting information (Excel file). The observed discrepancies 
might be partially caused by biological variation between the analyzed samples.
Rather low amounts of N-glycans with underivatized sialic acids were found, as expected 
due to the stable derivatization of both α2,3- and α2,6-linked sialic acids implemented in 
our workflow.222,223 The underivatized variants of the most abundant N-glycan (H5N4S2,62) 
and its isomeric variants (H5N4S2,61S2,31 and H5N4S2,32), only accounted for 1.8% ± 0.7% 
(H5N4S2,61Sunderivatized1) and 0.1% ± 0.04% (H5N4S2,31Sunderivatized1) of the total H5N4S2-related 
signals (Figure S-4.7, Supporting information). The H5N4S1-related signals reveal similarly 
high derivatization efficiencies, with the ethyl-esterified species dominating (H5N4S2,61; 
94.0% ± 0.9%) followed by the amidated variant (H5N4S2,31; 5.1% ± 0.6%), and only 0.9% 
± 0.03% of the area accounting for the underivatized sialic acid form (H5N4Sunderivatized1). 














































































































Figure 4.2: CE-ESI-MS analysis of the two N-glycan standards using DEN-gas, after sialic acid 
derivatization (EEA) and reducing end labeling with GirP on 5 fmol of both glycoforms. (A) Extracted 
ion electropherograms of H3N4 and H5N4 after injection of a final amount of 20 amol. Spectra of the 
doubly charged species corresponding to (B) H3N4 and (C) H5N4. GirP illustrates the Girard’s reagent P 
label, attached to the glycans.
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results in products that are stable over time and during subsequent processing at elevated 
temperatures. Furthermore, N-glycans without GirP-label, or sialylated species with more 
than one underivatized sialic acid, were not found in the CE-ESI-MS analysis. This may be 
partially due to the selectivity of the CE separation and ESI-MS detection, as we know that 
a minor fraction of the glycans was not reducing end-labeled, based on the MALDI-TOF-MS 
experiments (Table S-4.1, Supporting information).
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Figure 4.3: Extracted ion electropherograms of released TPNG N-glycans after sialic acid 
derivatization (EEA) and reducing end labeling with GirP. (A) The 10 most abundant N-glycans (> 2% 
relative abundance), (B) 10 medium abundant N-glycans (between 0.5 - 1.0% relative abundance) and 
(C) 10 low abundant N-glycans (< 0.25% relative abundance) are displayed. Separation was achieved 
using a bare fused silica capillary after dynamic neutral coating. The CE-ESI-MS analysis was performed 
using DEN-gas. GirP illustrates the Girard’s reagent P label, attached to the N-glycans. * Indicates in-
source decay of the Man6. # Shows the presence of doubly charged species of H5N5F1 of which the m/z 
values overlap with the ones of the triply charged species of H6N5F1S2,32S2,61.
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GirP carries a permanent positive charge on its quaternary amine group, enabling normal 
mode CE separation of labeled N-glycans under a broad range of conditions. Permanently 
charged N-glycans have shown before to result in a lower sensitivity during ESI than 
N-glycans with a more hydrophobic label, carrying a proton acceptor group.232,234 However, 
a permanent charge at the N-glycan reducing end aids the fragmentation in MS/MS by 
providing permanently charged Y-ions.233 Interestingly, some distinct diagnostic ions could 
be identified in the MS/MS data of the GirP-labeled N-glycans (Figure S-4.8 and Table 
S-4.3.3, Supporting information). The Y-ion detected at m/z 355.1621+ corresponds to the 
GirP label with an N-acetylglucosamine, while the ion at m/z 501.2201+ indicates the presence 
of core-fucosylation; [GirP + N-acetylglucosamine + fucose]+. Bisection was identified by a 
Y-ion present at m/z 923.3731+, or in combination with a core-fucose at m/z 1069.4311+. In 
addition, several diagnostic oxonium ions (B-ions) were detected. The signal at m/z 291.1191+ 
corresponds to an amidated sialic acid (α2,3-linked) while m/z 320.1341+ corresponds to an 
ethyl-esterified sialic acid (α2,6-linked). The observed B-ion at m/z 325.1131+ corresponds 
to two hexoses, mainly observed in high mannose N-glycans. The signal at m/z 366.1401+ 
typically indicates an antenna [hexose + N-acetylhexosamine]+, observed for complex and 
hybrid-type N-glycans. While a signal at m/z 512.1971+ indicates a fucose attached to an 
antenna [hexose + N-acetylhexosamine + fucose]+. Signals at m/z 656.2511+ and m/z 685.2601+ 
are B-ions indicating a full antenna loss with an amidated (α2,3-linked) or an ethyl-esterified 
(α2,6-linked) sialic acid, respectively. In the case of a fucosylated, α2,3-linked sialylated 
antenna, a B-ion at m/z 802.3091+ was observed. Notably, no fucosylation was observed for 
antennae with ethyl-esterified (α2,6-linked) sialic acids, indicating that antenna fucosylation 
in TPNG occurs solely in the context of sialyl Lewis-type structures such as sialyl Lewis X.235,236 
Furthermore, MS/MS of fucosylated N-glycans with more than two antennae, generally 
indicated antenna fucosylation (except from when they were exclusively α2,6-sialylated). 
Mono- and diantennary N-glycans, on the other hand, showed mainly core-fucosylation.
REPEATABILITY AND INTERMEDIATE PRECISION OF TPNG RELEASED N-GLYCAN 
ANALYSIS
The final CE-ESI-MS assay was evaluated for its repeatability and intermediate precision 
by preparing three separate samples per day on three consecutive days including the 
N-glycan release step, sialic acid derivatization (EEA) and reducing end labeling. Samples that 
underwent the same sample treatment except for the labeling procedure, were analyzed 
on a commonly used MALDI-TOF-MS platform. This allowed the comparison between the 
two analytical methods. The CE-ESI-MS platform detected 167 unique N-glycans, of which 
118 N-glycans could be quantified (ppm error ± 10 ppm, S/N > 9 and isotopic pattern 
quality score (IPQ) < 20%; Table S-4.3.1, Supporting information (Excel file)). After total 
area normalization of the 118 glycoforms, the median relative standard deviation (RSD) 
of the 20 most abundant N-glycans (accounting for about 80% of the summed N-glycans 
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quantified in TPNG) was found to be 6.8% for the repeatability (intraday variability day 1), 
while the intermediate precision (interday variability day 1 to 3) resulted in a median RSD of 
9.4% (Figure S-4.9, Supporting information). With the MALDI-TOF-MS platform, a total of 
76 N-glycans were detected, of which 54 N-glycans were quantified (ppm error ± 20 ppm, 
S/N > 9 and IPQ < 20%; Table S-4.3.1, Supporting information). The median RSD of the 20 
most abundant N-glycans was found to be 9.4% for the repeatability (intraday variability 
day 1) while the intermediate precision (interday variability) resulted in a median RSD of 
15.1% (Figure S-4.10, Supporting information), which was slightly higher than the level 
reported before for the MALDI-TOF-MS platform.160,208 The rather low RSDs obtained with 
the CE-ESI-MS method indicates that the extra sample preparation step required for the 
introduction of the cationic reducing end label hardly compromises the repeatability of the 
method. The higher variability of the MALDI-TOF-MS platform compared to the CE-ESI-MS 
platform is most likely introduced by the heterogeneous crystallization of the samples on the 
MALDI target. For the TPNG samples, the lowest abundant glycoform that could be reliably 
quantified using the MALDI-TOF-MS platform (H6N5F2S2,31S2,62) had a relative abundance 
of approximately 0.08%, while for the CE-ESI-MS platform this was about ten times lower at 
0.007% (H8N7F1S2,34), resulting in the coverage of a vaster range of N-glycan species.
FUTURE PERSPECTIVES
The current work describes an ultrahigh-sensitive CE-ESI-MS platform for the analysis of 
released N-glycans. The complete and straightforward workflow involves sialic acid linkage-
specific derivatization, purification of the N-glycans by HILIC SPE, reducing end labeling with 
the cationic GirP and, finally, separation and detection by CE-ESI-MS. 
This study allowed a relatively rapid CE separation (5 min separation window) using a 
dynamic, neutral capillary coating and a constant pressure of 0.5 psi. Further optimization 
of the CE conditions would enable the separation of isomeric structures, on top of the 
separation of sialic acid linkage-isomers already achieved with the current method. This 
could lead to an even deeper insight into complex samples, like the TPNG. For example, 
the differentiation between arm galactosylation and sialylation, and the presence of either 
a bisecting N-acetylglucosamine or an extra antenna would be of interest. We foresee 
opportunities to further enhance the CE separation by using different capillary coatings, for 
example ones that would minimize the EOF. Additionally, the effect of the use of different 
background electrolytes, including different organic modifiers, pH and leading electrolytes 
should be evaluated for this purpose.237,238 
It should be noted that GirP is a rather cost-efficient chemical compared to APTS which is 
commonly used for N-glycan labeling in CE and is comparable to 2-AB (2-aminobenzamide) 
often used in LC. The investigation of different hydrazide/hydrazine labels might improve 
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the separation efficiency and/or the sensitivity of the platform even further. For example, 
the use of a label with multiple charges (or chargeable groups under specific CE conditions), 
will likely improve the separation efficiency, while more hydrophobic labels will improve the 
ion-desolvation during the ESI process.234 Therefore, depending on the exact requirements 
of an assay, further research should focus on the use of labels with different properties. 
Another interesting aspect would be the comparison between the presented CE-ESI-MS 
platform (based on normal mode CE) and well-established assays using negatively charged 
(or chargeable) labels (e.g., APTS, ANTS or 2-aminobenzoic acid (2-AA)) on reversed mode 
CE-ESI-MS platforms with negative mode MS detection.216 Based on previous research, we 
expect an overall lower sensitivity when labeled N-glycans are detected in negative ionization 
mode MS, as compared to positive ionization mode.239 The main advantage of the presented 
CE-ESI-MS platform as compared to nano-LC-MS, is its ability to operate under very low flow 
rates (< 10 nL/min) which provides maximum sensitivity.199,226 It would be of great interest to 
compare the latter ultrahigh-sensitivity glycoanalytical platforms to assess their differences 
in sensitivity as well as their complementarity, for example in terms of separation.
CONCLUSION
In this work, an ultrahigh-sensitivity CE-ESI-MS(/MS) platform was presented for the 
sialic acid linkage-specific analysis of N-glycans with a cationic tag. This platform is highly 
complementary to more high-throughput MALDI-TOF-MS platforms, as the current CE-ESI-
MS(/MS) method provides in-depth information, even on low abundant N-glycan species 
(relative abundance of 0.007%) in highly complex samples. The CE-ESI-MS platform can 
be used on volume restricted samples with rather low concentrations when conventional 
methods are not able to provide the desired sensitivity. For the analyzed TPNG sample, 
a total of 167 unique N-glycan compositions was identified, compared to 76 unique 
compositions detected for the same sample with a MALDI-TOF-MS platform. The CE-ESI-
MS platform turned out to be 100 times more sensitive than the MALDI-TOF-MS method 
in terms of starting amounts used (5 fmol versus 500 fmol), and even 2500 times more 
sensitive regarding the absolute amounts analyzed (20 amol versus 50 fmol). We believe that 
the developed platform is of interest for thorough analysis of complex N-glycan samples as 
well as for samples that are too low in their concentration to be measured with conventional 
methods.
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ABSTRACT
The concentration of prostate-specific antigen (PSA) in serum is used as an early detection 
method of prostate cancer (PCa) showing, however, low sensitivity, specificity and a poor 
predictive value. Initial studies suggested the glycosylation of PSA to be a promising marker 
for a more specific yet non-invasive PCa diagnosis. Recent studies on the molecular features 
of PSA glycosylation (such as antenna modification and core-fucosylation) were not successful 
in demonstrating its potential for an improved PCa diagnosis, probably due to the lack of 
analytical sensitivity and specificity of the applied assays. In this study, we established for the 
first time a high-performance PSA Glycomics Assay (PGA), allowing differentiation of α2,3- 
and α 2,6-sialylated isomers, the first one being suggested to be a hallmark of aggressive 
types of cancer. After affinity purification from urine and tryptic digestion, PSA samples were 
analyzed by CE-ESI-MS (capillary electrophoresis - electrospray ionization coupled to mass 
spectrometry). Based on positive controls, an average interday relative standard deviation 
of 14% for 41 N-glycopeptides was found. The assay was further verified by analyzing PSA 
captured from patients’ urine samples. A total of 67 N-glycopeptides were identified from 
the PSA pooled from the patients. In summary, the first PGA successfully established in this 
study allows an in-depth relative quantitation of PSA glycoforms from urine. The PGA is a 
promising tool for the determination of potential glycomic biomarkers for the differentiation 
between aggressive PCa, indolent PCa and benign prostate hyperplasia in larger cohort 
studies.
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INTRODUCTION
Since 1994, the protein concentration of prostate-specific antigen (PSA) in serum is a FDA 
(Food and Drug administration) approved early detection method for prostate cancer 
(PCa), although its sensitivity is reportedly rather poor.2 When the PSA value is found to be 
elevated (above 3 ng/mL or 4 ng/mL), the patient will be advised to undergo more thorough 
investigations (e.g., digital rectal examination (DRE), multiparametric magnetic resonance 
imaging (mpMRI) and/or prostate biopsy).2,240 Additional examinations are mandatory 
since the PSA test lacks the specificity that is required for the early diagnosis of PCa, as 
age, benign prostate hyperplasia (BPH) or prostatitis can also result in elevated levels of 
PSA.2 Furthermore, a recent study by Foley et al. showed that the PSA test has an overall 
low predictive value for PCa and is incapable of discriminating between aggressive and 
non-aggressive prostate tumors.38,39 Therefore, the need for more specific and predictive 
biomarkers is eminent, to effectively discriminate between aggressive and non-aggressive 
tumors and to avoid unnecessary prostate biopsies. 
Literature suggests that the analysis of PSA glycosylation could offer a more efficient PCa 
diagnosis,33-35,214 since the single N-linked glycosylation site (N69) of PSA is occupied by a 
very heterogeneous group of glycans.33-35 Differences in the linkages of sialic acids, which 
can be α2,3-, α2,6- or α2,8-linked, have been associated with cancer progression,144 with 
α2,6-sialylated glycans involved in blocking the galectin binding to β-galactoside, and 
α2,3- sialylated glycans suggested to be involved in (aggressive) types of cancer.8,9 Further 
investigations into whether a higher abundance of α2,3-sialylated species present on 
PSA could be correlated to PCa, found an overall a higher specificity and sensitivity when 
compared to the conventional PSA test.3 However, this study disregarded the presence of 
α2,6-sialylated glycans and did not detect other molecular features such as fucosylation or 
bisection. Another recent study investigated the glycosylation features of PSA in urinary 
samples collected after DRE by using an immunopurification step.241 Lectins were used 
to investigate the level of core-fucosylation and the presence of α2,6-linked sialic acids, 
revealing, however, no association with the pathology of the disease (Gleason score). This 
observation could result from the rather small sample size (18 controls versus 36 PCa cases) 
and the partial coverage of the sialic acid linkages, since only the levels of α2,6-sialic acids 
were considered. Another study compared the total serum N-glycome of PCa patients and 
BPH patients, revealing differences with respect to sialylation as well as fucosylation.35 An 
overall increase of α2,3-sialylated glycans and alterations in fucosylation was shown in PCa 
patients, which is in agreement with previous studies.4,5 Notably, as these studies analyzed 
the total plasma or serum N-glycome after glycan release, no information was obtained 
regarding the protein carriers of the affected glycans. Several other groups explored 
specifically the level of fucosylation of serum PSA, demonstrating an overall increase in total 
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fucosylation for free PSA102 or total PSA,101 whilst another study reported decreased N-glycan 
core-fucosylation and an increase in α2,3-sialylated glycans for PSA in PCa patients.99 In a 
previous study by CE-ESI-MS (capillary electrophoresis - electrospray ionization coupled to 
mass spectrometry), on a proteolytically cleaved PSA standard (human seminal plasma) we 
could identify 75 different glycan species (including isomeric separation of differently linked 
sialic acids).6 Additionally, a recent in-depth-study by liquid chromatography - electrospray 
ionization coupled to mass spectrometry (LC-ESI-MS(/MS)) on a similar sample, identified 23 
glycan compositions on the single N-linked glycosylation site of PSA and in addition showed, 
with a relatively small cohort (61 BPH and 31 PCa cases), that for urinary PSA the fucosylation 
was decreased in PCa patients and the level of sialylation was increased compared to BPH 
patients.182 While some of these studies noted differences in the level of PSA sialylation and 
fucosylation, they often featured limited precision, sensitivity and/or resolution.4,99,101,102,144,182 
Answering to the need for an analytically more specific and sensitive high-resolution assay to 
assess PSA glycosylation features of benign, indolent or aggressive tumors, we report here 
on an in-depth high-performance urinary PSA Glycomics Assay (PGA) for patients suspected 
of PCa, combining the strengths of previously published assays. The assay includes the 
capturing of PSA from urine, an in-solution digestion, and the analysis of glycopeptides with 
CE-ESI-MS(/MS), taking advantage of the separation of sialylated isomers in CE. In addition, 
as restricted quantities of PSA are found in urine (before DRE),5 a sheathless interface (CESI) 
with a dopant enriched nitrogen (DEN)-gas was used, improving analytical sensitivity and 
repeatability for glycopeptide analysis,226 making this assay suitable to detect rather small 
differences in the relative abundance of different glycoforms. 
MATERIALS AND METHODS
MATERIALS
Ammonium bicarbonate (ABC), ethanol (EtOH), sodium bicarbonate (NaHCO3), sodium chloride 
(NaCl), sodium hydroxide (NaOH), sodium phosphate dibasic dihydrate (Na2HPO4·2H2O) and 
monopotassium phosphate (KH2PO4) were obtained from Merck (Darmstadt, Germany). Glacial 
acetic acid, DL-dithiothreitol (DTT), hydrochloric acid (HCl) and iodoacetamide (IAA) were acquired 
from Sigma-Aldrich (Steinheim, Germany). Ammonium acetate (AAC), formic acid (FA) and water 
of LC-MS grade water were purchased from Fluka (Steinheim, Germany). Trypsin from bovine 
pancreas was obtained from Promega (Madison, WI). Milli-Q water (MQ) was obtained using 
a Q-Gard 2 system (Millipore, Amsterdam, The Netherlands). HPLC supraGradient acetonitrile 
(MeCN) was acquired from Biosolve (Valkenswaard, The Netherlands). PSA standard derived 
from semen was purchased from Lee BioSolutions (St. Louis, MO). Five times concentrated (5x) 
PBS consisted out of 0.16 M Na2HPO4, 0.02 M KH2PO4, 0.73 M NaCl at pH 7.2. 1xPBS was prepared 
from the 5xPBS by diluting it with MQ, resulting in a pH of 7.6.
| AN IN-DEPTH GLYCOSYLATION ASSAY FOR URINARY PROSTATE-SPECIFIC ANTIGEN |
| 107 | 
5
CLINICAL SAMPLES
Urine samples from 10 healthy female volunteers were collected at the Leiden University 
Medical Center. As a negative control, a female urine pool (FUP) was made by pooling 10 urine 
portions. One urine sample from a healthy male volunteer was collected at the Academic 
Medical Center (AMC, Amsterdam, the Netherlands) as well 25 urine samples from patients 
suspected of PCa. All patients had a serum PSA level of > 3 ng/mL and donated their urine prior 
to prostate biopsy and before DRE. Clinical information and urine specimens were collected 
with the approval of the medical ethical committee of the AMC (W16_010#16.020). Table 5.1 
illustrates the clinical information of the patients. Urine was collected (8 - 72 mL) and cooled 
down to room temperature (RT) before storing it at -80˚C.
ANTI-PSA BEADS
Custom-made anti-PSA specific nanobodies based on sequence N7 from Saerens et al.242 
(antigen binding portion of the heavy chain from camelids, 0.49 mg/mL, PBS) were obtained 
from QVQ (Utrecht, The Netherlands) and coupled to NHS activated Sepharose 4 Fast Flow-
beads (GE Healthcare, Little Chalfont, United Kingdom) according to the manufacturer’s 
protocol. Briefly, 7 mL 0.49 mg/mL anti-PSA in PBS was added to 14 mL drained beads (1:1200 
molar ratio; anti-PSA:NHS), the mixture was incubated for 2 hours at RT, the solution was spun 
down, supernatant was removed and the beads were resuspended in 50 mL of 0.1 M Tris-HCl 
pH 8.5 and incubated for 2 hours at RT. Immobilization of the nanobodies was confirmed by 
analyzing the supernatant on a NuPAGE® sodium dodecyl sulfate (SDS)-PAGE gel (Thermo Fisher, 
Waltham, MA) with NuPAGE® MOPS (3-morpholinopropane sulfonic acid) SDS running buffer 
(Thermo Fisher) and after staining with Coomassie G-250 (SimplyBlue SafeStain, Colloidal Blue 
Staining Kit, Thermo Fisher). Antibody beads were stored as a 50% bead suspension (v/v) in 
20% EtOH (20:80, EtOH:H2O, v/v) at 4˚C. Before using the beads, the 50% bead suspension was 
washed with 1xPBS for ethanol removal and re-suspended in 1xPBS to produce a 50% bead 
suspension (v/v).
PSA CAPTURING
After thawing the urine samples to RT, cell debris and other particulates were precipitated 
by centrifugation (500 x g, 5 min) and removed from the supernatant. Almost all samples 
contained 20 mL urine, in case 20 mL was not available, MQ was added to the urine sample to 
obtain a total volume of 20 mL. For the intra- and interday variation and as positive control for 
the cohort analysis, a volume of 20 mL of the FUP was spiked with 15 µL of a 0.1 mg/mL PSA 
standard derived from semen.
For the capturing procedure, several parameters were tested such as, amount of bead 
suspension, potential non-specific binding of the beads, material of the retainer during capturing, 
pH of the sample, influence of a blocking agent and whether the elution would be hampered if 
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the beads ran dry during the washing procedure. In order to determine the optimal amount 
of beads, we added different volumes of 50% anti-PSA bead suspension to 5 mL of 5xPBS and 
20 mL urine. In addition, we tested whether NHS beads showed non-specific binding for PSA. 
For this, we added bare, inactivated NHS beads to a FUP spiked with a PSA standard. Next, 
we tested the material of the retainer used for the capturing procedure comparing plastic 
(Eppendorf tubes, Hamburg, Germany) with glass (Grace, Columbia, MD). This was combined 
with the testing of different volumes of spiked FUP (150 µL, 1,000 µL, 2,000 µL and 5,000 µL). 
Furthermore, we tested whether the pH of the FUP influenced the capturing efficiency. This 
was performed by adjusting the pH of the FUP to pH 6.0, 7.0 and 7.8 using PBS at pH 6, pH 7 
and a TRIS/NaCl solution to achieve pH 8. We then evaluated the addition of a blocking agent 
(bovine serum albumin (BSA) or casein) to the capturing mixture in order to limit possible 
non-specific binding of PSA to the retainer. Finally, the incubation time (2, 4, 6, 8 and 23 h) as 
well as the temperature (4˚C versus RT) were varied with incubation of the sample on a tube 
roller. For the capturing of PSA from patient material the following final parameters were 
used: 60 µL of 50% anti-PSA bead suspension, 20 mL plastic Falcon tube, urine adjusted to 
pH 7, no blocking agent and an overnight incubation at 4˚C. After capturing, the sample was 
centrifuged at 100 g for 1 min at RT. After removal of the supernatant, the remaining anti-
PSA bead suspension (roughly 500 µL) was transferred to a 96-well polypropylene filter plate 
(2 mL) containing a 10 µm pore size polyethylene frit (Orochem, Naperville, IL). The liquid 
was further removed by using a vacuum manifold (Merck Millipore, Darmstadt, Germany). 
Finally, it was tested whether the elution was hampered if the beads were completely dried 
(one minute of extra vacuum was applied) during the washing with 600 µL 1xPBS (pH 7.6) 
followed by two times 600 µL 50 mM ABC. After this step, PSA was eluted by adding 200 µL 
of 100 mM FA that was collected in a V-bottom microtiter plate; the sample was evaporated 
at 45˚C in a vacuum centrifuge (Eppendorf Concentrator 5301, Eppendorf) and reconstituted 
in 5 µL of 25 mM sodium bicarbonate.
SDS-PAGE AND IN-GEL TRYPTIC DIGESTION
For all SDS-PAGE experiments, samples were separated by NuPAGE® 4 - 12% gradient Bis-Tris 
gel (Thermo Fisher). For reduction, 2.5% of 2-mercaptoethanol (Sigma-Aldrich) was added 
to the sample prior to SDS-PAGE. The gel was stained with colloid blue (Novex). For in-gel 
digestions the PSA bands (~32 kDa) were excised and cut into pieces that were washed with 
100 µL 25 mM ABC with an incubation time of 5 min at RT. Supernatant was removed and 
the gel pieces were dehydrated by the addition of 100 µL 30% MeCN with an incubation 
time of 30 min at RT, followed by supernatant removal. A final volume of 100 µL 10% MeCN 
was added with an incubation time of 10 min at RT prior to reduction with 75 µL of 0.9 mM 
DTT for 30 min at 56˚C. After reduction, the supernatant was removed and 100% MeCN was 
added for 10 min at RT. After removal of the supernatant, 75 µL of 5 mM IAA was added and 
kept in the dark for 20 min at RT. The supernatant was removed after the alkylation and 100 
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µL of 100% MeCN was added for 5 min at RT. After removal, 25 mM ABC was added and the 
gel pieces were incubated for 10 min at RT. The supernatant was removed and an additional 
100% MeCN was added and incubated at RT for 5 min. After removal of the supernatant, the 
gel pieces were dried in a vacuum centrifuge for 30 min. Samples were reconstituted in a 
mixture containing the proteolytic enzyme (30 µL of 5 ng/µL trypsin in 25 mM ABC). Digestion 
was performed overnight at 37˚C. The capturing efficiency was determined using software 
package Gelanalyzer 2010. The software was used to quantify the capturing efficiency by 
comparing the intensities of the PSA protein bands in SDS-PAGE gel (.png file) before and 
after capturing.
IN-SOLUTION TRYPTIC DIGESTION
The 5 µL reconstituted eluates, described in Section PSA Capturing of Chapter 5, were 
reduced and alkylated by adding 1 µL of 12 mM DTT with an incubation time of 30 min at 
60˚C followed by the addition of 1 µL 42 mM IAA with an incubation of 30 min performed 
in the dark at RT. To ensure that the sulfide alkylation was stopped, 1 µL of 48 mM DTT was 
added and incubated for 20 min in full light at RT. After addition of 1 µL of 0.15 mg/mL trypsin 
in 25 mM ABC, the digestion was performed overnight at 37˚C.
CAPILLARY ELECTROPHORESIS - ELECTROSPRAY IONIZATION - MASS 
SPECTROMETRY
All experiments were performed under optimized conditions previously established.226 
Briefly, a 90 cm long bare-fused capillary (30 μm internal diameter and 150 μm outer 
diameter) was used on a CESI 8000 system (SCIEX, Framingham, MA). The system had a 
temperature-controlled sampling tray and for all experiments a voltage of 20 kV was applied. 
Prior to each analysis, the separation capillary was thoroughly rinsed with 0.1 M NaOH (2.5 
min), LC-MS grade water (3 min), 0.1 M HCl (2.5 min), water (3 min) and 3 min with the 
background electrolyte (BGE) of 10% acetic acid (v/v, 1.74 M, pH 2.3). The conductive liquid 
line was supplemented with BGE, by rinsing with BGE for 3 min. An on-line pre-concentration 
step was applied, transient isotachophoresis, by adding 1.0 μL of the leading electrolyte (LE, 
250 mM AAC at pH 4.0) to 1.5 μL of the sample. All samples were injected hydro-dynamically 
by applying 1 psi pressure for 60 s, corresponding to 1.4% of the total capillary volume (9 nL). 
After each sample injection, a BGE postplug was injected by applying 0.5 psi for 25 s (0.3% 
of the capillary volume). 
The CE system was coupled to a UHR-QqTOF maXis Impact HD MS (Bruker Daltonics, 
Bremen, Germany) via a sheathless CE-ESI-MS interface (SCIEX). The complete housing of the 
nozzle was a customized platform from SCIEX, which allowed the optimal alignment of the 
position of the capillary spray tip in front of the nanospray shield (Bruker Daltonics). A stable 
electrospray was obtained by applying a glass capillary voltage between -1100 V and -1300 V. 
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All experiments were performed in positive ionization mode. The flow rate and temperature 
of the drying gas (nitrogen) were adjusted to 1.2 L/min and 150˚C, respectively. MS data 
were acquired between m/z 200 and 2200 with a 1 Hz spectral acquisition frequency. An 
internal polymer cone was attached onto the porous tip housing to enable the usage of a 
DEN-gas with MeCN as a dopant (ca. 4%, mole percent).226 
DATA ANALYSIS
CE-ESI-MS data was analyzed with Data Analysis 4.2 (Build 395, Bruker Daltonics). Calibration 
of the MS spectra was performed prior to data analysis with sodium adducts that were 
present at the beginning of the electropherogram. The data was manually screened for 
glycopeptides based on the exact mass, migration order and relative intensities (Table 
S-5.1, Supporting information). Fragmentation spectra were acquired for 30% of the 
identified compositional glycopeptide variants of PSA (Figures S-5.1.A - S-5.1.T, , Supporting 
information), an additional 16% was identified on the basis of previous research.6 Extracted 
ion electropherograms (EIEs, smoothed with a Gaussian fit) were acquired with the first 
three isotopes of the double, triple and quaternary charged analytes using a width of ± m/z 
0.05 unit.
RESULTS AND DISCUSSION
A PGA for the glycosylation analysis of PSA from urine of patients suspected of PCa was 
established and verified (N = 25 ). For this, PSA was captured from typically 20 mL of urine, 
subjected to tryptic treatment, and the obtained glycopeptides were analysed by CE-ESI-MS. 
For data processing, glycopeptide signals were integrated, and ratios of the glycopeptide 
signal intensities were determined. The PGA was further verified by examining factors 
such as capturing procedure, repeatability, intermediate precision and biological variation 
between patients.
CAPTURING PROCEDURE
Several parameters of the capturing procedure were optimized and are summarized in Table 
S-5.2, Supporting information. Briefly, a volume of 60 µL of anti-PSA beads was found to 
give the highest capturing efficiency (N = 2, Figure S-5.2, Supporting information). The use 
of bare NHS Sepharose beads did not result in non-specific binding of PSA as the PSA was 
observed only in the flow-through and not in the eluate of the bare NHS Sepharose beads, 
while anti-PSA beads did capture PSA and no PSA was observed in the flow through (Figure 
S-5.3, Supporting information). PSA recoveries were largely comparable when using plastic 
versus glass retainers, and plastic retainers were chosen for their convenience for further 
experiments (N = 1, Figure S-5.4, Supporting information). Furthermore, the pH of the FUP 
(N = 2 ) was investigated and a similar recovery was found for all conditions (pH 6, 7 and 8) 
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(Figure S-5.5, Supporting information). For subsequent experiments pH 7 was chosen. It 
was tested whether the addition of a blocking agent prevented nonspecific binding of PSA to 
the walls of the retainer and could improve the capturing efficiency (Figure S-5.6, Supporting 
information). Notably, the use of BSA and casein as a blocking agent contaminated the 
affinity-purified sample, but did not result in increased PSA yields. Therefore, for further 
experiments no blocking agent was added to the FUP. Incubation at RT showed a wide 
variation in capturing efficiency, with 4˚C being the most preferable temperature (Figure S-5.7, 
Supporting information). The incubation time did not appear to influence the PSA recovery, 
as a recovery between 72% and 78% was observed across the range of incubation times (2, 
4, 6, 8 h and overnight, N = 1 ). Due to practical considerations, further experiments were 
performed with an overnight incubation. As a vacuum system was used with a 96-well format 
for the washing and elution of the PSA from the anti-PSA beads, it was tested whether PSA 
yields changed when the 96-well plate was run dry during the washing procedure (an extra 
minute of vacuum was applied, Figure S-5.8, Supporting information). A similar capturing 
efficiency was observed when the well was completely dried compared to wells that were 
kept wet during the washing procedure (80% versus 73%, N = 2 ). FA (100 mM) proved to 
be a suitable elution reagent, as no PSA was detected post-elution on the beads after the 
beads were incubated with the loading buffer and analyzed on a NuPAGE® SDS-PAGE gel 
(data not shown). Furthermore, PSA quantitation by SDS-PAGE with Coomassie staining (N = 
3, Figure S-5.9, Supporting information) revealed that the capturing procedure recovered 
approximately 58% of the PSA spiked into a FUP. To reveal any potential glycosylation bias 
of the affinity capturing procedure, glycosylation profiles of PSA before and after capturing 
were compared, applying in-gel tryptic cleavage of PSA followed by CE-ESI-MS. We chose 
for a gel-based approach in order to remove any possible sample matrix confounders. A 
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Figure 5.1: Relative 
abundance of the 10 most 
abundant glycopeptides of 
prostate-specific antigen 
(PSA) after either capturing 
(from spiked female urine 
pool) or no capturing 
(PSA standard, 1.5 µg) 
procedure. All samples 
were loaded on to a SDS-
PAGE gel, the approximately 
~32 kDa band was excised 
from the gel and underwent 
a tryptic in-gel digestion 
prior to CE-ESI-MS analysis. 
Error bars represent the 
standard deviation (N = 3). 
PEP illustrates the tryptic 
peptide sequence N69K.
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total of 41 N-glycopeptides were detected, and comparable profiles were obtained before 
and after affinity purification (N = 3, Figure S-5.10, Supporting information). The relative 
abundances of the 10 most abundant N-glycopeptides are compared in Figure 5.1 and show 
no bias of the glycosylation profile induced by the affinity purification procedure, with an 
average relative standard deviation (RSD) of 6.5% (non-captured) and 3.0% (captured) for 
the ten most abundant glycopeptides (normalized to the sum of all identified glycoforms). In 
addition, an average RSD of 14.8% (non-captured) and 8.3% (captured) for all glycopeptides 
was observed. However, it has to be noted that the in-gel digestion was performed on the 
~32 kDa band and possible discrimination of potential nicked forms of PSA that may migrate 
at different heights is, therefore, not taken into account.
PSA GLYCOPEPTIDE DETECTION BY CE-ESI-MS
The analysis of a tryptic digest of the captured PSA standard identified 41 N-glycopeptides 
with the CE-ESI-MS setup. All glycans were attached to the dipeptide N69K as listed in Table 
S-5.1, Supporting information. The base peak electropherogram of a typical PSA tryptic 
digest analysis (Figure 5.2) shows three distinctive glycopeptide clusters separated on the 
basis of the level of sialylation (Figures 5.2.B and 5.2.C). Furthermore, isomer separation 
was achieved for α2,3- and α2,6-sialylated species, in accordance with our previous work.6 
Figures 5.2.B and 5.2.C demonstrate that α2,3- and α2,6-linked isomers are baseline 
resolved, confirming the ability of CE-ESI-MS to discriminate between the different linkages. 
However, compared to our previous work,6 non-sialylated glycoforms were not detected in 
this sample. The difference is most likely due to the use of different PSA batches in the two 
studies. Notably, the peaks that are observed in the base peak electropherogram in the non-
sialylated region (area marked by an asterisk in Figure 5.2.A) correspond to other analytes in 
the sample such as tryptic unglycosylated peptides.
REPEATABILITY AND INTERMEDIATE PRECISION
Since SDS-PAGE demonstrated sufficient purity of the affinity-enriched PSA, an in-solution 
proteolytic cleavage was chosen for the PGA. For the precision evaluation of the assay 20 mL 
FUP was spiked with 1.5 µg of a PSA standard and the complete assay (including capturing) 
was executed three times on the same day (repeatability, intraday variability) and repeated 
over three days (intermediate precision, interday variability). As illustrated in Figure 5.3, the 
average intraday and interday RSD were below 3% and 7%, respectively, for the ten most 
abundant glycopeptides (normalized to the sum of all identified glycoforms). Results for the 
remaining 31 identified N-glycopeptides (relative abundance of low abundant glycopeptides) 
are shown in Figure S-5.11, Supporting information. The RSDs for all glycopeptides showed 
an average intraday variation of 5% and an average interday variation of 14%.
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ANALYSIS OF PSA GLYCOPEPTIDES CAPTURED FROM PATIENT URINES
The biological variation in PSA glycosylation was examined using the developed PGA applied 
to urine samples of 25 patients. Before sample treatment, the patient urine samples were 
split into three batches, each of them processed on one of three consecutive days. Each 
batch included a negative (FUP) and a positive control (FUP spiked with 1.5 µg of standard 
PSA). Furthermore, after tryptic digest, a small portion (0.5 µL) of all the patient samples 
was pooled. This pool was used for the identification of the glycopeptides and structural 
elucidation by tandem MS (N = 3 ). A total of 67 N-glycopeptides could be identified in the 
pooled patient sample. All glycans were attached to the dipeptide N69K, in agreement with 
the previous result, and a complete overview of the glycopeptides is given in Table S-5.1, 
Supporting information. After data treatment, 23 of the 25 patient samples passed the 
quality criteria (> 20 glycopeptides identified with S/N > 9, ppm error < 10 ppm), resulting in 
13 PCa patients and 10 non-PCa patients. The whole assay, including sample preparation and 
CE-ESI-MS measurement, was completed per batch (11 samples) within 60 hours, of which 8 
hours dedicated to hands-on time; the remaining hours consisted of all incubation steps as 
well as the analysis of the samples on the analytical platform.
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Figure 5.2: CE-ESI-MS analysis of tryptic N-(glyco)peptides from PSA standard. (A) Representative base 
peak electropherogram observed for a tryptic digest of PSA. The migration window assigned with the 
*-symbol typically contains the non-sialylated N-glycopeptides of PSA, which were not detected in this 
sample. Two distinct clusters (B and C) were observed, both containing N-glycopeptides. Extracted ion 
electropherograms for mono-sialylated N-glycopeptides (B) and di-sialylated N-glycopeptides (C) of PSA 
are illustrated, each color represents an individual glycopeptide in its isomeric forms (multiple peaks). In 
total, 41 different N-glycopeptides were identified (not all data shown, a complete overview can be found 
in Table S-5.1, Supporting Information). PEP illustrates the tryptic peptide sequence N69K.
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In order to assess the intermediate variation of the PGA, one positive control (spiked FUP, 
N = 3 ) was included each day with the sample preparation of the patient urines (Figures 
S-5.12 and S-5.13, Supporting information). The complete PGA showed an average RSD 
of 6% for the ten most abundant glycopeptides of the positive controls. The CE-ESI-MS 
detection method showed a low technical variation, with an average RSD of 2% for the ten 
most abundant glycopeptides as determined using the sample of the pooled PSA digests. A 
large variation with an average RSD of 50.1% (non-PCa patients), 47.2% (PCa patients) and 
48.6% (all patients) was observed between the patients’ PSA glycosylation profiles, which 
are believed to largely reflect biological variation (Figures S-5.12, S-5.13 and Table S-5.3, 
Supporting information). The much higher biological variation as compared to the technical 
variation highlights the potential use of the established PGA for biomarker discovery. The 
biological variation within the clinical samples and the two different patients groups (non-PCa 
versus PCa patients) was systematically examined in relation to specific glycosylation traits, 
as illustrated in Figure S-5.14, Supporting information. A clear urinary PSA glycosylation 
profile could be obtained for a healthy volunteer, with low levels of α2,3-sialylated glycans 
when compared to the patient profiles which is in agreement with the literature.3 The most 
abundant glycan type was found to be the complex type (ranging from 85% up to 94% of the 
relative abundance for the non-PCa patients while a similar profile was found for the PCa 
patients ranging from 87% up to 95%), followed by minor amounts of the hybrid type (4.9% 
- 8.6% (non-PCa patients) and 3.8% - 7.4% (PCa patients)), and high-mannose type glycans 
(0.7% - 7.9% (non-PCa patients) and 1.5% - 6.2% (PCa patients)). Furthermore, by grouping the 
identified glycoforms according to their degree of fucosylation (Figure S-4.15, Supporting 
information), the most abundant group corresponded to the mono-fucosylated species (all 
core-fucosylated, 55% - 82% (non-PCa patients) and 55% - 89% (PCa patients)), followed 
by non-fucosylated (17% - 45% (non-PCa patients) and 11% - 45% (PCa patients)), and a 
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Figure 5.3: Relative 
abundance observed 
for the most abundant 
glycopeptides of prostate-
specific antigen (PSA). PSA 
was spiked into a female 
urine pool, digestion was 
performed in-solution 
and was used to test the 
repeatability (intraday, 
N = 3) and intermediate 
precision (interday, N = 
3) of the PSA Glycomics 
Assay with CE-ESI-MS. 
PEP illustrates the tryptic 
peptide sequence N69K.
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small group of di-fucosylated species (0.2% - 2.1% (non-PCa patients) and 0.3% - 1.3% (PCa 
patients)). With respect to sialylation (Figure 5.4.A), di-sialylation (two sialic acids present on 
the glycan) was most prevalent (70% - 84% (non-PCa patients) and 69% - 88% (PCa patients)) 
followed by mono-sialylation (14% - 15% (non-PCa patients) and 9% - 25% (PCa patients)) 
and non-sialylated glycan species (1.3% - 9.0% (non-PCa patients) and 1.9% - 7.9% (PCa 
patients)), with a minor part being tri-sialylated (0.2% - 1.0% (non-PCa patients) and 0.0% - 
0.5% (PCa patients)). A large variation of sialic acid linkages was observed between patient 
PSA samples (Figures 5.4.B and 5.4.C). As indicated in the introduction, sialic acid linkages 
may be indicative of the disease state of the patient; however, with the current sample size 
no significant differences could be observed between non-PCa patients and PCa patients. 
Moreover, the relationship between the observed sialic acid linkage and the measured PSA 
serum concentration as well as the prostate volume was studied (Figure S-5.16, Supporting 
information). No direct correlation could be observed and it is therefore recommended to 
perform additional studies using the present PGA or related high-resolution platforms on 
medium- to large-size cohorts of patient materials (urine, serum) to further evaluate these 
glycosylation traits as a biomarker candidate. Even though the preliminary results of this 
study did not reveal any significant differences, most likely due to the small sample size, 
several studies have already shown that the fucosylation and sialylation traits of PSA seem 
to be of relevance for potential markers able to discriminate between PCa and BPH. 3,101,102,182
Besides fucosylation and sialylation, a small portion of the glycan species appeared to be 
bisected within the patient group (< 0.3%). Furthermore, one of the high mannose glycans 
(H6N2) appeared to be present in two forms, either phosphorylated or non-phosphorylated, 
of which the phosphorylated form appeared to be more abundant in both groups (Figure 
S-5.17, Supporting information). In addition, a phosphorylated species (H6N3) was observed 
which most likely represents a Man6 N-glycan with a GlcNAc-capped mannose-6-phosphate 
residue generated by GlcNAc-1-phosphotransferase, although an alternative structure such 
as a phosphorylated hybrid-type species cannot be ruled out. Next to phosphorylation, 
sulfation was also observed on two complex species containing an N-acetylgalactosamine 
with either no or one sialic acid attached (Figure S-5.18, Supporting information). 
Sulfation or phosphorylation on the glycan species that did not contain mannoses nor 
N-acetylgalactosamines was not observed, suggesting that this modification can only appear 
on these monosaccharides and should definitely be added to other observed glycosylation 
features (sialylation including linkage information, fucosylation, bisection) when searching 
for possible disease-specific markers. 
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CONSIDERATIONS
During this study, urine samples of 23 of the 25 patients were investigated and a high 
biological variation was observed between the patients. As a result of the small sample 
size, one should be cautious when drawing conclusions regarding the clinical and diagnostic 
potential of PSA glycosylation features. Further research is essential to assess whether PSA 
glycosylation of urine and blood samples can be of diagnostic value. Nonetheless, this study 
showed that the established PGA is capable of characterizing PSA glycosylation, after affinity 
capture from urinary samples of either healthy volunteers or patients, thoroughly and in a 
repeatable manner.
Minor questions were prompted by the current study and are worthy of consideration 
in upcoming investigations such as the chemical stability of PSA in urine matrix, the role 
played by PSA subforms and the concentration of urinary PSA. Firstly, it is known that for 
various major plasma glycoproteins chemical degradation is minimal.243 Little is known about 
the stability of glycoproteins such as PSA in urine matrix, neither under healthy nor under 
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Figure 5.4: PSA Glycomics Assay derived sialylation traits of all 23 patient urine samples, a “trait” 
is the relative abundance of all glycopeptides observed within a patient complying with specific 
characteristics (no sialic acid, one, two or three- sialic acids present on the glycan portion of the 
glycopeptide). (A) Di-sialylation was the most abundant sialylation trait observed in the patient group, 
followed by mono-sialylation, no sialylation and tri-sialylation. Mono-sialylation and di-sialylation show a 
clear inverse correlation. The sialic acid linkage in the mono-sialylated glycopeptides (B) and di-sialylated 
glycopeptides (C) could be further explored, revealing that the α2,6-linked sialic acid was the most 
abundant species, however no direct correlation could be found between the level of α2,3 and α2,6 
-linked sialic acids. Letters in the legend indicates each patient individually (patient characteristics can be 
found in Supporting Information, Table S-5.3).
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disease conditions, and this should be investigated in the future. In addition, while comparing 
the obtained results of the in-gel (Figure 5.2) and in-solution digestion (Figure 5.3), small 
discrepancies could be found in the overall glycosylation profile. These small differences 
could be caused by the presence of nicked PSA forms, which were not taken into account 
in the in-gel digestion (after reduction) as only the main PSA form (~32 kDa) was excised 
for the digestion.56,244,245 It is uncertain if the PSA antibody captures these nicked forms of 
PSA; however, a study by Sarrats et al.,183 noticed slight differences in glycosylation profiles 
between different PSA subforms (subforms which we think could be ascribed to nicked PSA 
forms). It is, therefore, of great interest to study the differences between the main PSA form 
and its nicked forms, especially, if these differences could be correlated with different stages 
of PCa. However, as each PSA form would result in a glycopeptide with a dipeptide N69K, 
a different approach would be needed, such as intact protein analysis or the analysis of 
different gel bands after reduction and in-gel digestion. Furthermore, the concentration of 
PSA in urine should be monitored in relation to the volume of urine produced in a given time-
frame, as it is currently unknown whether larger urine volumes will provide a higher amount 
of PSA or will result in a more diluted PSA sample. It is unclear whether morning collected 
urine would result in a more concentrated PSA sample. Another possibility for higher PSA 
concentration in urine would be to collect the patients’ urine after DRE (as routinely done 
for other urine marker tests, like PCA3), giving the possibility to lower the current amount of 
urine (20 mL) that is needed for the PGA assay.5,241,246 We envision expanding the current PGA 
assay towards PSA quantitation by including relevant internal peptide standards facilitating 
absolute quantitation by MS of proteolytically generated PSA peptides.
CONCLUSION
The established high performance PSA Glycomics Assay reveals multiple glycoforms of 
urinary PSA, including sialic acid linkage isomers as well the level of (core-)fucosylation. We 
could envision a similar assay for analyzing the glycosylation of serum PSA, which, however, 
poses major challenges with regards to sample purification and analytical sensitivity of 
the assay. Using the high-performance PGA, we plan to evaluate the PSA glycosylation for 
early detection of PCa as well as for potential differentiation between aggressive and non-
aggressive tumors. For this, a large set of patient urines will be analyzed, and the results of 
the PGA will be compared to state-of-the-art diagnosis on the basis of serum PSA levels and 
histology. Likewise, we plan to evaluate the prognostic value of the PGA on the basis of a 
longitudinal study.
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DISCUSSION AND FUTURE PERSPECTIVES
The aim of this thesis was to explore the analysis of glycans and glycopeptides using the 
powerful analytical platform CE-ESI-MS (capillary electrophoresis - electrospray ionization - 
mass spectrometry) employing a porous nano-sprayer for the MS coupling. In addition, the 
developed platform was used to study in-depth the glycosylation of prostate-specific antigen 
(PSA). This platform was included in a PSA Glycomics Assay (PGA) that captures PSA from 
urine in order to study the glycosylation profiles of PSA from patient samples and evaluate 
their potential as a biomarker for patient stratification in prostate cancer (PCa).
SENSITIVITY ENHANCEMENT WITH 
CE-ESI-MS
Even though CE-ESI-MS is known for its limited sample injection it still is able to achieve 
a high sensitivity, especially when using a sheathless electrospray ionization interface. In 
this thesis, the sensitivity was further pushed by implementing a dopant enriched nitrogen 
(DEN)-gas. Significantly higher sensitivities and an improved repeatability were observed for 
glycopeptide (Chapter 3) and glycan analysis (Chapter 4). The implementation of the DEN-
gas resulted in a 25-fold increase of sensitivity compared to conventional sheathless CE-
ESI-MS platform, with a glycopeptide amount of 0.2 amol injected representing the lower 
limit of detection. Interestingly, a similar study was performed in 2013,177 where a limit 
of detection (LOD) of 20 amol was determined for immunoglobulin G (IgG) glycopeptides 
on a conventional sheathless CE-ESI-MS platform, revealing a 4-fold increase in sensitivity 
between the two conventional CE-ESI-MS platforms (present (no DEN-gas) versus the study 
in 2013). It should be noted that a higher sample injection was used in 2013 with a capillary 
volume of 37% compared to 7% in the current study. The former most likely compromised 
the separation power resulting in a lower signal-to-noise ratio and a decrease in sensitivity. 
Thereby, an overall 100-fold increase in sensitivity could be observed when the DEN-gas was 
implemented compared to the sheathless CE-ESI-MS platform in 2013.
One may speculate with respect to the mechanisms underlying the observed enhancement 
in sensitivity when various dopants are introduced during electrospray ionization. Two 
electrospray ionization mechanisms that may be involved are the charge residue model 
(CRM), which was already proposed in 1968 by Dole et al. and the ion evaporation mechanism 
(IEM) first described by Iribarne and Thomson in 1975 (Figure 6.1).247 Both models describe 
possible mechanisms for the formation of gas-phase ions in electrospray ionization. The CRM 
starts with the assumption that evaporation of the solvent decreases the size of a droplet 
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until its Rayleigh limit is reached (maximum level of tension a droplet can handle), leading 
to the division of the droplet into smaller droplets (Coulomb explosion). This process will 
repeat itself until final droplets are formed, containing a single analyte. When the last solvent 
surrounding the analyte evaporates, the charges of the droplet are being transferred onto 
the analyte resulting in a charged residue.248 As reported in the literature, this process seems 
to apply most likely to large molecules.249 According to the IEM model, the gas-phase ions are 
considered to be formed due to evaporation and desorption. The starting point is assumed 
to be the same as for CRM, with the evaporation of the solvent and the division of the droplet 
into smaller ones; this process will repeat itself until analyte desorption (ejection of solvated 
ions from the droplet surface) takes place, resulting in the formation of gas-phase ions. This 
mechanism seems to be most applicable for smaller molecules. The involvement of an IEM-
mechanism in the increased sensitivity (when using a DEN-gas) is supported by a study by 
Nguyen and Fenn in 2007, where the effect of solvent vapors added to the sheath gas was 
studied and how this influenced the ion formation.191 By increasing the solvent portion in the 
gas phase, a better desolvation of ions was observed when the vapor contained polar organic 
solvents such as methanol or butanol compared to a solvent vapor that only contained water 
or the non-polar solvent cyclohexane. Moreover, researchers suggest that the difference in 
gas-phase basicity and proton affinity between MeCN and water could be a crucial factor 


























































































Figure 6.1: A schematic illustration of two different models of the formation of gas-phase ions from a solvent 
droplet; charge residue model (CRM) and ion evaporation mechanism (IEM). The main difference between the 
two different models is that gas-phase ions in CRM are generated by evaporation of the solvent surrounding the 
analyte and charges of the solvent are being transferred on the analyte. IEM suggests that the gas-phase ions are 
formed through evaporation followed by desorption.
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to the CRM mechanism.211 Both in Chapters 3 and 4 an increase in multiple protonated ions 
was found, and it is thought that this is due to the adsorption of solvent vapor molecules to 
the surface of the droplet, leading to “hot spots” that aid to the ejection of the analyte from 
the droplet.191 As presented in Chapter 3, the use of different organics (isopropanol (IPA), 
ethanol (EtOH) and acetonitrile (MeCN)) resulted in a variation in the relative abundances of 
glycopeptides. Interestingly, IPA and EtOH revealed similar relative peak areas and seemed 
to favor the less complex analytes with smaller glycan portions such as G0F (H3N4F1) while 
MeCN seemed to favor more complex types such as G2F (H5N4F1) and G2FS (H5N4F1S1). 
When comparing the charge state distributions of G0F the most abundant charge state 
observed with IPA and EtOH as a dopant is the doubly charged species while for MeCN this 
is the triply charged state. A similar difference is observed for G2FS, were the triply charged 
species are barely present when IPA or EtOH are used as dopants while they are the most 
abundant form for MeCN, followed by the quadruply charged state with the doubly charged 
state is almost non-existing. As previously mentioned, the gas-phase basicity and proton 
affinity could play a role in this phenomenon as the gas-phase basicity is 660 kJ/mol and 748 
kJ/mol for water and MeCN, respectively. The proton affinity is 691 kJ/mol for water and 779 
kJ/mol for MeCN, respectively.250 However, the gas-phase basicity and proton affinities of all 
dopants used in this study are not that far apart from each other, as EtOH has a gas-phase 
basicity and proton affinity of 746 kJ/mol and 776 kJ/mol, while this is 763 kJ/mol and 793 
kJ/mol for IPA,250 respectively. Most likely the gas-phase basicity and proton affinity play 
an important role for the increased sensitivity, however, it does not explain the ionization 
difference that is observed between the dopants. One of the differences that can be found 
between the solutions is the fact that MeCN is a weak base in solution (weaker than water), 
while this is not the case for EtOH and IPA. This implies that MeCN is unlikely to take up 
protons, and during condensation of MeCN into the droplets, the property of the droplet 
will change to an overall lower basicity of the solvents, which may promote supercharging 
of the analyte. Moreover, based on the abovementioned facts, it is plausible that both IEM 
and CRM are involved in signal modulation and enhancement. However, dependent on the 
dopant that is being used a different mechanism can be involved. Namely, it could be that 
IPA and EtOH are more involved in the IEM mechanisms while MeCN seems to be involved 
in the CRM model. Since the increased sensitivity could be due to a better desorption of 
the analytes (creating hot-spots of desorption by dopants condensation to the electrospray 
microdroplets) and, therefore, the IEM model will be most likely. Moreover, EtOH and IPA 
seem to have a preference for smaller molecules that is in agreement with the IEM model. 
In the case of MeCN, supercharging is being observed and this is most likely related to 
the CRM model as, according to this model, charges from the droplet can be transferred 
onto the analyte resulting in higher charge states, and this dopant favors larger molecules. 
However, how the ionization exactly takes place remains unclear and further research is 
needed to better understand this process. Therefore, it is suggested to investigate a range 
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of less polar dopants (such as pentane or hexane) complementing the abovementioned 
dopants, in order to confirm that the less polar solvents indeed do not aid in the improved 
ionization efficiency. Moreover, the addition of volatile acids, such as acetic acid and formic 
acid, in minor concentrations, should be investigated as well as the influence of the pH of 
the solution in relation to the observed ESI response. Another interesting study would be 
the effect of adding organics to the background electrolyte (BGE) and not to the nebulizer 
gas; however, this would inevitably also influence the separation of the molecules. Further 
studies should not only focus on the effects of DEN-gas on glycopeptide ionization, but also 
consider other analyte groups such as small molecules (metabolites), medium-sized analytes 
molecules (peptides and various modified peptides) and large molecules (intact proteins). By 
covering a vast range of physicochemical properties of different analytes, it will be possible 
to gain a better insight into which molecular properties are involved in the sensitivity 
enhancement upon the use of a DEN-gas. During this thesis, the effect of the DEN-gas was 
further examined by investigating the effect on released N-glycans carrying a cationic label 
(Chapter 4) next to the effect of DEN-gas on glycopeptides. For the labeled N-glycans similar 
results were found to those described in Chapter 3 for PSA glycodipeptides, with an overall 
improvement of 3-fold in signal-to-noise ratio as well as a 2-fold increase in peak area. 
Obtaining similar results for PSA glycopeptides and labeled N-glycans was rather expected 
as the backbone of both analytical species was rather small and most probably only played a 
small role in the observed enhancement.
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GLYCAN AND GLYCOPEPTIDE ANALYSIS 
WITH CE-ESI-MS
The CE-ESI-MS proved to be an excellent technique for high separation efficiencies, 
especially beneficial for the separation of isomers with differently linked sialic acids (Chapter 
2). While other platforms often require extra sample treatment for glycopeptides, such as 
derivatization or complex analytical setups, this is not the case for CE-ESI-MS. However, 
the analysis of released N-glycans in normal mode CE (detection at the cathodic end of the 
capillary) did benefit from additional derivatization steps, namely, by reducing the charge 
heterogeneity of N-glycans, mainly caused by the presence of sialic acids (from zero to up to 
four). By derivatizing the sialylated species, these N-glycans were made neutral and then, to 
enable separation in CE, a positive charge was added allowing analysis in normal mode. This 
included an additional step where the reducing end was labeled with a permanent cation, 
Girard’s reagent P (GirP). This workflow enabled the identification of 167 N-glycoforms with 
CE-ESI-MS, including differentiation between differently linked sialic acids. In addition, we 
got insights into the electrophoretic mobility of the N-glycans (Chapter 4). Namely, bisected 
structures have a rather small hydrodynamic volume as compared to non-bisected structures 
of similar molecular mass and, therefore, a higher electrophoretic mobility. This is illustrated 
by comparing the migration times (tm) of H3N5 (1653.638 Da) and H4N4 (1612.611 Da) where 
a difference of 18 s was observed with the bisected structure migrating earlier (35.5 min 
versus 35.8 min) despite the higher molecular mass, which is in agreement with literature.217 
This phenomenon might be useful for the differentiation between isomeric N-glycans with 
antenna-branching and bisecting GlcNAc. A similar difference in electrophoretic mobility 
can be observed for high mannose types structures, e.g., H8N2 (tm: 36.1 min, 1854.664 Da), 
which have a rather high electrophoretic mobility compared to complex structures, e.g., 
H5N4 (tm : 36.2, 1774.664 Da) while having a higher molecular weight. However, no direct 
correlation could be found between the hydrodynamic volume of differently linked sialic 
acids of mono-sialylated species and their electrophoretic mobility, e.g., H5N4Am1 (α2,3 
sialylated, 2064.775 Da) and H5N4E1 (α2,6 sialylated, 2093.791 Da) both migrated at 36.8 
min. While the di-antennary species did result in slight different mobilities, e.g., H5N4F1Am2 
(m/z 2500.945 Da), H5N4F1Am1E1 (2529.960 Da), H5N4F1E2 (2558.975 Da) migrated at 
37.6 min, 37.4 min and 37.4 min, respectively. Notably, a tri-antennary N-glycan with two 
N-acetylneuraminic acids (H6N5Am1E1, 2749.034 Da) resulted in a later migration (37.8 min) 
than a tetra-antennary N-glycan with one N-acetylneuraminic acid (H7N6E1, 2824.055 Da) 
detected at 37.7 min, suggesting that the presence of two N-acetylneuraminic acids has a 
larger impact on the hydrodynamic volume than the addition of an antenna (galactose + 
N-acetylglucosamine). 
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Figure 6.2: Extracted ion electropherograms of total plasma N-glycome after derivatization (ethyl-
esterified amidation) and labeling with GirP. (A.1) Separation observed for TPNG glycans using a dynamic 
neutral coated bare fused silica (BFS) capillary, (B.1-C.1) Separation observed for TPNG glycans using a 
static neutral coated BFS capillary, with either (B) a constant 0.5 psi flow, (C) 0.5 psi flow after 20 min or (D) 
0.5 psi flow after 50 min. (A.2-D.2) Insets show the extracted ion electropherogram of N-glycan species 
H4N4F1. All analyses were performed with CE-ESI-MS using the DEN-gas. GirP illustrates the label, Girard’s 
reagent P, attached to the glycans. The following settings were used: The background electrolyte was 10% 
HAc, the temperature of capillary coolant was set at 25˚C, 20kV was applied and injection was performed 
with 1 psi for 60 sec (9 nL), sample was diluted in 100 mM ammonium acetate pH 4.0.
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However, to further explore structural differentiation in relation to hydrodynamic volume, 
higher separation efficiency is needed. The use of a neutrally coated sheathless capillary 
could provide the desired resolution. Here, as the electro-osmotic flow (EOF) is very low, the 
mobility of the analytes will be mainly determined by their own electrophoretic mobility. 
Unfortunately, to enable detection by MS, a constant flow should be created to generate 
an electrospray, hampering the separation power of a neutral capillary. This flow can be 
created by applying a mechanical pressure, which will, however, disturb the advantageous 
planar flow created by the EOF. Instead a parabolic flow profile could be created resulting in 
broader peaks and a loss in resolution. While a dynamic neutral coating (Ultratrol) was used 
in Chapter 4, this did not result in an efficient suppression of the EOF as an electrospray 
was obtained while no mechanical pressure was applied, suggesting that the capillary was 
not completely coated with the dynamic neutral coating or that the coating is actually not 
neutral. Therefore, a static coating was explored which resulted in sufficient suppression 
of the EOF, as no electrospray was observed when no mechanical pressure was applied. To 
initiate electrospray ionization a continuous pressure of 0.5 psi was applied (Figure 6.2.A.1). 
By applying a zero-flow principle (no flow) for a certain period right after sample injection, 
a better separation could be achieved. Just recently, this process has been explored and 
preliminary data revealed promising results with extraordinary resolution, allowing the 
resolution of isomeric species (Figure 6.2.B.1 till D.1). As illustrated in the insets A.2 till 
D.2 of Figure 6.2 for glycan species H4N4F1, isomer separation improved by applying the 
zero-flow principle for a longer period. Based on literature, the first migrating species is 
most likely the species with a galactosylated α6 arm, while the second migrating peak 
has an occupied α3 arm.251 Mechref and coworkers further investigated the separation 
by computer modeling.251 They demonstrated that the glycan with an occupied α6 arm is 
more compact than its isomeric species, due to the closer proximity of the core-fucose 
and the galactose (~6.7 Å distance) when compared to the galactose on the α3 arm (~14.1 
Å).251 Notably, the galactosylated α3 did not only show a slower mobility in CE, but also 
less retention on porous graphitized carbon liquid chromatography (PGC-LC)-ESI-MS(/
MS).251 However, further research is needed to structurally characterize the various isomeric 
species. For this purpose, endo- and exoglycosidases, together with well-characterized 
glycan standards, could be used. In addition, as the zero-flow process comes with rather long 
analysis time, further optimization is necessary and the use of different BGE, the addition of 
organic modifiers, but also the applied voltage, capillary temperature, pH and composition 
of the leading electrolyte should be optimized with respect to effects on separation and 
analysis time.237,238 Another aspect to be investigated is the use of labels containing more 
than one charge, either permanently charged or chargeable under specific CE conditions, 
and see how this influences separation and the MS detection. The ion desolvation during 
the ESI could be further improved by investigating more hydrophobic labels.234 Furthermore, 
studies are needed that compare the developed platform to other well-established assays 
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involving labeling with negatively charged (or chargeable) labels on reversed mode CE-ESI-
MS platforms with negative mode MS detection such as the study by Snyder et al. where the 
label APTS (8-aminopyrene-1,3,6-trisulfonic acid) was used.216 These studies should provide 
information on which labels are most suitable for isomeric separation, to which extent and 
how well they can be detected (sensitivity). For this, it should be taken into account that 
an overall lower sensitivity is expected when labeled N-glycans are detected in negative 
ionization mode MS, as compared to positive ionization mode,239 which would be the case for 
APTS labeled glycans. However, in comparison to the “zero-flow” analysis, the APTS labeled 
glycans appear to migrate fast and in a rather small separation window with an excellent 
resolution that can be seen as a major advantage.252 Moreover, no sialic acid derivatization 
is needed when samples are measured in negative ionization mode MS. Additionally, the 
negative charge of the sialic acids leads to faster migration and an increase of the separation 
window. APTS-labeled glycans are normally analyzed on CE-laser-induced fluorescence (LIF) 
or CE-ultraviolet (UV) platforms, which tend to be extremely repeatable at rather low-costs. 
One of the key attributes to its repeatability is the detectors that are being used and in 
many analytical settings LIF or UV detection will suffice. Only when in-depth information is 
required, for example when new peaks are found in the electropherogram or when there 
is an expectancy of overlapping analytes, the CE has to be coupled to MS to identify the 
analytes under peaks observed in the electropherogram. Therefore, it is suggested to study 
whether the cationic label GirP is also detectable with a UV or a LIF detector allowing for 
simplified analyses without MS detection.
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PERSONALIZED MEDICINE
Nowadays, more and more research is devoted to personalized medicine, which is, as 
stated by Nature,253 “a therapeutic approach involving the use of an individual’s genetic and 
epigenetic information to tailor drug therapy or preventive care.” This means that every 
individual is treated taking into account his/her health, lifestyle and the disease state, leading 
to a personalized treatment, which is expected to optimize effectiveness and minimize side 
effects, while providing an improvement in the quality of life. This is especially relevant 
when diseases are found in an early stage and a direct tailored treatment can be initiated. 
Furthermore, personalized medicine should lead to lower treatment costs due to a faster 
recovery of the patients or to the inhibition of the disease progression. This principle is gaining 
importance in the health care sector and receives increased attention from governments 
and funding agencies. For example, the Dutch government wrote in the coalition agreement 
of 2017 - 2021 that personalized medicine is seen as one of the innovations in relation to the 
prescription of pharmaceuticals for patients.254 Personalized medicine is increasingly making 
use of molecular signatures, in which glycomics and glycoproteomics are emerging fields. 
Here, glycosylation profiles could provide an indication of the health of the patient.87,97,255,256 
Though preliminary studies show promising results for using glycoprotein signatures in early 
diagnosis, patient stratification and treatment monitoring, more studies are still required to 
determine their significance.87,94,256 
Specific molecular features that can be correlated to a certain disease are known as clinical 
biomarkers, described by the National Cancer Institute as “a biological molecule found in 
blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of 
a condition or disease. A biomarker may be used to see how well the body responds to a 
treatment for a disease or condition. Also called molecular marker and signature molecule.”257 
Therefore, a biomarker can provide insight into whether a patient has a certain disease, and 
if so, how to proceed within the clinical pathway. It needs to be noted that a biomarker 
can consist of a single molecule or a set of molecules that can provide a certain signature 
for the disease. Additionally, the obtained information contributes to the knowledge on the 
molecular pathway and potential irregularities that are related to a certain disease, enabling 
patient risk stratification, e.g., in early screening, or the differentiation between disease 
states such as indolent and aggressive tumors.258 
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BIOMARKER DISCOVERY
It is remarkable that on a yearly basis many potential clinical biomarkers are identified, while 
only a minor fraction will eventually find its way into the clinics.259 The process of translating 
a potential biomarker into the clinic is slow and often takes many years, making it time-
consuming and costly while there is a need for instant new biomarkers. The slow progress 
and the very limited translation is often a result of poorly designed experiments in the 
discovery phase, due to a lack of communication between the different collaborators, also 
known as stakeholders, such as the clinicians, industry, academic researchers and clinical 
laboratory professionals, even though they may all strive for improving the diagnosis and 
prognosis of a disease.
The academic researcher may often be focused on finding new biomarkers and overlook 
which criteria apply for the development of a new clinical test or critical steps that largely 
influence the robustness of a developed assay (e.g., sample collection, storage conditions), 
leading to irreproducible results. While the clinical laboratory professional might not be fully 
aware of the fact that not all critical steps can be thoroughly tested and taken into account 
when a new biomarker is still in the discovery phase (and, therefore, its potential has not 
yet been validated). It should be noted that, aside from more specific biomarkers, there is 
also a need for a better translation from the discovery phase into the validation phase. For 
example, it should be taken into account that most analytical platforms that are used in 
the biomarker discovery phase are chosen for their ability to analyze and characterize the 
sample to a considerable depth to cover as many features as possible. Therefore, different 
requirements are often set for the desired analytical platform in the biomarker discovery 
phase compared to the clinical setting, leading to platforms that are most often not suitable 
in a clinical setting. Resulting in the fact that the translation should not only be focused 
on validating the outcomes, but also on the development of more simplistic assays that 
allow high-throughput and robustness. Moreover, it would be beneficial if the different 
stakeholders jointly identify at an early stage the crucial factors with respect to sample 
collection, transportation and handling during pre-, mid- and post-processing, also known 
as the pre-analytics.258,260 Examples of questions to be addressed are: How do the samples 
have to be collected? Is the sample container crucial? Could the matrix of the sample bias 
the results? Is there a need for a stabilization agent? Does the sample require direct storage 
or is it required to cool the sample down to a certain temperature prior to storage? At which 
temperature does the sample need to be stored? Do several freeze-and-thaw cycles change 
the sample composition? All these factors can be critical for the outcome of a biomarker assay 
as well as influence the reproducibility and reliability of the assay. Therefore, prior to testing 
an established assay within a small cohort, the whole workflow should be critically evaluated 
and an inventory of crucial steps should be made. As a result, the needs and critical points 
are better understood and repetition of experiments can be avoided when transferring from 
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the discovery phase to the validation phase, eventually saving time and resources, providing 
more reliable results and giving more confidence in an actual biomarker that will find its way 
into the clinics. Moreover, the analytical validity should also be evaluated, which takes into 
account the technical aspects of an assay.258,260 Here, the robustness of an assay is determined, 
such as its accuracy, repeatability, but more importantly its reproducibility, which provides 
information about how well the assay performs when performed by different analysts, with 
other instruments and at different laboratories. By testing pre-analytical factors and clinical 
validity, the outcomes become more reliable since findings can be reproduced. Another 
crucial point of a successful biomarker is its clinical validity.258,260 The biomarker should 
provide evidence that it is able to distinguish patients with or without a disease. In the case 
of PCa, this can be the distinction between indolent and aggressive PCa or between benign 
prostate hyperplasia (BPH) and PCa patients. Whenever a biomarker seems to be clinically valid 
it should be reproduced with an independent sample set; whether the original researchers 
should perform this, is still under debate.258,259 Biomarkers that do not provide any advantage 
on assays that are currently used in the clinical pathway do not show their clinical utility and 
in the end they will not be utilized.258,260 Biomarkers are expected to address “any missing 
or inadequately performing component of a clinical pathway”, which is defined by the Test 
Evaluation Group of the European Federation of Clinical Chemistry and Laboratory Medicine 
as an unmet clinical need.261 This federation proposed a 4-step process that helps to identify 
these unmet clinical needs in a clinical pathway.260,261 The first step is scrutinizing literature, 
critically evaluating described biomarkers, identifying the current practice, the gap in the 
clinical pathway and what the desired outcomes are if these gaps are filled. The second step 
investigates whether there is already an existing and satisfying solution for this gap. If yes, 
there is no unmet clinical need, if not, a study is needed to identify a possible solution. The 
third step includes the question if a potential biomarker would contribute to the solution and 
what its impact would be and where in the clinical pathway it should be placed. For example, 
would it be included as an additional, a replacement or a triage test (determining which patient 
should be treated immediately). What would be the advantage of including this test, what are 
the potential harms and will the advantages expectedly outweigh these harms. The fourth and 
final step considers if the proposed solution would be practically feasible, not only in terms 
of technical feasibility, but also with regard to performance and standardization of the assay, 
as well as capital investment. The commercial feasibility is also taken into account by defining 
its cost-effectiveness, e.g., how well the new test performs compared to the current process 
and are the costs worth the improvements. Another feasibility evaluation is made on what is 
needed on an organizational level: will the improvement be acknowledged by the patients and 
all stakeholders and, if not, what is needed to change this? What facilities are required? Is there 
a special training needed for the staff? The accessibility should also be taken into account, e.g., 
will this be a test that can be performed in every hospital or are there specialized laboratories 
needed and, if so, what would be the availability and accessibility in this case? 
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PSA GLYCOSYLATION AS POTENTIAL BIOMARKER
The last section of this thesis is focused on the application of PSA glycosylation analysis and 
its evaluation as a PCa biomarker. Chapter 5 describes the development of a PSA Glycomics 
Assay, which allows the capture of intact PSA from patients’ urine followed by tryptic 
digestion and the analysis with the optimized CE-ESI-MS platform (Chapters 2 and 3). 
In the case of PCa, there are two unmet clinical needs: the need for a better marker in 
the early diagnosis of PCa and, most importantly, the differentiation between indolent from 
aggressive tumors. Early diagnosis of the disease would lead to early treatment and less 
chance for disease progression. While early screening tests seem to be a crucial step in 
the clinical pathway, the current PSA test lacks specificity, leading to many false positives 
resulting in unnecessary investigations.262 Concerning the differentiation between indolent 
and aggressive disease, patients with low-grade PCa (Gleason score ≤ 6) often do not require 
immediate treatment while those with aggressive PCa (Gleason score ≥ 7) do.24 However, 
as the current PSA test is unable to identify the aggressiveness of the cancer, additional 
tests are needed such as biopsies, which are invasive and can be harmful for the patient 
(pain, anxiety and infections). Biopsies can provide more information whether a tumor is 
present and how aggressive it is, however, the outcome is operator dependent and this only 
reflects the status of the biopsy tissue. Namely, the cancer stage of the patient may not be 
accurately reflected as it does not always represent the status of the entire prostate gland. 
In this respect, if a positive biopsy is found it can be confirmed if a patient has PCa, however, 
the most aggressive form found in the biopsy can only define the disease status. This could 
result in undertreatment when (more) malignant tumors were missed during biopsy. This 
indicates that there is still a gap in accurate identification of PCa and its aggressiveness. 
Therefore, a potential biomarker should be evaluated on its specificity and ability to provide 
more in-depth information regarding the disease status of the patient. Once an elevated 
PSA-concentration has been detected, a biopsy will be taken and a second assay is needed to 
provide more confidence that a biopsy is truly negative and there is indeed no indication for 
the presence of an aggressive PCa. When this assay does not provide any indication no further 
investigations will be needed other than repeat testing of PSA as well as performing the 
newly developed secondary assay (step 1). Even though several attempts have been made to 
overcome this unmet need, none of them have provided enough evidence of their advantages 
over the use of the current PSA test (step 2).78,80 However, the glycan modifications of PSA 
can be a useful biomarker. Namely, based on preliminary results, the glycosylation profile of 
PSA, especially alterations in the molecular features (sialylation and fucosylation)3,35,99,101-103 
could improve the PCa diagnosis leading to better patient stratification. The minimum clinical 
performance that is required for a new biomarker is at least a better specificity compared to 
the gold standard (PSA test in combination with a biopsy). This would be achieved if indolent 
PCa can be distinguished from aggressive PCa with a lower number of false positives (PSA 
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test) and false negatives (biopsy) (step 3). Finally, the feasibility of the identified biomarker 
should be studied (step 4), however, this is dependent on how the biomarker is defined. 
Ideally, a platform will be developed that will be largely operator independent, providing 
a certain value that advises the clinician how to proceed further, e.g., is there a need for 
more in-depth examination or would active surveillance be a better option for this patient 
and if so, in which time period they should be examined again. Currently, patients under 
active surveillance will have a PSA test every three months and a biopsy after one year, 
making this a very bothering process for the patients. Ideally, the value from the test should 
distinguish patients that need examination e.g., every three months from those that need an 
examination every two years or even five years, that would significantly improve the quality 
of life for a patient.
Additionally, it is worth noting that the biopsy is acknowledged as the gold standard for 
PCa diagnosis, however, this is a rather biased gold standard as this is mainly based on 
histology which is operator dependent and, moreover, a tumor could be missed during 
biopsy leading to misdiagnosis. Therefore, a suitable clinical endpoint would be e.g., a 10-
year long follow-up and see if the disease progresses over time. However, this would still 
be biopsy dependent. Another option would be radical prostatectomy as this could provide 
more accurate information about the current status of the disease as the whole prostate can 
be examined. However, this procedure will lead to information loss in the case of indolent 
PCa, as it will be uncertain if the disease would have progressed over time. Taking this 
into account, none of the abovementioned proposals seems to be a perfect gold standard 
to evaluate a new biomarker which makes it rather complicated to find biomarkers that 
perform better than a biopsy.
PSA GLYCOMICS ASSAY
The PSA Glycomics Assay developed at our department (Chapter 5) was used to study the 
PSA glycosylation profile of captured PSA from patients’ urine and showed that an in-depth 
relative quantitation could be performed. While the PGA showed excellent repeatability over 
different days, no direct correlations could be made between the clinical and diagnostic value 
of PSA glycosylation features in urine. It was hypothesized that this might be due to the small 
sample size, however, a larger cohort did not result in any new findings (data not shown), 
suggesting that the urinary PSA glycosylation profile does not have any biomarker potential 
in early assessment of PCa. The epithelial cells secrete PSA, and in the case of PCa these 
cells are altered, which could lead to alterations in PSA as well as in its glycosylation (which 
is initiated in the lumen of the endoplasmic reticulum).97 It is hypothesized that, in PCa, the 
PSA that enters the circulation is more derived from altered cells, because the cells are more 
misaligned and more PSA can leak into the circulation. On the other hand, urine contains 
already high amounts of PSA under normal conditions, and might not contain a high amount 
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of the altered PSA. Therefore, it would be of special interest to compare the urinary to the 
serum PSA glycosylation of patients, to test whether differences can be observed between 
the two biofluids. The urinary PSA glycosylation profile would provide an unbiased (unaffected 
by PCa) profile, and this could be used as a baseline to test whether the PSA glycosylation 
appears changed in the serum. This is especially interesting as the glycosylation between 
individuals can be rather variable while each patient has its own consistent glycosylation 
fingerprint, which would make such an assay perfect for personalized medicine.106
However, many different factors should be taken into account, such as: does the matrix 
influence the glycosylation? Does the concentration difference play a role and bias the 
glycosylation analysis? How stable is PSA in both biofluids? Do different PSA subforms contain 
different glycosylation features and, if so, can this influence the overall PSA glycosylation 
profile? Therefore, more research is needed to study in-depth the biosynthetic pathway of 
PSA and its N-linked glycosylation. Because little is known about when the glycoprotein enters 
the biofluid, a better insight in this process would provide knowledge on why unglycosylated 
PSA seems to be more abundant in urine while (differently) nicked PSA subforms seem to 
be more present in seminal fluid (data not shown). Knowing this background would also 
help to further explore the possibilities for treatment of the disease. While not covered in 
this thesis, the intact analysis of PSA could provide the desired knowledge, by identifying 
the presence and abundance of these different subforms. Different analytical platforms are 
available which could provide information on different levels, such as based on rough mass 
differences (SDS-PAGE gel or two-dimensional polyacrylamide gel electrophoresis),56,244 or 
charge distribution by anion-exchange chromatography or CE-ESI-MS.56,263
Preliminary studies with CE-ESI-MS on the intact analysis of PSA captured from patients’ 
urine showed that, next to the conventional PSA, many different subforms could be identified 
in urinary PSA (data not shown). Subforms such as inactive PSA (iPSA) and benign PSA (bPSA) 
could be found, and bPSA was found in different varieties (with one or more internal cleavages 
and with non, one or two amino acids losses), similar subforms were previously identified in 
PSA derived from seminal plasma.56,264 Furthermore, no complexed PSA (cPSA) was found, 
while bPSA and conventional PSA were found glycosylated as well as unglycosylated with 
H5N4F1S2 being the most abundant glycan for both forms. These results reveal the added 
value to study PSA as an intact glycoprotein, next to the analysis on a glycopeptide level. 
Additional research should focus on further development of the analytical platform by 
pushing its sensitivity, resolution power and complete assignment of the detected analytes. 
Additionally, other glycoproteins correlated with PCa can be studied for their biomarker 
potential such as prostatic acid phosphatase. This protein is known as the predecessor of 
PSA as it has been used as a serum marker of PCa as it also seems to be elevated in prostate 
related diseases.265,266 Another interesting study would be the analysis of various cell lines 
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and its glycosylation, which hopefully could provide more knowledge about the disease. Until 
now, most research has been performed on the cell line LNCaP (supraclavicular lymph node, 
androgen-sensitive human carcinoma of the prostate), however, this cell line seems to have 
a complete different PSA glycosylation distribution than that observed in urine or plasma, 
with less sialylation, a higher amount of fucosylation and antennaes.34,103,267 Therefore, it is 
suggested to further explore different cell lines that are related to PCa.
BIOMARKER DISCOVERY WITH CE-ESI-MS
As stated previously, information regarding disease-specific changes could provide in-depth 
knowledge about alterations of the physiological properties of a glycoprotein. Even minor 
changes as well as low abundant glycosylation features could potentially lead to the desired 
glycan biomarkers. In this thesis, implementations were made to the CE-ESI-MS platform 
to further improve the sensitivity in combination with a sheathless interface, and to use 
these improvements for biomarker discovery in the field of PCa. The sensitivity of the CE-
ESI-MS platform has been assessed and compared with other well-established analytical 
platforms such as nanoLC-ESI-MS (Chapter 3) and MALDI-TOF-MS (Chapter 4), and has 
shown to outperform these platforms. Here, the highly sensitive CE-ESI-MS method allowed 
identifying slight changes and minor abundant glycosylation features that would be missed 
with other analytical platforms.
It should be noted that the use of CE-ESI-MS(/MS) in a clinical environment is, for now, not 
envisioned and should be mainly adapted for biomarker discovery, because the analytical 
platform still has its limitations (no high-throughput and limited sample loadability) and might 
be too complex to be used in a clinical setting (e.g., operation of the system, repeatability 
and data complexity). Therefore, the current vision would be to use the obtained knowledge 
from the in-depth measurements in order to define simpler assays for the clinical setting that 
focus on the specific features that were found in these studies, allowing high-throughput 
and more robustness (e.g., lectin arrays, immunoaffinity, aptamer binding assays).255,256,268 
If the current drawbacks of CE-ESI-MS could be resolved, it may have a future in a clinical 
setting. For example, sample loadability is currently seen as a major disadvantage, as, 
normally, no more than 2% of the capillary should be filled to avoid loss of resolution,269 and 
this often means a sample injection of 9 nL up to a maximum of 70 nL, which is only a minor 
fraction (0.5% up to 3.5%) of the total volume that is required in the sample vial (2 µL). This 
is in major contrast to other analytical platforms where larger volumes can be applied (for 
nanoLC-ESI-MS the volume is up to 10 µL, while for MALDI-TOF-MS it is usually 1 - 2 µL), 
containing a large part of the sample. Therefore, further developments are needed that 
enable higher injection volumes in order to enhance the overall sensitivity of CE-ESI-MS 
workflows. Several studies have already shown promising results;270 e.g., implementation 
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of a monolithic column allowing an on-line pre-concentration step of the sample prior to 
analysis,200,271,272 the development of new sheathflow and sheathless interfaces273-275 as well 
as the use of immunoaffinity.276 Additionally, the long analysis time could also be seen as 
another drawback of the current CE-ESI-MS platform and further investigations could be 
focused on the use of multi-segment injection. During this process several samples (e.g., N 
= 5) can be injected with a BGE plug as a spacer;277,278 however, it should be noted that here 
sample loadability could be an issue, as the capillary volume will be filled for a larger part and 
resolution might be lost.
STUDY DESIGN 
Next to sample collection and handling, the overall study design is a crucial factor in 
biomarker discovery. Dependent on the research question, the study should be differently 
designed and different factors need to be taken into account. During this study the aim was 
to distinguish BPH from PCa patients but, more importantly, to differentiate the different 
PCa patient groups, indolent from aggressive, specifically in the grey zone of the PSA test 
(PSA concentration of 3 - 10 ng/mL). For this study a proof-of-principle of the developed PSA 
Glycomics Assay was shown, however, to validate the outcome, a proper cohort design is 
needed, ensuring that the patient groups are well matched. Currently, the histology of the 
biopsy defines the disease status of the patient, however, as stated earlier, tumors can then 
be missed. Therefore, during the evaluation of a new biomarker, the biomarker should not 
be compared to the histology of a fresh biopsy but rather on longitudinal information of a 
patient, preferably data of several years that provides the information if the patient indeed 
did not harbour PCa at that time or that the diagnosis changed over time. Moreover, the 
mean average of the total PSA (tPSA) concentration should be similar between the different 
patient groups and, as age has shown to influence the glycosylation profile in total plasma 
N-glycome,138,279 it is also important to ensure that the patient groups are age-matched 
to prevent any age bias. In addition, proper controls need to be taken along, which would 
preferably be from healthy donors. Unfortunately, as these healthy donors should also be 
age-matched, they will be mostly above age 60, and there is a good chance that the healthy 
donors might have a prostate related disease that could bias the outcome of the study. In 
this case, it is suggested not to have healthy donors as a control sample, but rather to study 
the glycosylation profiles of the different patient groups and potential differences that are 
disease specific. Another crucial aspect, which was shown in this thesis, is the biofluid that is 
selected. While most studies revealed specific glycosylation features for PCa, this was mainly 
performed on the total N-glycome or PSA derived from serum. The study in this thesis 
provided in-depth information regarding the PSA glycosylation from patients’ urine. Even 
though the obtained results were negative for the proposed hypothesis, it is still suggested 
to validate the results by repeating the same assay on a different cohort. Preferably a cohort 
from which the samples were retrieved in a different research group. If similar results can 
| DISCUSSION AND FUTURE PERSPECTIVES |
| 139 | 
6
be obtained, there is a higher probability that the glycosylation of urinary PSA indeed does 
not contain disease related features. The same accounts for an assay that aims for an altered 
glycosylation profile of PSA derived from serum between different patient groups. If certain 
results are found, they should always be validated with another sample set.
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CONCLUDING REMARKS
While several studies have already shown the potential of using the glycosylation of PSA 
as a potential biomarker for PCa, there is still a need for a deeper understanding of this 
glycoprotein and how the protein and its glycosylation is correlated to PCa. However, to 
further examine this glycoprotein, technological innovations were needed to enable better 
sensitivity and repeatability. During these developments questions were raised such as: What 
is the mechanism behind the isomer separation of the sialylated glycopeptides (Chapter 2)? 
What is the mechanism behind the improved sensitivity when a dopant enriched nitrogen gas 
is used (Chapter 3)? Does the signal enhancement with dopant enriched nitrogen gas apply 
to other molecule classes as well (Chapter 3)? Can the separation be even further pushed 
for isomeric separation with CE-ESI-MS (Chapter 4)? Furthermore, the improved CE-ESI-MS 
platform led to the development of a PSA Glycomics Assay allowing an in-depth study on the 
urinary PSA N-glycome of patients with elevated PSA levels (> 3 ng/mL) in their circulation, 
which lead to another question: Does the in-depth information on PSA glycosylation obtained 
with the improved CE-ESI-MS platform lead to new biomarkers for PCa (Chapter 5)? As the 
preliminary results of the PSA Glycomics Assay did not show any PCa biomarker candidates 
in urine, it is suggested that the observed PSA glycosylation profile can be seen as an 
unbiased glycosylation PSA profile (unaffected by PCa). This observation lead to the following 
questions: does the glycosylation of PSA in serum harbor potential biomarkers for PCa? If so, 
can the unbiased PSA glycosylation profile of urine be used as a personal baseline for each 
patient? While, this is just a small selection of all the questions that arose during this project, 
it provides an indication of how complex research can be and one should be aware that 
obtaining a single clear answer is most often not the case. Moreover, this thesis provided a 
deeper insight into the urinary PSA N-glycome, which is just the beginning of a longer journey 
to study and understand how this information could be of potential use to improve the early 
differentiation of aggressive versus indolent PCa. However, it is of utmost importance that a 
single stakeholder does not get blindsided by his/her own interest and that the overall goal 
should be clear and valuable for all stakeholders. Therefore, it is crucial in the early stages 
that the different stakeholders share their knowledge, interests and desires with each other 
to ensure that indeed the right questions are being asked, crucial factors are being tackled 
and the efforts will lead in the end to: 






| 145 | 
B
(1)  Bray, F., et al. Global cancer statistics 2018: 
GLOBOCAN estimates of incidence and 
mortality worldwide for 36 cancers in 185 
countries, CA Cancer J. Clin., 2018, 68, 394-
424.
(2)  Wolf, A.M., et al. American Cancer Society 
guideline for the early detection of prostate 
cancer: update 2010, CA Cancer J. Clin., 
2010, 60, 70-98.
(3)  Yoneyama, T., et al. Measurement of 
aberrant glycosylation of prostate specific 
antigen can improve specificity in early 
detection of prostate cancer, Biochem. 
Biophys. Res. Commun., 2014, 448, 390-
396.
(4)  Kyselova, Z., et al. Alterations in the serum 
glycome due to metastatic prostate cancer, 
J. Proteome Res., 2007, 6, 1822-1832.
(5)  Vermassen, T., et al. Capillary 
electrophoresis of urinary prostate 
glycoproteins assists in the diagnosis of 
prostate cancer, Electrophoresis, 2014, 35, 
1017-1024.
(6)  Kammeijer, G.S.M., et al. Sialic acid linkage 
differentiation of glycopeptides using 
capillary electrophoresis - electrospray 
ionization - mass spectrometry, Sci. Rep., 
2017, 7, 3733.
(7)  Kammeijer, G.S.M., et al. An In-Depth 
Glycosylation Assay for Urinary Prostate-
Specific Antigen, Anal. Chem., 2018, 90, 
4414-4421.
(8)  Schultz, M.J., et al. Regulation of the 
metastatic cell phenotype by sialylated 
glycans, Cancer Metastasis Rev., 2012, 31, 
501-518.
(9)  Zhuo, Y.; Bellis, S.L. Emerging role of 
alpha2,6-sialic acid as a negative regulator 
of galectin binding and function, J. Biol. 
Chem., 2011, 286, 5935-5941.
(10)  Incidences of prostate cancer in the 
Netherlands from 1990-2017 from the 
Netherlands Comprehensive Cancer 
Organization: Retrieved from www.
cijfersoverkanker.nl.
(11)  Blanker, M.H., et al. Prostate cancer 
detection in older men with and without 
lower urinary tract symptoms: A 
population-based study, J. Am. Geriatr. 
Soc., 2003, 51, 1041-1042.
(12)  Collin, S.M., et al. Associations of lower 
urinary tract symptoms with prostate-
specific antigen levels, and screen-detected 
localized and advanced prostate cancer: 
a case-control study nested within the UK 
population-based ProtecT (Prostate testing 
for cancer and Treatment) study, BJU Int., 
2008, 102, 1400-1406.
(13)  Kheirandish, P.; Chinegwundoh, F. Ethnic 
differences in prostate cancer, Br. J. Cancer, 
2011, 105, 481-485.
(14)  Bruner, D.W., et al. Relative risk of prostate 
cancer for men with affected relatives: 
systematic review and meta-analysis, Int. J. 
Cancer, 2003, 107, 797-803.
(15)  Chen, Y.C., et al. Family history of prostate 
and breast cancer and the risk of prostate 
cancer in the PSA era, Prostate, 2008, 68, 
1582-1591.
(16)  Valeri, A., et al. Early onset and familial 
predisposition to prostate cancer 
significantly enhance the probability for 
breast cancer in first degree relatives, Int. J. 
Cancer, 2000, 86, 883-887.
(17)  Wong, M.C., et al. Global Incidence and 
Mortality for Prostate Cancer: Analysis 
of Temporal Patterns and Trends in 36 
Countries, Eur. Urol., 2016, 70, 862-874.
(18)  US Preventive Services Task Force, et al. 
Screening for Prostate Cancer: US Preventive 
Services Task Force Recommendation 
Statement, JAMA, 2018, 319, 1901-1913.
(19)  Nederlandse Vereniging voor Urologie, 
Prostaatcarcinoom, Landelijke Richtlijn; 
2014.
(20)  Ahmed, H.U., et al. Diagnostic accuracy 
of multi-parametric MRI and TRUS biopsy 
in prostate cancer (PROMIS): a paired 
validating confirmatory study, Lancet, 
2017, 389, 815-822.
(21)  Gittes, R.F. Carcinoma of the Prostate, N. 
Engl. J. Med., 1991, 324, 236-245.
(22)  Gleason, D.F.; Mellinger, G.T. Prediction of 
Prognosis for Prostatic Adenocarcinoma by 
Combined Histological Grading and Clinical 
| 146 |  
| BIBLIOGRAPHY |
Staging, J. Urol., 1974, 111, 58-64.
(23)  Epstein, J.I., et al. The 2005 International 
Society of Urological Pathology (ISUP) 
Consensus Conference on Gleason Grading 
of Prostatic Carcinoma, Am. J. Surg. Pathol., 
2005, 29, 1228-1242.
(24)  Chan, T.Y., et al. Prognostic significance of 
Gleason score 3+4 versus Gleason score 4+3 
tumor at radical prostatectomy, Urology, 
2000, 56, 823-827.
(25)  American Joint Committee on Cancer, AJCC 
Cancer Staging Manual: Seventh edition, 
Edge, S.B.; Byrd, D.R.; Compton, C.C.; Fritz, 
A.G.; Greene, F.L.; Trotti, A., Eds.; Springer, 
2010, pp 457-464.
(26)  Keetch, D.W., et al. Serial prostatic biopsies 
in men with persistently elevated serum 
prostate specific antigen values, J. Urol., 
1994, 151, 1571-1574.
(27)  Abdelkhalek, M., et al. Hemosepermia after 
transrectal ultrasound-guided prostatic 
biopsy: A prospective study, Urol. Ann., 
2013, 5, 30-33.
(28)  Loeb, S., et al. Systematic review of 
complications of prostate biopsy, Eur. Urol., 
2013, 64, 876-892.
(29)  El-Shater Bosaily, A., et al. PROMIS--
Prostate MR imaging study: A paired 
validating cohort study evaluating the role 
of multi-parametric MRI in men with clinical 
suspicion of prostate cancer, Contemp. Clin. 
Trials, 2015, 42, 26-40.
(30)  Day, J.R., et al. PCA3: from basic molecular 
science to the clinical lab, Cancer Lett., 
2011, 301, 1-6.
(31)  Catalona, W.J. Management of cancer of 
the prostate, N. Engl. J. Med., 1994, 331, 
996-1004.
(32)  Bubendorf, L., et al. Metastatic patterns of 
prostate cancer: an autopsy study of 1,589 
patients, Hum. Pathol., 2000, 31, 578-583.
(33)  Janković, M.M.; Kosanović, M.M. 
Glycosylation of urinary prostate-specific 
antigen in benign hyperplasia and cancer: 
assessment by lectin-binding patterns, Clin. 
Biochem., 2005, 38, 58-65.
(34)  Peracaula, R., et al. Altered glycosylation 
pattern allows the distinction between 
prostate-specific antigen (PSA) from normal 
and tumor origins, Glycobiology, 2003, 13, 
457-470.
(35)  Saldova, R., et al. Core fucosylation and 
alpha2-3 sialylation in serum N-glycome is 
significantly increased in prostate cancer 
comparing to benign prostate hyperplasia, 
Glycobiology, 2011, 21, 195-205.
(36)  Lilja, H., et al. Seminal vesicle-secreted 
proteins and their reactions during gelation 
and liquefaction of human semen, J. Clin. 
Invest., 1987, 80, 281-285.
(37)  Peter, A., et al. Semenogelin I and 
semenogelin II, the major gel-forming 
proteins in human semen, are substrates 
for transglutaminase, Eur. J. Biochem., 
1998, 252, 216-221.
(38)  Bokhorst, L.P., et al. Positive predictive 
value of prostate biopsy indicated by 
prostate-specific-antigen-based prostate 
cancer screening: trends over time in a 
European randomized trial*, BJU Int., 2012, 
110, 1654-1660.
(39)  Foley, R.W., et al. European Randomised 
Study of Screening for Prostate Cancer 
(ERSPC) risk calculators significantly 
outperform the Prostate Cancer Prevention 
Trial (PCPT) 2.0 in the prediction of prostate 
cancer: a multi-institutional study, BJU Int., 
2016, 118, 706-713.
(40)  Lövgren, J., et al. Measurement of prostate-
specific antigen and human glandular 
kallikrein 2 in different body fluids, J. 
Androl., 1999, 20, 348-355.
(41)  Howarth, D.J., et al. Immunohistochemical 
localization of prostate-specific antigen in 
benign and malignant breast tissues, Br. J. 
Cancer, 1997, 75, 1646-1651.
(42)  Yu, H.; Diamandis, E.P. Measurement of 
serum prostate specific antigen levels in 
women and in prostatectomized men with 
an ultrasensitive immunoassay technique, 
J. Urol., 1995, 153, 1004-1008.
(43)  Yu, H.; Diamandis, E.P. Prostate-specific 
antigen immunoreactivity in amniotic fluid, 
Clin. Chem., 1995, 41, 204-210.
(44)  Schmidt, S., et al. Prostate-specific antigen 
| BIBLIOGRAPHY |
| 147 | 
B
in female urine: a prospective study 
involving 217 women, Urology, 2001, 57, 
717-720.
(45)  Balk, S.P., et al. Biology of prostate-specific 
antigen, J. Clin. Oncol., 2003, 21, 383-391.
(46)  Gilgunn, S., et al. Aberrant PSA 
glycosylation—a sweet predictor of 
prostate cancer, Nat. Rev. Urol., 2013, 10, 
99.
(47)  Mikolajczyk, S.D., et al. A precursor form of 
PSA (pPSA) is a component of the free PSA 
in prostate cancer serum, Urology, 1997, 
50, 710-714.
(48)  Takayama, T.K., et al. Characterization of 
hK4 (prostase), a prostate-specific serine 
protease: activation of the precursor of 
prostate specific antigen (pro-PSA) and 
single-chain urokinase-type plasminogen 
activator and degradation of prostatic 
acid phosphatase, Biochemistry, 2001, 40, 
15341-15348.
(49)  Kumar, A., et al. Expression of pro form of 
prostate-specific antigen by mammalian 
cells and its conversion to mature, active 
form by human kallikrein 2, Cancer Res., 
1997, 57, 3111-3114.
(50)  Lövgren, J., et al. Activation of the zymogen 
form of prostate-specific antigen by human 
glandular kallikrein 2, Biochem. Biophys. 
Res. Commun., 1997, 238, 549-555.
(51)  Mikolajczyk, S.D., et al. Seminal plasma 
contains “BPSA,” a molecular form of 
prostate-specific antigen that is associated 
with benign prostatic hyperplasia, Prostate, 
2000, 45, 271-276.
(52)  Mikolajczyk, S.D., et al. “BPSA,” a specific 
molecular form of free prostate-specific 
antigen, is found predominantly in the 
transition zone of patients with nodular 
benign prostatic hyperplasia, Urology, 
2000, 55, 41-45.
(53)  Wang, T.J., et al. Benign prostatic 
hyperplasia-associated prostate-
specific antigen (BPSA) shows unique 
immunoreactivity with anti-PSA 
monoclonal antibodies, Eur. J. Biochem., 
2000, 267, 4040-4045.
(54)  Wang, T.J., et al. PSA concentrations in 
seminal plasma, Clin. Chem., 1998, 44, 895-
896.
(55)  Christensson, A.; Lilja, H. Complex 
formation between protein C inhibitor and 
prostate-specific antigen in vitro and in 
human semen, Eur. J. Biochem., 1994, 220, 
45-53.
(56)  Zhang, W.M., et al. Purification and 
characterization of different molecular 
forms of prostate-specific antigen in human 
seminal fluid, Clin. Chem., 1995, 41, 1567-
1573.
(57)  Jung, K., et al. Ratio of free or complexed 
prostate-specific antigen (PSA) to total 
PSA: which ratio improves differentiation 
between benign prostatic hyperplasia and 
prostate cancer?, Clin. Chem., 2000, 46, 55-
62.
(58)  Lilja, H., et al. Prostate-specific antigen and 
prostate cancer: prediction, detection and 
monitoring, Nat. Rev. Cancer, 2008, 8, 268-
278.
(59)  Brawer, M.K., et al. Serum Prostate-Specific 
Antigen and Prostate Pathology in Men 
Having Simple Prostatectomy, Am. J. Clin. 
Pathol., 1989, 92, 760-764.
(60)  Djavan, B., et al. Complexed prostate-
specific antigen, complexed prostate-
specific antigen density of total and 
transition zone, complexed/total prostate-
specific antigen ratio, free-to-total 
prostate-specific antigen ratio, density 
of total and transition zone prostate-
specific antigen: results of the prospective 
multicenter European trial, Urology, 2002, 
60, 4-9.
(61)  Catalona, W.J., et al. Use of the percentage 
of free prostate-specific antigen to enhance 
differentiation of prostate cancer from 
benign prostatic disease: a prospective 
multicenter clinical trial, JAMA, 1998, 279, 
1542-1547.
(62)  Catalona, W.J., et al. Evaluation of 
percentage of free serum prostate-specific 
antigen to improve specificity of prostate 
cancer screening, JAMA, 1995, 274, 1214-
1220.
(63)  Nurmikko, P., et al. Discrimination of 
| 148 |  
| BIBLIOGRAPHY |
prostate cancer from benign disease 
by plasma measurement of intact, free 
prostate-specific antigen lacking an internal 
cleavage site at Lys145-Lys146, Clin. Chem., 
2001, 47, 1415-1423.
(64)  Leinonen, J., et al. Double-label time-
resolved immunofluorometric assay of 
prostate-specific antigen and of its complex 
with alpha 1-antichymotrypsin, Clin. Chem., 
1993, 39, 2098-2103.
(65)  Lilja, H., et al. Prostate-specific antigen in 
serum occurs predominantly in complex 
with alpha 1-antichymotrypsin, Clin. Chem., 
1991, 37, 1618-1625.
(66)  Stenman, U.H., et al. A complex between 
prostate-specific antigen and alpha 
1-antichymotrypsin is the major form 
of prostate-specific antigen in serum of 
patients with prostatic cancer: assay of the 
complex improves clinical sensitivity for 
cancer, Cancer Res., 1991, 51, 222-226.
(67)  Okihara, K., et al. Comparative analysis of 
complexed prostate specific antigen, free 
prostate specific antigen and their ratio in 
detecting prostate cancer, J. Urol., 2002, 
167, 2017-2023.
(68)  Partin, A.W., et al. Complexed prostate 
specific antigen improves specificity for 
prostate cancer detection: Results of a 
prospective multicenter clinical trial, J. 
Urol., 2003, 170, 1787-1791.
(69)  Jung, K., et al. Molecular forms of prostate-
specific antigen in malignant and benign 
prostatic tissue: Biochemical and diagnostic 
implications, Clin. Chem., 2000, 46, 47-54.
(70)  Jansen, F.H., et al. Prostate-specific antigen 
(PSA) isoform p2PSA in combination with 
total PSA and free PSA improves diagnostic 
accuracy in prostate cancer detection, Eur. 
Urol., 2010, 57, 921-927.
(71)  Loeb, S., et al. The prostate health index 
selectively identifies clinically significant 
prostate cancer, J. Urol., 2015, 193, 1163-
1169.
(72)  Vickers, A.J., et al. A Four-Kallikrein Panel 
Predicts Prostate Cancer in Men with 
Recent Screening: Data from the European 
Randomized Study of Screening for Prostate 
Cancer, Rotterdam, Clin. Cancer Res., 2010, 
16, 3232-3239.
(73)  Deras, I.L., et al. PCA3: a molecular urine 
assay for predicting prostate biopsy 
outcome, J. Urol., 2008, 179, 1587-1592.
(74)  Hessels, D., et al. DD3(PCA3)-based 
molecular urine analysis for the diagnosis 
of prostate cancer, Eur. Urol., 2003, 44, 
8-15; discussion 15-16.
(75)  Schalken, J.A., et al. New targets for therapy 
in prostate cancer: differential display code 
3 (DD3(PCA3)), a highly prostate cancer-
specific gene, Urology, 2003, 62, 34-43.
(76)  Marks, L.S.; Bostwick, D.G. Prostate Cancer 
Specificity of PCA3 Gene Testing: Examples 
from Clinical Practice, Rev. Urol., 2008, 10, 
175-181.
(77)  Merola, R., et al. PCA3 in prostate cancer 
and tumor aggressiveness detection on 
407 high-risk patients: a National Cancer 
Institute experience, J. Exp. Clin. Cancer 
Res., 2015, 34, 15.
(78)  Ferro, M., et al. Prostate Health Index 
(Phi) and Prostate Cancer Antigen 3 (PCA3) 
significantly improve prostate cancer 
detection at initial biopsy in a total PSA 
range of 2-10 ng/ml, PLOS One, 2013, 8, 
e67687.
(79)  Nordström, T., et al. Comparison Between 
the Four-kallikrein Panel and Prostate 
Health Index for Predicting Prostate Cancer, 
Eur. Urol., 2015, 68, 139-146.
(80)  Stephan, C., et al. Comparative assessment 
of urinary prostate cancer antigen 3 and 
TMPRSS2:ERG gene fusion with the serum 
[-2]proprostate-specific antigen-based 
prostate health index for detection of 
prostate cancer, Clin. Chem., 2013, 59, 280-
288.
(81)  Laine, R.A. Invited Commentary: A 
calculation of all possible oligosaccharide 
isomers both branched and linear yields 
1.05 × 1012 structures for a reducing 
hexasaccharide: the Isomer Barrier to 
development of single-method saccharide 
sequencing or synthesis systems, 
Glycobiology, 1994, 4, 759-767.
(82)  Varki, A.; al., e. Essentials of Glycobiology, 
| BIBLIOGRAPHY |
| 149 | 
B
rd; Varki, A.; Cummings, R.D.; Esko, J.D.; 
Stanley, P.; Hart, G.W.; Aebi, M.; Darvill, 
A.G.; Kinoshita, T.; Packer, N.H.; Prestegard, 
J.H.; Schnaar, R.L.; Seeberger, P.H., Eds.: 
Cold Spring Harbor (NY), 2015.
(83)  Varki, A., et al. Symbol Nomenclature for 
Graphical Representations of Glycans, 
Glycobiology, 2015, 25, 1323-1324.
(84)  Ohtsubo, K.; Marth, J.D. Glycosylation in 
cellular mechanisms of health and disease, 
Cell, 2006, 126, 855-867.
(85)  Karsten, C.M., et al. Anti-inflammatory 
activity of IgG1 mediated by Fc 
galactosylation and association of 
FcgammaRIIB and dectin-1, Nat. Med., 
2012, 18, 1401-1406.
(86)  Shields, R.L., et al. Lack of fucose on human 
IgG1 N-linked oligosaccharide improves 
binding to human Fcgamma RIII and 
antibody-dependent cellular toxicity, J. 
Biol. Chem., 2002, 277, 26733-26740.
(87)  Almeida, A.; Kolarich, D. The promise of 
protein glycosylation for personalised 
medicine, Biochim. Biophys. Acta. Gen. 
Subj., 2016, 1860, 1583-1595.
(88)  Thomann, M., et al. In vitro glycoengineering 
of IgG1 and its effect on Fc receptor binding 
and ADCC activity, PLOS One, 2015, 10, 
e0134949.
(89)  Holst, S., et al. Glycosylation characteristics 
of colorectal cancer, Adv. Cancer Res., 2015, 
126, 203-256.
(90)  Taniguchi, N.; Kizuka, Y. Glycans and 
cancer: role of N-glycans in cancer 
biomarker, progression and metastasis, 
and therapeutics, Adv. Cancer Res., 2015, 
126, 11-51.
(91)  Adamczyk, B., et al. Glycans as cancer 
biomarkers, Biochim. Biophys. Acta, 2012, 
1820, 1347-1353.
(92)  Ruhaak, L.R., et al. Developments in the 
identification of glycan biomarkers for the 
detection of cancer, Mol. Cell. Proteomics, 
2013, 12, 846-855.
(93)  Ueda, K. Glycoproteomic strategies: From 
discovery to clinical application of cancer 
carbohydrate biomarkers, Proteomics Clin. 
Appl., 2013, 7, 607-617.
(94)  Kirwan, A., et al. Glycosylation-Based 
Serum Biomarkers for Cancer Diagnostics 
and Prognostics, Biomed. Res. Int., 2015, 
2015, 490531.
(95)  Arrieta, O., et al. The progressive elevation 
of alpha fetoprotein for the diagnosis of 
hepatocellular carcinoma in patients with 
liver cirrhosis, BMC Cancer, 2007, 7, 28.
(96)  Duffy, M.J. Carcinoembryonic antigen as a 
marker for colorectal cancer: Is it clinically 
useful?, Clin. Chem., 2001, 47, 624-630.
(97)  Drake, P.M., et al. Sweetening the Pot: 
Adding Glycosylation to the Biomarker 
Discovery Equation, Clin. Chem., 2010, 56, 
223-236.
(98)  Pihikova, D., et al. Aberrant sialylation of a 
prostate-specific antigen: Electrochemical 
label-free glycoprofiling in prostate cancer 
serum samples, Anal. Chim. Acta, 2016, 
934, 72-79.
(99)  Llop, E., et al. Improvement of Prostate 
Cancer Diagnosis by Detecting PSA 
Glycosylation-Specific Changes, 
Theranostics, 2016, 6, 1190-1204.
(100)  Ferrer-Batalle, M., et al. Comparative Study 
of Blood-Based Biomarkers, alpha2,3-Sialic 
Acid PSA and PHI, for High-Risk Prostate 
Cancer Detection, Int. J. Mol. Sci., 2017, 18.
(101)  Li, Q.K., et al. Serum fucosylated prostate-
specific antigen (PSA) improves the 
differentiation of aggressive from non-
aggressive prostate cancers, Theranostics, 
2015, 5, 267-276.
(102)  Dwek, M.V., et al. A sensitive assay 
to measure biomarker glycosylation 
demonstrates increased fucosylation of 
prostate specific antigen (PSA) in patients 
with prostate cancer compared with benign 
prostatic hyperplasia, Clin. Chim. Acta, 
2010, 411, 1935-1939.
(103)  Fukushima, K., et al. alpha1,2-Fucosylated 
and beta-N-acetylgalactosaminylated 
prostate-specific antigen as an efficient 
marker of prostatic cancer, Glycobiology, 
2010, 20, 452-460.
(104)  Vermassen, T., et al. Urinary prostate 
| 150 |  
| BIBLIOGRAPHY |
protein glycosylation profiling as a 
diagnostic biomarker for prostate cancer, 
Prostate, 2015, 75, 314-322.
(105)  Vermassen, T., et al. Diagnostic accuracy 
of urinary prostate protein glycosylation 
profiling in prostatitis diagnosis, Biochem. 
Med. (Zagreb), 2015, 25, 439-449.
(106)  Aizpurua-Olaizola, O., et al. Mass 
spectrometry for glycan biomarker 
discovery, TrAC, Trends Anal. Chem., 2018, 
100, 7-14.
(107)  Ruhaak, L.R., et al. Mass Spectrometry 
Approaches to Glycomic and 
Glycoproteomic Analyses, Chem. Rev. , 
2018, DOI: 10.1021/acs.chemrev.7b00732.
(108)  Tiselius, A. A new apparatus for 
electrophoretic analysis of colloidal 
mixtures, Trans. Faraday Soc., 1937, 33, 
524-531.
(109)  Hjertén, S. Free zone electrophoresis, 
Chromatogr. Rev., 1967, 9, 122-219.
(110)  Mikkers, F.E.P., et al. High-performance 
zone electrophoresis, J. Chromatogr. A, 
1979, 169, 11-20.
(111)  Jorgenson, J.W.; Lukacs, K.D. Zone 
Electrophoresis in Open-Tubular Glass-
Capillaries, Anal. Chem., 1981, 53, 1298-
1302.
(112)  Busnel, J.M., et al. High capacity capillary 
electrophoresis-electrospray ionization 
mass spectrometry: coupling a porous 
sheathless interface with transient-
isotachophoresis, Anal. Chem., 2010, 82, 
9476-9483.
(113)  Boček, P., et al. Analytical Isotachophoresis 
Concept of Separation Capacity, J. 
Chromatogr., 1978, 160, 1-9.
(114)  Lauer, H.H.; Rozing, G.P. High Performance 
Capillary Electrophoresis, a primer; Agilent 
Technologies: Germany, 2009.
(115)  Mala, Z., et al. Analytical capillary 
isotachophoresis after 50 years of 
development: Recent progress 2014-2016, 
Electrophoresis, 2017, 38, 9-19.
(116)  Liu, J.P., et al. Capillary electrophoresis 
of amino sugars with laser-induced 
fluorescence detection, Anal. Chem., 1991, 
63, 413-417.
(117)  Olivares, J.A., et al. Online Mass-
Spectrometric Detection for Capillary Zone 
Electrophoresis, Anal. Chem., 1987, 59, 
1230-1232.
(118)  Smith, R.D.; Udseth, H.R. Capillary zone 
electrophoresis-MS, Nature, 1988, 331, 
639-640.
(119)  Wojcik, R., et al. Capillary electrophoresis 
with Orbitrap-Velos mass spectrometry 
detection, Talanta, 2012, 88, 324-329.
(120)  Moini, M. Simplifying CE-MS operation. 2. 
Interfacing low-flow separation techniques 
to mass spectrometry using a porous tip, 
Anal. Chem., 2007, 79, 4241-4246.
(121)  Himmelsbach, M. 10 years of MS 
instrumental developments--impact on LC-
MS/MS in clinical chemistry, J. Chromatogr. 
B Analyt. Technol. Biomed. Life Sci., 2012, 
883-884, 3-17.
(122)  Hoffmann, de E.; Stroobant, V. Mass 
spectrometry: Principles and applications, 
3rd Ed., John Wiley & Sons Ltd., 2007.
(123)  Jensen, P.H., et al. Structural analysis of N- 
and O-glycans released from glycoproteins, 
Nat. Protoc., 2012, 7, 1299-1310.
(124)  Zauner, G., et al. Protein O-glycosylation 
analysis, Biol. Chem., 2012, 393, 687-708.
(125)  Johnson, R.S., et al. Novel fragmentation 
process of peptides by collision-induced 
decomposition in a tandem mass 
spectrometer: differentiation of leucine 
and isoleucine, Anal. Chem., 1987, 59, 2621-
2625.
(126)  Roepstorff, P.; Fohlman, J. Letter to the 
editors, Biol. Mass Spectrom., 1984, 11, 
601-601.
(127)  Wuhrer, M., et al. Glycoproteomics 
based on tandem mass spectrometry of 
glycopeptides, J. Chromatogr. B Analyt. 
Technol. Biomed. Life Sci., 2007, 849, 115-
128.
(128)  Domon, B.; Costello, C.E. A systematic 
nomenclature for carbohydrate 
fragmentations in FAB-MS/MS spectra of 
glycoconjugates, Glycoconj. J., 1988, 5, 
397-409.
| BIBLIOGRAPHY |
| 151 | 
B
(129)  Halim, A., et al. Assignment of saccharide 
identities through analysis of oxonium ion 
fragmentation profiles in LC-MS/MS of 
glycopeptides, J. Proteome Res., 2014, 13, 
6024-6032.
(130)  Harvey, D.J., et al. Structural and 
quantitative analysis of N-linked glycans by 
matrix-assisted laser desorption ionization 
and negative ion nanospray mass 
spectrometry, Anal. Biochem., 2008, 376, 
44-60.
(131)  Huddleston, M.J., et al. Collisional 
fragmentation of glycopeptides by 
electrospray ionization LC/MS and LC/
MS/MS: methods for selective detection 
of glycopeptides in protein digests, Anal. 
Chem., 1993, 65, 877-884.
(132)  Hinneburg, H., et al. The Art of Destruction: 
Optimizing Collision Energies in Quadrupole-
Time of Flight (Q-TOF) Instruments for 
Glycopeptide-Based Glycoproteomics, J. 
Am. Soc. Mass Spectrom., 2016, 27, 507-
519.
(133)  Jenkins, N.; Curling, E.M. Glycosylation 
of recombinant proteins: problems and 
prospects, Enzyme Microb. Technol., 1994, 
16, 354-364.
(134)  Sinclair, A.M.; Elliott, S. Glycoengineering: 
the effect of glycosylation on the properties 
of therapeutic proteins, J. Pharm. Sci., 2005, 
94, 1626-1635.
(135)  Taylor, M.E.; Drickamer, K. Introduction 
to Glycobiology; Oxford University Press: 
Oxford, 2011.
(136)  Parekh, R.B., et al. Association of rheumatoid 
arthritis and primary osteoarthritis with 
changes in the glycosylation pattern of 
total serum IgG, Nature, 1985, 316, 452-
457.
(137)  Pinho, S.S.; Reis, C.A. Glycosylation 
in cancer: mechanisms and clinical 
implications, Nat. Rev. Cancer, 2015, 15, 
540-555.
(138)  Ruhaak, L.R., et al. Plasma protein N-glycan 
profiles are associated with calendar age, 
familial longevity and health, J. Proteome 
Res., 2011, 10, 1667-1674.
(139)  Albrecht, S., et al. Glycosylation as a 
marker for inflammatory arthritis, Cancer 
Biomark., 2014, 14, 17-28.
(140)  Bondt, A., et al. Association between 
galactosylation of immunoglobulin G and 
improvement of rheumatoid arthritis during 
pregnancy is independent of sialylation, J. 
Proteome Res., 2013, 12, 4522-4531.
(141)  Lauc, G., et al. Mechanisms of disease: The 
human N-glycome, Biochim. Biophys. Acta, 
2016, 1860, 1574-1582.
(142)  Byrne, B., et al. Sialic acids: carbohydrate 
moieties that influence the biological and 
physical properties of biopharmaceutical 
proteins and living cells, Drug. Discov. 
Today, 2007, 12, 319-326.
(143)  Jørgensen, T., et al. Up-regulation of 
the oligosaccharide sialyl LewisX: a new 
prognostic parameter in metastatic 
prostate cancer, Cancer Res., 1995, 55, 
1817-1819.
(144)  Wang, F.L., et al. High expression of alpha 
2, 3-linked sialic acid residues is associated 
with the metastatic potential of human 
gastric cancer, Cancer Detect. Prev., 2009, 
32, 437-443.
(145)  Hsu, D.K., et al. Galectins in apoptosis, 
Methods Enzymol. 2006, 417, 256-273.
(146)  Reis, C.A., et al. Alterations in glycosylation 
as biomarkers for cancer detection, J. Clin. 
Pathol., 2010, 63, 322-329.
(147)  Jenkins, N., et al. Getting the glycosylation 
right: implications for the biotechnology 
industry, Nat. Biotechnol., 1996, 14, 975-
981.
(148)  Wacker, C., et al. Glycosylation profiles of 
therapeutic antibody pharmaceuticals, Eur. 
J. Pharm. Biopharm., 2011, 79, 503-507.
(149)  Egrie, J.C.; Browne, J.K. Development and 
characterization of novel erythropoiesis 
stimulating protein (NESP), Br. J. Cancer, 
2001, 84 Suppl 1, 3-10.
(150)  Fernandes, A.I.; Gregoriadis, G. The effect of 
polysialylation on the immunogenicity and 
antigenicity of asparaginase: implication in 
its pharmacokinetics, Int. J. Pharm., 2001, 
217, 215-224.
(151)  Solá, R.J.; Griebenow, K. Glycosylation of 
| 152 |  
| BIBLIOGRAPHY |
therapeutic proteins: an effective strategy 
to optimize efficacy, BioDrugs, 2010, 24, 
9-21.
(152)  Weikert, S., et al. Engineering Chinese 
hamster ovary cells to maximize sialic acid 
content of recombinant glycoproteins, Nat. 
Biotechnol., 1999, 17, 1116-1121.
(153)  Desaire, H. Glycopeptide analysis, recent 
developments and applications, Mol. Cell. 
Proteomics, 2013, 12, 893-901.
(154)  Guttman, M.; Lee, K.K. Site-Specific 
Mapping of Sialic Acid Linkage Isomers by 
Ion Mobility Spectrometry, Anal. Chem., 
2016, 88, 5212-5217.
(155)  Haan, de N., et al. Linkage-specific sialic 
acid derivatization for MALDI-TOF-MS 
profiling of IgG glycopeptides, Anal. Chem., 
2015, 87, 8284-8291.
(156)  Lee, E.U., et al. Alteration of terminal 
glycosylation sequences on N-linked 
oligosaccharides of Chinese hamster ovary 
cells by expression of beta-galactoside 
alpha 2,6-sialyltransferase, J. Biol. Chem., 
1989, 264, 13848-13855.
(157)  Anthony, R.M., et al. Recapitulation of 
IVIG anti-inflammatory activity with a 
recombinant IgG Fc, Science, 2008, 320, 
373-376.
(158)  Fuguet, E., et al. A fast method for pKa 
determination by capillary electrophoresis, 
Chem. Biodivers., 2009, 6, 1822-1827.
(159)  Ruhaak, L.R., et al. Hydrophilic interaction 
chromatography-based high-throughput 
sample preparation method for N-glycan 
analysis from total human plasma 
glycoproteins, Anal. Chem., 2008, 80, 6119-
6126.
(160)  Reiding, K.R., et al. High-throughput 
profiling of protein N-glycosylation by 
MALDI-TOF-MS employing linkage-specific 
sialic acid esterification, Anal. Chem., 2014, 
86, 5784-5793.
(161)  Selman, M.H., et al. Cotton HILIC SPE 
microtips for microscale purification and 
enrichment of glycans and glycopeptides, 
Anal. Chem., 2011, 83, 2492-2499.
(162)  Jansen, B.C., et al. LaCyTools: A 
Targeted Liquid Chromatography-Mass 
Spectrometry Data Processing Package for 
Relative Quantitation of Glycopeptides, J. 
Proteome Res., 2016, 15, 2198-2210.
(163)  Palmblad, M., et al. Improving mass 
measurement accuracy in mass 
spectrometry based proteomics by 
combining open source tools for 
chromatographic alignment and internal 
calibration, J. Proteomics, 2009, 72, 722-
724.
(164)  Mancera-Arteu, M., et al. Identification 
and characterization of isomeric N-glycans 
of human alfa-acid-glycoprotein by stable 
isotope labelling and ZIC-HILIC-MS in 
combination with exoglycosidase digestion, 
Anal. Chim. Acta, 2016, 940, 92-103.
(165)  Stavenhagen, K., et al. Clinical Glycomics 
Employing Graphitized Carbon Liquid 
Chromatography-Mass Spectrometry, 
Chromatographia, 2015, 78, 307-320.
(166)  Costello, C.E., et al. A glycomics platform 
for the analysis of permethylated 
oligosaccharide alditols, J. Am. Soc. Mass. 
Spectrom., 2007, 18, 1799-1812.
(167)  Everest-Dass, A.V., et al. Structural feature 
ions for distinguishing N- and O-linked 
glycan isomers by LC-ESI-IT MS/MS, J. Am. 
Soc. Mass. Spectrom., 2013, 24, 895-906.
(168)  Harvey, D.J., et al. Fragmentation of 
negative ions from N-linked carbohydrates, 
part 4. Fragmentation of complex glycans 
lacking substitution on the 6-antenna, J. 
Mass. Spectrom., 2010, 45, 528-535.
(169)  Human Metabolomics Database, 
Metabocard for 3’-Sialyllacotse 
(HMDB00825), 2005 ed.: 2005; http://
www.hmdb.ca/metabolites/HMDB00825
(170)  Human Metabolomics Database, 
Metabocard for 6’-Sialyllacotse 
(HMDB06569): 2005; http://www.hmdb.
ca/metabolites/HMDB06569
(171)  Hardy, M., et al. Techniques in Glycobiology; 
Dekker, Inc: New York, 1997.
(172)  Geiser, L., et al. Determination of pKa 
values by capillary zone electrophoresis 
with a dynamic coating procedure, J. Sep. 
Sci., 2005, 28, 2374-2380.
| BIBLIOGRAPHY |
| 153 | 
B
(173)  Galuska, S.P., et al. Glycomic strategy for 
efficient linkage analysis of di-, oligo- and 
polysialic acids, J. Proteomics, 2012, 75, 
5266-5278.
(174)  Gahoual, R., et al. Full antibody 
primary structure and microvariant 
characterization in a single injection using 
transient isotachophoresis and sheathless 
capillary electrophoresis-tandem mass 
spectrometry, Anal. Chem., 2014, 86, 9074-
9081.
(175)  Haselberg, R., et al. Low-flow sheathless 
capillary electrophoresis-mass 
spectrometry for sensitive glycoform 
profiling of intact pharmaceutical proteins, 
Anal. Chem., 2013, 85, 2289-2296.
(176)  Ramautar, R., et al. Enhancing the 
coverage of the urinary metabolome by 
sheathless capillary electrophoresis-mass 
spectrometry, Anal. Chem., 2012, 84, 885-
892.
(177)  Heemskerk, A.A.M., et al. Coupling porous 
sheathless interface MS with transient-ITP 
in neutral capillaries for improved sensitivity 
in glycopeptide analysis, Electrophoresis, 
2013, 34, 383-387.
(178)  Leymarie, N., et al. Interlaboratory study on 
differential analysis of protein glycosylation 
by mass spectrometry: the ABRF 
glycoprotein research multi-institutional 
study 2012, Mol. Cell. Proteomics, 2013, 12, 
2935-2951.
(179)  Catalona, W.J., et al. Measurement of 
prostate-specific antigen in serum as a 
screening test for prostate cancer, N. Engl. 
J. Med., 1991, 324, 1156-1161.
(180)  Carlsson, S., et al. Influence of blood 
prostate specific antigen levels at age 60 
on benefits and harms of prostate cancer 
screening: population based cohort study, 
BMJ, 2014, 348, g2296.
(181)  Moyer, V.A.; U.S. Preventive Services Task 
Force,. Screening for prostate cancer: 
U.S. Preventive Services Task Force 
recommendation statement, Ann. Intern. 
Med., 2012, 157, 120-134.
(182)  Hsiao, C.J., et al. Analysis of Urinary 
Prostate-Specific Antigen Glycoforms in 
Samples of Prostate Cancer and Benign 
Prostate Hyperplasia, Dis. Markers, 2016, 
2016, 8915809.
(183)  Sarrats, A., et al. Glycan characterization of 
PSA 2-DE subforms from serum and seminal 
plasma, OMICS, 2010, 14, 465-474.
(184)  Tajiri, M., et al. Oligosaccharide profiles of 
the prostate specific antigen in free and 
complexed forms from the prostate cancer 
patient serum and in seminal plasma: a 
glycopeptide approach, Glycobiology, 
2008, 18, 2-8.
(185)  Gale, D.C.; Smith, R.D. Small volume and 
low flow-rate electrospray lonization mass 
spectrometry of aqueous samples, Rapid 
Commun. Mass Spectrom., 1993, 7, 1017-
1021.
(186)  Wilm, M.; Mann, M. Analytical properties 
of the nanoelectrospray ion source, Anal. 
Chem., 1996, 68, 1-8.
(187)  Bonvin, G., et al. Capillary electrophoresis-
electrospray ionization-mass spectrometry 
interfaces: fundamental concepts and 
technical developments, J. Chromatogr. A, 
2012, 1267, 17-31.
(188)  Covey, T.R., et al. Atmospheric pressure ion 
sources, Mass Spectrom. Rev., 2009, 28, 
870-897.
(189)  Juraschek, R., et al. Nanoelectrospray-
-more than just a minimized-flow 
electrospray ionization source, J. Am. Soc. 
Mass Spectrom., 1999, 10, 300-308.
(190)  Schmidt, A., et al. Effect of different solution 
flow rates on analyte ion signals in nano-
ESI MS, or: when does ESI turn into nano-
ESI?, J. Am. Soc. Mass Spectrom., 2003, 14, 
492-500.
(191)  Nguyen, S.; Fenn, J.B. Gas-phase ions of 
solute species from charged droplets of 
solutions, Proc. Natl. Acad. Sci. U.S.A., 
2007, 104, 1111-1117.
(192)  Zhu, Y.; Nugent, K.D., Method and Apparatus 
for Nano-Capillary/Micro Electrospray 
for use in lqiud Chromatography-Mass 
Spectrometry, United States, US8227750 
B1, 2012.
(193)  CaptiveSpray nanoBooster - The Revolution 
| 154 |  
| BIBLIOGRAPHY |
in Proteomics Ionization: Bruker Daltonics 
Inc., 2013.
(194)  Meyer, J.G.; Komives, E.A. Charge State 
Coalescence During Electrospray Ionization 
Improves Peptide Identification by Tandem 
Mass Spectrometry, J. Am. Soc. Mass 
Spectrom., 2012, 23, 1390-1399.
(195)  Marx, K., et al. Identification of a Second 
N-glycosylation Site in a Human PSA Sample 
by Combined CID/ETD Fragmentation, 
Bruker Daltonics Inc., 2012, Application 
Note LCMS-76.
(196)  Peterman, S.M.; Mulholland, J.J. A 
novel approach for identification and 
characterization of glycoproteins using 
a hybrid linear ion trap/FT-ICR mass 
spectrometer, J. Am. Soc. Mass Spectrom., 
2006, 17, 168-179.
(197)  Mysling, S., et al. Utilizing ion-
pairing hydrophilic interaction 
chromatography solid phase extraction 
for efficient glycopeptide enrichment in 
glycoproteomics, Anal. Chem., 2010, 82, 
5598-5609.
(198)  Heemskerk, A.A.M., et al. Ultra-low flow 
electrospray ionization-mass spectrometry 
for improved ionization efficiency in 
phosphoproteomics, Anal. Chem., 2012, 84, 
4552-4559.
(199)  Sarg, B., et al. Comparing and Combining 
Capillary Electrophoresis Electrospray 
Ionization Mass Spectrometry and Nano-
Liquid Chromatography Electrospray 
Ionization Mass Spectrometry for the 
Characterization of Post-translationally 
Modified Histones, Mol. Cell. Proteomics, 
2013, 12, 2640-2656.
(200)  Wang, Y., et al. Improving the 
comprehensiveness and sensitivity of 
sheathless capillary electrophoresis-
tandem mass spectrometry for proteomic 
analysis, Anal. Chem., 2012, 84, 8505-8513.
(201)  Huffman, J.E., et al. Comparative 
performance of four methods for high-
throughput glycosylation analysis 
of immunoglobulin G in genetic and 
epidemiological research, Mol. Cell. 
Proteomics, 2014, 13, 1598-1610.
(202)  Jansen, B.C., et al. MassyTools: A High-
Throughput Targeted Data Processing 
Tool for Relative Quantitation and Quality 
Control Developed for Glycomic and 
Glycoproteomic MALDI-MS, J. Proteome 
Res., 2015, 14, 5088-5098.
(203)  Reusch, D., et al. Comparison of methods for 
the analysis of therapeutic immunoglobulin 
G Fc-glycosylation profiles-Part 2: Mass 
spectrometric methods, MAbs, 2015, 7, 
732-742.
(204)  Breadmore, M.C., et al. Recent advances in 
enhancing the sensitivity of electrophoresis 
and electrochromatography in 
capillaries and microchips (2010-2012), 
Electrophoresis, 2013, 34, 29-54.
(205)  Timerbaev, A.R.; Hirokawa, T. Recent 
advances of transient isotachophoresis-
capillary electrophoresis in the analysis of 
small ions from high-conductivity matrices, 
Electrophoresis, 2006, 27, 323-340.
(206)  Sanz-Nebot, V., et al. Comparison of 
sheathless and sheath-flow electrospray 
interfaces for the capillary electrophoresis-
electrospray ionization-mass spectrometry 
analysis of peptides, Electrophoresis, 2005, 
26, 1457-1465.
(207)  Selman, M.H., et al. Fc specific IgG 
glycosylation profiling by robust nano-
reverse phase HPLC-MS using a sheath-flow 
ESI sprayer interface, J. Proteomics, 2012, 
75, 1318-1329.
(208)  Bladergroen, M.R., et al. Automation of 
High-Throughput Mass Spectrometry-
Based Plasma N-Glycome Analysis with 
Linkage-Specific Sialic Acid Esterification, J. 
Proteome Res., 2015, 14, 4080-4086.
(209)  Jefferis, R. Glycosylation as a strategy to 
improve antibody-based therapeutics, Nat. 
Rev. Drug Discov., 2009, 8, 226-234.
(210)  Varki, A. Biological roles of oligosaccharides: 
all of the theories are correct, Glycobiology, 
1993, 3, 97-130.
(211)  Ehrmann, B.M., et al. Relative importance 
of basicity in the gas phase and in solution 
for determining selectivity in electrospray 
ionization mass spectrometry, J. Am. Soc. 
Mass. Spectrom., 2008, 19, 719-728.
| BIBLIOGRAPHY |
| 155 | 
B
(212)  Kim, K., et al. Evaluation of glycomic 
profiling as a diagnostic biomarker 
for epithelial ovarian cancer, Cancer 
Epidemiol., Biomarkers Prev., 2014, 23, 
611-621.
(213)  Rombouts, Y., et al. Anti-citrullinated 
protein antibodies acquire a pro-
inflammatory Fc glycosylation phenotype 
prior to the onset of rheumatoid arthritis, 
Ann. Rheum. Dis., 2015, 74, 234-241.
(214)  Vermassen, T., et al. Glycosylation of 
prostate specific antigen and its potential 
diagnostic applications, Clin. Chim. Acta, 
2012, 413, 1500-1505.
(215)  Anderson, N.L., et al. A Human Proteome 
Detection and Quantitation Project, Mol. 
Cell. Proteomics, 2009, 8, 883-886.
(216)  Snyder, C.M., et al. Capillary 
electrophoresis-mass spectrometry for 
direct structural identification of serum 
N-glycans, J. Chromatogr. A, 2017, 1523, 
127-139.
(217)  Mitra, I., et al. Structural Characterization 
of Serum N-Glycans by Methylamidation, 
Fluorescent Labeling, and Analysis by 
Microchip Electrophoresis, Anal. Chem., 
2016, 88, 8965-8971.
(218)  Maxwell, E.J., et al. A promising 
capillary electrophoresis-electrospray 
ionization-mass spectrometry method for 
carbohydrate analysis, Electrophoresis, 
2011, 32, 2161-2166.
(219)  Gennaro, L.A., et al. Capillary 
electrophoresis/electrospray ion trap mass 
spectrometry for the analysis of negatively 
charged derivatized and underivatized 
glycans, Rapid Commun. Mass Spectrom., 
2002, 16, 192-200.
(220)  Zhong, X., et al. Capillary Electrophoresis-
Electrospray Ionization-Mass Spectrometry 
for Quantitative Analysis of Glycans 
Labeled with Multiplex Carbonyl-Reactive 
Tandem Mass Tags, Anal. Chem., 2015, 87, 
6527-6534.
(221)  Khatri, K., et al. Microfluidic Capillary 
Electrophoresis-Mass Spectrometry 
for Analysis of Monosaccharides, 
Oligosaccharides, and Glycopeptides, Anal. 
Chem., 2017, 89, 6645-6655.
(222)  Holst, S., et al. Linkage-Specific in Situ Sialic 
Acid Derivatization for N-Glycan Mass 
Spectrometry Imaging of Formalin-Fixed 
Paraffin-Embedded Tissues, Anal. Chem., 
2016, 88, 5904-5913.
(223)  Nishikaze, T., et al. Differentiation of Sialyl 
Linkage Isomers by One-Pot Sialic Acid 
Derivatization for Mass Spectrometry-
Based Glycan Profiling, Anal. Chem., 2017, 
89, 2353-2360.
(224)  Wheeler, S.F., et al. Derivatization of 
sialic acids for stabilization in matrix-
assisted laser desorption/ionization 
mass spectrometry and concomitant 
differentiation of alpha(2 -> 3)- and alpha(2 
-> 6)-isomers, Rapid Commun. Mass 
Spectrom., 2009, 23, 303-312.
(225)  Lattova, E.; Perreault, H. The usefulness 
of hydrazine derivatives for mass 
spectrometric analysis of carbohydrates, 
Mass. Spectrom. Rev., 2013, 32, 366-385.
(226)  Kammeijer, G.S.M., et al. Dopant Enriched 
Nitrogen Gas Combined with Sheathless 
Capillary Electrophoresis-Electrospray 
Ionization-Mass Spectrometry for 
Improved Sensitivity and Repeatability in 
Glycopeptide Analysis, Anal. Chem., 2016, 
88, 5849-5856.
(227)  Li, H.H., et al. MALDI-MS analysis of 
sialylated N-glycan linkage isomers using 
solid-phase two step derivatization method, 
Anal. Chim. Acta, 2016, 924, 77-85.
(228)  Yamada, K.; Kakehi, K. Recent advances 
in the analysis of carbohydrates for 
biomedical use, J. Pharmaceut. Biomed., 
2011, 55, 702-727.
(229)  Ruhaak, L.R., et al. Glycan labeling 
strategies and their use in identification 
and quantification,  Anal. Bioanal. 
Chem., 2010, 397, 3457-3481.
(230)  Kalia, J.; Raines, R.T. Hydrolytic stability of 
hydrazones and oximes, Angew. Chem. Int. 
Edit, 2008, 47, 7523-7526.
(231)  Naven, T.J.P.; Harvey, D.J. Cationic 
Derivatization of Oligosaccharides 
with Girard’s T Reagent for Improved 
Performance in Matrix-assisted Laser 
| 156 |  
| BIBLIOGRAPHY |
Desorption/Ionization and Electrospray 
Mass Spectrometry, Rapid Commun. Mass 
Spectrom., 1996, 10, 829-834.
(232)  Walker, S.H., et al. Hydrophobic 
derivatization of N-linked glycans for 
increased ion abundance in electrospray 
ionization mass spectrometry, J. Am. Soc. 
Mass Spectrom., 2011, 22, 1309-1317.
(233)  Wang, C., et al. Simplified quantitative 
glycomics using the stable isotope 
label Girard’s reagent p by electrospray 
ionization mass spectrometry, J. Proteome 
Res., 2014, 13, 372-384.
(234)  Walker, S.H., et al. Interplay of permanent 
charge and hydrophobicity in the 
electrospray ionization of glycans, Anal. 
Chem., 2010, 82, 6636-6642.
(235)  Johnson, P.H., et al. Purification, properties 
and possible gene assignment of an alpha 
1,3-fucosyltransferase expressed in human 
liver, Glycoconj. J., 1995, 12, 879-893.
(236)  Johnson, P.H., et al. Reassessment of the 
acceptor specificity and general properties 
of the Lewis blood-group gene associated 
alpha-3/4-fucosyltransferase purified from 
human milk, Glycoconj. J., 1992, 9, 251-264.
(237)  Sarmini, K.; Kenndler, E. Influence of organic 
solvents on the separation selectivity in 
capillary electrophoresis, J. Chromatogr. A, 
1997, 792, 3-11.
(238)  Tran, A.D., et al. Separation of Carbohydrate-
Mediated Microheterogeneity of 
Recombinant-Human-Erythropoietin by 
Free Solution Capillary Electrophoresis 
- Effects of Ph, Buffer Type and Organic 
Additives, J. Chromatogr., 1991, 542, 459-
471.
(239)  Pabst, M., et al. Comparison of fluorescent 
labels for oligosaccharides and introduction 
of a new postlabeling purification method, 
Anal. Biochem., 2009, 384, 263-273.
(240)  Mottet, N., et al. EAU-ESTRO-SIOG 
Guidelines on Prostate Cancer. Part 1: 
Screening, Diagnosis, and Local Treatment 
with Curative Intent, Eur. Urol., 2017, 71, 
618-629.
(241)  Barrabés, S., et al. Analysis of urinary PSA 
glycosylation is not indicative of high-risk 
prostate cancer, Clin. Chim. Acta, 2017, 470, 
97-102.
(242)  Saerens, D., et al. Single domain antibodies 
derived from dromedary lymph node and 
peripheral blood lymphocytes sensing 
conformational variants of prostate-
specific antigen, J. Biol. Chem., 2004, 279, 
51965-51972.
(243)  Gornik, O., et al. Stability of N-glycan 
profiles in human plasma, Glycobiology, 
2009, 19, 1547-1553.
(244)  Isono, T., et al. Structural diversity of 
cancer-related and non-cancer-related 
prostate-specific antigen, Clin. Chem., 
2002, 48, 2187-2194.
(245)  Stura, E.A., et al. Crystal structure of human 
prostate-specific antigen in a sandwich 
antibody complex, J. Mol. Biol., 2011, 414, 
530-544.
(246)  Hessels, D., et al. Detection of TMPRSS2-
ERG fusion transcripts and prostate cancer 
antigen 3 in urinary sediments may improve 
diagnosis of prostate cancer, Clin. Cancer 
Res., 2007, 13, 5103-5108.
(247)  Iribarne, J.V.; Thomson, B.A. On the 
evaporation of small ions from charged 
droplets, J. Chem. Phys., 1976, 64, 2287-
2294.
(248)  Konermann, L., et al. Unraveling the 
mechanism of electrospray ionization, Anal. 
Chem., 2013, 85, 2-9.
(249)  Iavarone, A.T.; Williams, E.R. Mechanism of 
charging and supercharging molecules in 
electrospray ionization, J. Am. Soc. Mass. 
Spectrom., 2003, 125, 2319-2327.
(250)  Hunter, E.P.L.; Lias, S.G. Evaluated gas 
phase basicities and proton affinities of 
molecules: An update, J. Phys. Chem. Ref. 
Data, 1998, 27, 413-656.
(251)  Zhou, S.Y., et al. Isomeric Separation 
of Permethylated Glycans by Porous 
Graphitic Carbon (PGC)-LC-MS/MS at High 
Temperatures, Anal. Chem., 2017, 89, 6590-
6597.
(252)  Heemskerk, A.A.M. Exploring the proteome 
by CE-ESI-MS - Chapter 3 - Optimization 
of capillary electrophoresis-mass 
| BIBLIOGRAPHY |
| 157 | 
B
spectrometry loadability and separation 
power. Leiden University Medical Center, 
Leiden, The Netherlands, 2016.
(253)  Nature: Retrieved from https://www.
nature.c o m/subj ec t s/p er so na l ized -
medicine, Description of Personalized 
Medicine.
(254)  VVD, et al.: Regeerakkoord ‘Vertrouwen in 
de toekomst’ - 2017-2021, 2017.
(255)  Hsu, K.L.; Mahal, L.K. Sweet tasting chips: 
microarray-based analysis of glycans, Curr. 
Opin. Chem. Biol., 2009, 13, 427-432.
(256)  Svarovsky, S.A.; Joshi, L. Cancer glycan 
biomarkers and their detection - past, 
present and future, Anal. Methods, 2014, 6, 
3918-3936.
(257)  National Cancer Institute, Dictionary of 
Cancer Terms - Biomarker - Retrieved from: 
https://www.cancer.gov/publications/
dictionaries/cancer-terms/def/biomarker.
(258)  Henry, N.L.; Hayes, D.F. Cancer biomarkers, 
Mol. Oncol., 2012, 6, 140-146.
(259)  Ransohoff, D.F. How to improve reliability 
and efficiency of research about molecular 
markers: roles of phases, guidelines, and 
study design, J. Clin. Epidemiol., 2007, 60, 
1205-1219.
(260)  Horvath, A.R., et al. From biomarkers to 
medical tests: the changing landscape of 
test evaluation, Clin. Chim. Acta, 2014, 427, 
49-57.
(261)  Monaghan, P.J., et al. Biomarker 
development targeting unmet clinical 
needs, Clin. Chim. Acta, 2016, 460, 211-219.
(262)  Eggener, S.E., et al. Prostate Cancer 
Screening, JAMA, 2015, 314, 825-826.
(263)  Santos, M.R., et al. Separation and Analysis 
of Intact Prostate Specific Antigen (PSA) 
and its Proteoforms by CESI-MS Under 




(264)  Mattsson, J.M., et al. Structural 
characterization and anti-angiogenic 
properties of prostate-specific antigen 
isoforms in seminal fluid, Prostate, 2008, 
68, 945-954.
(265)  Stamey, T.A., et al. Prostate-specific antigen 
as a serum marker for adenocarcinoma of 
the prostate, N. Engl. J. Med., 1987, 317, 
909-916.
(266)  Gutman, A.B.; Gutman, E.B. An “ Acid “ 
Phosphatase Occurring in the Serum of 
Patients with Metastasizing Carcinoma of 
the Prostate Gland, J. Clin. Invest., 1938, 17, 
473-478.
(267)  Tabares, G., et al. Free PSA forms in 
prostatic tissue and sera of prostate cancer 
patients: analysis by 2-DE and western 
blotting of immunopurified samples, Clin. 
Biochem., 2007, 40, 343-350.
(268)  Clark, D.; Mao, L. Cancer biomarker 
discovery: lectin-based strategies targeting 
glycoproteins, Dis. Markers, 2012, 33, 1-10.
(269)  Heemskerk, A.A.M., et al. CE-ESI-MS 
for bottom-up proteomics: Advances in 
separation, interfacing and applications, 
Mass. Spectrom. Rev., 2016, 35, 259-271.
(270)  Breadmore, M.C., et al. Recent advances in 
enhancing the sensitivity of electrophoresis 
and electrochromatography in 
capillaries and microchips (2008-2010), 
Electrophoresis, 2011, 32, 127-148.
(271)  Medina-Casanellas, S., et al. Low-
picomolar analysis of peptides by on-line 
coupling of fritless solid-phase extraction 
to sheathless capillary electrophoresis-
mass spectrometry, J. Chromatogr. A, 2014, 
1328, 1-6.
(272)  Zhang, Z., et al. Integrated strong cation-
exchange hybrid monolith coupled 
with capillary zone electrophoresis and 
simultaneous dynamic pH junction for 
large-volume proteomic analysis by mass 
spectrometry, Talanta, 2015, 138, 117-122.
(273)  Guo, X., et al. Capillary Electrophoresis-
Nanoelectrospray Ionization-Selected 
Reaction Monitoring Mass Spectrometry 
via a True Sheathless Metal-Coated Emitter 
Interface for Robust and High-Sensitivity 
Sample Quantification, Anal. Chem., 2016, 
88, 4418-4425.
(274)  Konášová, R., et al. Comparison of two 
low flow interfaces for measurement 
| 158 |  
| BIBLIOGRAPHY |
of mobilities and stability constants by 
affinity capillary electrophoresis-mass 
spectrometry, J. Chromatogr. A, 2018,  DOI: 
10.1016/j.chroma.2018.07.014.
(275)  Sun, L., et al. Third-generation 
electrokinetically pumped sheath-flow 
nanospray interface with improved stability 
and sensitivity for automated capillary 
zone electrophoresis-mass spectrometry 
analysis of complex proteome digests, J. 
Proteome Res., 2015, 14, 2312-2321.
(276)  Guzman, N.A., et al. Immunoaffinity 
capillary electrophoresis as a powerful 
strategy for the quantification of low-
abundance biomarkers, drugs, and 
metabolites in biological matrices, 
Electrophoresis, 2008, 29, 3259-3278.
(277)  DiBattista, A., et al. High Throughput 
Screening Method for Systematic 
Surveillance of Drugs of Abuse by 
Multisegment Injection-Capillary 
Electrophoresis-Mass Spectrometry, Anal. 
Chem., 2017, 89, 11853-11861.
(278)  Zhang, S., et al. Profiling B-Type Natriuretic 
Peptide Cleavage Peptidoforms in Human 
Plasma by Capillary Electrophoresis with 
Electrospray Ionization Mass Spectrometry, 
J. Proteome Res., 2017, 16, 4515-4522.
(279)  Clerc, F., et al. Plasma N-Glycan Signatures 
Associate With Features of Inflammatory 













| LIST OF ABBREVIATIONS |
| 163 | 
&
µa Electrophoretic mobility of  
 the analyte (µe + µEOF)
µe Electrophoretic mobility 
µeff Effective electrophoretic 
 mobility 
µEOF Electrophoretic mobility of  
 electro-osmotic flow
2-AA 2-aminobenzoic acid 
2-AB 2-aminobenzamide
4K Four kallikrein subforms
AAC Ammonium acetate 
ABC Ammonium bicarbonate 
AFP α-Fetoprotein
ai Degree of ionization




 trisulfonic acid 
Asn Asparagine
BFS Bare fused silica
BGE Background electrolyte
BPH Benign prostate hyperplasia
bPSA Benign prostate-specific 
 antigen
BSA Bovine serum albumin 
CE Capillary electrophoresis
CEA Carcinoembryonic antigen
CEC Capillary    
 electrochromatography 
CE-ESI-MS Capillary electrophoresis -  
 electrospray ionization - mass  
 spectrometry 
CE-MS Capillary electrophoresis -  
 mass spectrometry 
CGE Capillary gel electrophoresis
CHES  2-(Cyclohexylamino)ethane 
 sulfonic acid
CHO Chinese hamster ovary
CID Collision induced dissociation 
CIEF Capillary iso-electrofocusing 
CNS Chaperones calnexin
cPSA Complexed prostate-specific  
 antigen
CRM Charge residue model 
CRT Calreticulin
CZE Capillary zone electrophoresis 
DA Double amidation
DEN Dopant enriched nitrogen
dol Dolichol
DRE Digitial rectal examination
DTT DL-diothiotreitol
E Electric fied (V/cm)
EBRT External beam radiation  
 therapy
ECD Electron capture dissociation 
EDC 1-Ethyl-3-(3-(dimethylamino) 
 propyl)-carbodiimide
EEA Ethyl esterification and  
 amidation 





ETD Electron transfer dissociation 
EtOH Ethanol
F Fucose
FA Formic acid 
Fc Fragment crystallizable 
FDA Food and drug administration
FLD Fluorescence
fPSA Free PSA
FT-ICR Fourier-transform Ion  
 Cyclotron Resonance 
Fuc α-L-Fucose
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GalNAc β-N-acetyl-D-galactosamine
GalNAcT4 β1,4 N-acetyl-D-  
 galactosaminyltransferase




HAc Glacial acetic acid 
HCD Higher-energy collision  
 induced dissociation
HCl Hydrochloric acid
HER2 Human epidermal growth  
 factor receptor 2
HILIC Hydrophilic interaction liquid  
 chromatography 
hK2 Human kallikrein 2
hK3 Human kallikrein 3





IEM Ion evaporation mechanism 
IgG Immunoglobulin G
IgGmAb1 Recombinant monoclonal  
 IgG1 antibody 
IPA Isopropanol
IPQ Isotopic pattern quality score 
iPSA Inactive PSA
IS Internal standard
IT Ion trap 
ITP Isotachophoresis
IVIgG Intravenous immunoglobulin  
 G, human polyclonal IgG
KLK-3 Human kallikrein 3
l Effective capillary length (until  
 detector, cm)
L Total capillary length (cm)
LacNAc Poly-β-D-galactose-β-N- 
 acetyl-D-glucosamine
LC Liquid chromatography 
LE Leading electrolyte
LIF Laser induced fluorescence
LNCaP Lymph node carcinoma of the  
 prostate
LOD Limit of detection
m Mass
m/z Mass to charge ratio   
 (Thomson)
mAbs Monoclonal antibodies 
MALDI-TOF-MS Matrix assisted laser/  
 desorption ionization time-of- 
 flight mass spectrometry
Man β-D-mannose
MeCN Acetonitrile 





MOPS  3-Morpholinopropane sulfonic  
 acid
mpMRI Multi-parametric magnetic  
 resonance imaging
MQ Milli-Q water 














PGA PSA Glycomics Assay
PGC Porous graphitized carbon
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PHI Prostate health index
pKa Acid dissociation constant
PNGase F Peptide-N-glycosidase F 
preproPSA Prepropolyprotein of  
 prostate-specific antigen
proPSA Precursor protein of prostate- 
 specific antigen
PSA Prostate-specific antigen
q Charge of the ion 
Q Quadrupole 
r Radius of the ion 
RSD Relative standard deviation
RT Room temperature
S Sialic acid
S/N Signal to noise ratio
SDS Sodium dodecyl sulfate 
Ser Serine




ta Migration time of the analyte 
 (sec)
TE Terminating electrolyte
TFA Trifluoroacetic acid 
Thr Threonine
t-ITP Transient-isotachophoresis
TMT Aminoxy-tandem mass tag 
TNM Tumor size, involved lymph
 nodes and distant metastasis
TOF Time-of-flight 






TSNG Total serum N-glycome
UDP Uridine diphosphate
UEA-1 Ulex europaeus
UGM Urine glycoprofile marker
UV Ultraviolet 
V Applied voltage
v Velocity of the analyte





η Viscosity of the buffer
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With more than 10,000 new patients diagnosed on a yearly basis in the Netherlands, prostate 
cancer (PCa) is the second leading cancer in men. Currently, the serum concentration of the 
glycoprotein prostate-specific antigen (PSA) is being used as an indicator for PCa. While, this 
test is clinically applied worldwide, the PSA test lacks specificity, exhibits low sensitivity and 
more importantly it has a poor predictive value, resulting in a high number of unnecessary 
biopsies. Therefore, a marker is needed that can stratify the patient in a more accurate 
manner (e.g., the differentiation between aggressive and non-aggressive prostate cancer). The 
aim of this thesis was to explore and gain a better insight in the glycosylation of PSA in urine, 
its correlation with PCa and the potential of using glycan biomarkers for the prediction or 
reflection for the progression of the disease. For this purpose the powerful analytical platform 
capillary electrophoresis hyphenated with mass spectrometry via electrospray ionization (CE-
ESI-MS(/MS)) was explored with a special focus on the analysis of glycan and glycopeptides, by 
employing a porous nano-sprayer for the MS coupling.
To achieve this goal, first a better insight is needed of the current clinical pathway, the unmet 
clinical need of PCa and its relation to PSA. Therefore, the first part of this thesis provides an in-
depth overview on these topics (Chapter 1). Moreover, this chapter describes the biosynthetic 
pathway of glycosylation as well as the biological role of glycosylation and if glycan biomarkers 
have the potential of overcoming unmet clinical needs, which, for PCa is the need for a better 
marker in the early diagnosis of PCa and, most importantly, the differentiation between 
indolent from aggressive tumors. In addition, to understand why CE-ESI-MS was chosen as 
analytical platform, a basic overview is provided in this chapter.
The second part is focused on the developments that have been made and implemented for 
the analysis of PSA with CE-ESI-MS (Chapters 2 and 3). As indicated by literature, a specific 
glycosylation feature of PSA, namely sialylation, could be a potential glycan biomarker for 
PCa. In particular the elevation of the α2,3-linked sialylated species seems to be a promising 
marker. Since differentially sialylated species cannot be readily distinguished by mass 
spectrometry, it was investigated if the different isoforms of the sialic acids (α2,3 versus α2,6) 
could be separated on a high-resolution separation platform (CE-ESI-MS; Chapter 2). Due to a 
difference in electrophoretic mobilities, a baseline separation of the α2,3- and α2,6-sialylated 
glycopeptides was achieved by CE. Interestingly, while the isomeric sialylated glycopeptides 
have similar physicochemical properties it was found that there was a relative small difference 
in pKa units of 3.4·10
-2, providing a possible explanation for the difference in electrophoretic 
mobility. Notably, no extra sample treatment was needed besides the common procedures 
for a bottom-up approach (reduction, alkylation and digestion of the glycoprotein). In addition, 
this study revealed the micro-heterogeneity of the single N-linked glycosylation site of 
PSA. The sensitivity of the CE-ESI-MS platform was assessed in Chapter 3. Previous studies 
demonstrated that, when acetonitrile is used as a dopant gas around the ESI emitter, using 
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nanoLC-ESI-MS as a platform an overall higher sensitivity could be achieved for glycopeptides. 
In Chapter 3, we introduced for the first time a dopant enriched nitrogen (DEN) gas between 
the CE and MS instrument. Compared to conventional CE-ESI-MS, 25-fold higher sensitivities 
for model glycopeptides were obtained, allowing for limits of detection unreached by state-
of-the-art nanoLC-ESI-MS. Interestingly, the DEN-gas appeared to positively affect the 
repeatability and intermediate precision compared to the conventional CE-ESI-MS platform. 
This development opened up new avenues for analyzing the heterogeneous glycosylation of 
PSA even more in-depth due to the improved sensitivity and precision when compared to the 
obtained results in Chapter 2. Chapter 4, the last chapter of the method development section 
investigates the usage of the CE-ESI-MS platform equipped with DEN-gas for the analysis of 
released N-glycans. This is especially important when minor abundant glycoforms need to be 
investigated in complex mixtures (< 0.01 % relative abundance). In addition, the development 
could also be applied on samples that contain low abundant proteins or when limited sample 
amounts are available. As N-glycans can be either negatively charged (carrying one or several 
sialic acids) or neutral (non-sialylated) the separation of the CE can be hampered, as well as the 
detection with MS could be biased. For this purpose an easy workflow was developed for the 
neutralization of sialic acids, which simultaneously enabled the differentiation between α2,3- 
and α2,6-linked sialic acids by MS (based on the difference in their derivatized mass). With the 
introduction of a cationic hydrazide tag (Girard’s reagent P) at the reducing end, a uniform 
charge was attributed to all N-glycans. An in-depth study of the total human plasma protein 
N-glycome (TPNG) allowed the identification of 167 glycoforms, including sialic acid linkage-
isomers, which is hitherto the highest identified number of glycoforms for TPNG thereby 
establishing CE-ESI-MS as a powerful tool in the field of N-glycan analysis. 
In the third part of this thesis, the findings and improvements from Chapters 2 and 3 were 
combined and used to study the correlation of PSA glycosylation with PCa. Here, for the first 
time a high-performance PSA Glycomics Assay (PGA) was presented (Chapter 5). PSA was 
captured and purified from patients’ urine followed by tryptic digestion and was analyzed 
with CE-ESI-MS equipped with a DEN-gas. In total, 67 N-glycopeptides were identified from 
the PSA that was pooled from patients’ urine. Moreover, based on positive controls (PSA 
standard spiked to a female urine pool) an average interday relative standard deviation of 
14% was found for 41 N-glycopeptides. While we established a powerful tool for the in-depth 
relative quantitation of different PSA glycoforms in patients’ urine, these data did not allow 
differentiating PCa patients from non-PCa patients.
Finally, the last part of this thesis (Chapter 6) offers a general discussion about future 
developments as well as the potential use of a PSA glycosylation assay in the clinical setting, 
showing the relevance of the results and how these may contribute to further clinical 
applications towards personalized medicine. 
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Met jaarlijks 10,000 nieuwe diagnoses in Nederland is prostaatkanker de meest voorkomende 
kankersoort bij mannen. Wanneer er een verdenking van prostaatkanker is wordt er een 
PSA-test uitgevoerd. Deze test is gebaseerd op het eiwit prostaat specifiek antigeen (PSA), 
dat geproduceerd wordt in de prostaat met als functie het sperma vloeibaar te maken 
zodat spermacellen kunnen zwemmen. In een normale situatie (geen prostaatkanker) kan 
er een klein beetje van dit eiwit “lekken” vanuit de prostaatklier naar de bloedsomloop. Bij 
prostaatkanker zijn de cellen minder mooi gerangschikt en kan de PSA vanuit de prostaatklier 
beter toegang krijgen tot de bloedsomloop. Hierdoor kunnen verhoogde PSA concentraties 
geobserveerd worden in het bloed. Bij verhoogde PSA concentraties (boven de 3,0 ng/mL) 
zal vervolgonderzoek worden aangeraden. Hoewel deze test wereldwijd klinisch wordt 
toegepast, is de PSA-test niet zo gevoelig dat de aan- of afwezigheid van prostaatkanker met 
zekerheid kan worden bepaald. Dit komt mede door het feit dat prostaatkanker niet de enige 
veroorzaker is van verhoogde PSA concentraties in het bloed. Andere prostaataandoeningen 
zoals een goedaardige vergroting of ontsteking van de prostaat kunnen ook resulteren in 
een verhoogde PSA concentratie. Daarnaast is prostaatkanker onder te verdelen in twee 
groepen namelijk, histologische prostaatkanker en klinische prostaatkanker. In het geval 
van histologische prostaatkanker gaat het om een langzaam groeiende kankersoort. De 
patiënt heeft geen klachten en de kans is groot dat de patiënt eerder zal overlijden aan 
ouderdom of andere aandoeningen dan aan prostaatkanker. In zo’n geval wordt dan ook 
vaak een actief afwachtend beleid aangeraden, wat betekent dat de patiënt regelmatig 
terug zal moeten komen voor controles. Deze prostaatkanker zou men dan ook liever niet 
willen diagnosticeren. Men spreekt van klinische prostaatkanker als de kanker agressieve 
kenmerken heeft, waarvan de patiënt symptomen kan krijgen of heeft. In dit stadium zal 
er een behandeling worden gestart welke (afhankelijk van het stadium van de ziekte) kan 
bestaan uit uitwendige of inwendige bestraling of het verwijderen van de prostaat middels 
operatie, hormoontherapie of chemotherapie. Helaas, is het soms lastig om een onderscheid 
te maken tussen histologische en klinische prostaatkanker waardoor de kans bestaat dat 
de patiënt wordt onder- of over behandeld. Dit illustreert dan ook de noodzaak voor een 
betere diagnostische methode dan de huidige PSA-test om prostaatkanker van andere 
prostaatklachten te onderscheiden zodat de patiënt zo goed mogelijk kan worden geholpen.
Om een beter onderscheid te kunnen makken tussen prostaatkanker, de soort 
prostaatkanker (histologisch of klinisch) en andere prostaat gerelateerde ziekten zouden 
mogelijke modificaties die aanwezig kunnen zijn op PSA een uitkomst bieden. Een van deze 
modificaties is glycosylering, bij deze modificatie zijn er suikergroepen aan het eiwit vast 
gemaakt. Veranderingen in deze suikergroepen blijken een rol te spelen bij verschillende 
kankersoorten en aan auto-immuunziekten zoals reuma. Het doel van dit proefschrift was het 
onderzoeken van de mogelijke link tussen prostaatkanker en de aanwezige (veranderingen 
van) suikergroepen op PSA. Mogelijkerwijs kunnen deze observaties (veranderingen 
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van bepaalde suikergroepen op PSA) ook dienen om een onderscheid te maken tussen 
histologische de klinische prostaatkanker. Dit in tegenstelling tot de huidige PSA-test welke 
geen onderscheid kan maken tussen deze verschillende agressiviteitskenmerken van 
prostaatkanker. Tijdens dit onderzoek is er gebruik gemaakt van een analytische platform 
bestaande uit capillaire elektroforese gekoppeld aan een massaspectrometer door middel 
van elektrospray ionisatie (CE-ESI-MS(/MS)). Met dit platform kan er een speciale focus 
worden gelegd op de analyse van deze suikerstructuren op glycaan en glycopeptide niveau. 
In hoofdstuk 1 van dit proefschrift wordt er een beschrijving gegeven over prostaatkanker, 
de huidige klinische route maar ook wat de onbeantwoorde behoeften zijn vanuit de kliniek 
omtrent prostaatkanker. Er is namelijk een grote vraag naar een meer betrouwbare test 
die prostaatkanker van andere prostaatklachten kan onderscheiden maar ook een test 
die overbehandeling en invasieve onderzoeken van histologische prostaatkanker kan 
voorkomen. Daarnaast beschrijft dit hoofdstuk ook in detail de biosynthese en biologische 
rol van de suikergroepen (glycosylering) en of de onbeantwoorde behoeften vanuit de kliniek 
mogelijk beantwoord kunnen worden met glycaan biomarkers. Tevens geeft dit hoofdstuk 
een basale uitleg van CE-ESI-MS als analytisch platform en waarom juist dit platform geschikt 
is voor dit onderzoek.
Het tweede deel van dit proefschrift bespreekt de ontwikkelingen en implementaties 
omtrent de analyse van glycosylering met CE-ESI-MS (hoofdstukken 2, 3 en 4). Een specifiek 
glycosylerings kenmerk van PSA, namelijk sialylering, wordt in literatuur beschreven als 
een potentiele biomarker voor prostaatkanker, waarbij een verhoging van de siaalzuur die 
α2,3-gebonden is aan een galactose erg veelbelovend lijkt. Aangezien het gebruik van alleen 
een massaspectrometer geen onderscheid kan maken tussen de verschillende bindingen 
(α2,3 versus α2,6), is er onderzocht of capillaire elektroforese de benodigde scheiding kon 
verwezenlijken (hoofdstuk 2). Terwijl α2,3- en α2,6-siallyllactose beschikken over dezelfde 
fysisch-chemische eigenschappen, blijken ze een andere elektroforetische mobiliteit te 
hebben dat zeer waarschijnlijk veroorzaakt wordt door een relatief klein verschil in pKa 
(3.4·10-2). Opvallend was het feit dat er geen verdere monster voorbewerking nodig was naast 
de algemene procedures voor een bottom-up benadering (reductie, alkylatie en digestie van 
het suikereiwit). Tevens liet deze studie de hoge heterogeniteit in suikergroepen zien op de 
enige glycosyleringsplek van PSA. In hoofdstuk 3 wordt de gevoeligheid van het CE-ESI-MS 
platform geëvalueerd en verbeterd. Voorgaande studies hebben namelijk aangetoond dat 
een verhoogde gevoeligheid kon worden bereikt voor de analyse van glycopeptiden met een 
nanoLC-ESI-MS platform, wanneer er gebruik werd gemaakt van acetonitril als doteringsgas 
rond de ESI emitter. Voor de allereerste keer hebben wij (hoofdstuk 3) een soortgelijk 
principe toegepast voor een CE-ESI-MS platform. In vergelijking met de conventionele CE-
ESI-MS platform kon de gevoeligheid met het gebruik van deze doteringsgas 25-voudig 
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worden verbeterd. Dit resulteerde in een detectie grens dat ongeëvenaard is voor nano-
LC-ESI-MS platforms. Een interessante observatie was het feit dat de toevoeging van het 
doteringsgas een positief effect had op de herhaalbaarheid en de intermediaire precisie 
in vergelijking met het conventionele CE-ESI-MS platform. Het laatste hoofdstuk van 
de methode ontwikkeling (hoofdstuk 4) beschrijft de analyse van de suikergroepen die 
enzymatisch geknipt zijn van alle glyco-eiwitten afkomstig uit de bloedcirculatie. Door de 
implementatie van de ontwikkelingen uit hoofdstuk 3 (de toepassing van het gedoteerde 
gas) kunnen suikergroepen die aanwezig zijn in lage hoeveelheden (relatieve hoeveelheid 
<0.01 %) in complexe monsters (zoals plasma) worden bestudeerd. Daarnaast biedt deze 
toepassing ook mogelijkheden voor het bestuderen van de suikergroepen op suikereiwitten 
die alleen beschikbaar zijn in lage concentraties. De scheiding van de CE kan worden 
belemmerd doordat de suikergroepen negatief geladen kunnen zijn (door de aanwezigheid 
van één of meerderde siaalzuren) of neutraal (geen siaalzuren aanwezig), tevens kan dit 
een afwijking in de detectie van de MS veroorzaken. Met dit probleem voor ogen is er een 
simpele procedure ontwikkeld voor de neutralisatie van de siaalzuren, waarbij gelijktijdig 
ook een onderscheid gemaakt kan worden tussen de α2,3- en α2,6-gebonden siaalzuren 
met massaspectrometrie (gebaseerd op een verschil in massa door de derivatisatie). De 
introductie van een permanent positief label aan het uiteinde van de suikergroep (hydrazide 
binding) zorgt er voor dat alle suikergroepen een identieke lading krijgen. Deze ontwikkeling 
heeft ervoor gezorgd dat 167 unieke suikergroepen geïdentificeerd konden worden in 
plasma, inclusief het onderscheid tussen de verschillende siaalzuur bindingen. Tot nu toe is 
dit het hoogste aantal geïdentificeerde suikergroepen in plasma, wat tegelijkertijd aangeeft 
dat CE-ESI-MS een krachtig platform is op het gebied van glycaan analyse.
Het derde deel van dit proefschrift combineert de bevindingen en verbeteringen van 
methode ontwikkeling om de correlatie tussen de PSA suikergroepen en prostaatkanker te 
bestuderen. Hoofdstuk 5 beschrijft de ontwikkeling van een hoogwaardige PSA Glycomics 
Assay. Voor deze studie, hebben patiënten met een verhoogde PSA concentratie (> 3,0 ng/
mL) urine gedoneerd. De PSA is ingevangen en opgeschoond vanuit deze urinemonsters 
en doordat het PSA enzymatisch in stukken werd geknipt, konden de glycopeptiden 
geanalyseerd worden met CE-ESI-MS dat gebruik maakte van het gedoteerde gas. In 
totaal, konden er 67 unieke suikergroepen geïdentificeerd worden in een samengevoegd 
urinemonster van alle patiënten. Ondanks dat dit een zeer uitvoerig onderzoek is voor de 
identificatie van de aanwezige suikergroepen op PSA kon er helaas, met dit onderzoek, geen 
onderscheid worden gemaakt tussen het PSA urine suikerprofiel van patiënten die wel of 
geen prostaatkanker hebben bij biopten. Dit komt zeer waarschijnlijk doordat de PSA uit 
urine voor het grootste gedeelte afkomstig is van de gezonde prostaatcellen.
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Het laatste deel van het proefschrift (hoofdstuk 6) bevat een algemene discussie over 
toekomstige ontwikkelingen en de potentie van de beschreven PSA Glycomics Assay 
in hoofdstuk 5 in een klinische omgeving. Veelbelovend lijkt de uitbreiding van de assay 
om de PSA suikerprofielen te bestuderen in bloed. Dit doordat de kankercellen ook PSA 
produceren en juist deze PSA zal in hogere mate terecht kunnen komen in het bloed. Het 
is namelijk de verwachting dat de PSA afkomstig van de kankercellen makkelijker naar de 
bloedsomloop kunnen lekken doordat de kankercellen (in vergelijking tot gezonde cellen) 
door de membraan kunnen breken. De verwachting is dat de suikergroepen van het PSA dat 
afkomstig is van de kankercellen afwijkende profielen zullen laten zien ten opzichte van PSA 
dat geproduceerd is door gezonde prostaatcellen. Uit verder onderzoek zal moeten blijken 
of dit ook daadwerkelijk het geval is en hoe deze resultaten wellicht kunnen bijdragen voor 
de klinische toepassing richting gepersonaliseerde geneeskunde (personalized medicine).
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10 & 11-10-2018 Global CESI-MS Symposium - SCIEX, Leiden, The Netherlands
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| 186 |  
| PHD PORTFOLIO |
TEACHING EXPERIENCE
Frontiers of Science Course - Parasitology, Leiden University Medical Center 
January 2019 
Course about glyco(proteo)mics for BSc students
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